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The ability of immune cells to migrate to distinct niches and peripheral sites is critical for 
their appropriate differentiation and for execution of their effector functions. This 
migration is facilitated to a large degree by the expression of chemokine receptors, which 
allow for migration in a spatiotemporally-controlled manner. The work presented in this 
thesis addresses two distinct issues regarding how regulation of immune cell migration 
affects development of anti-tumour immunity and infectious immunity. 
 
In the first part of this thesis, a novel role for the atypical chemokine receptor ACKR4 in 
controlling anti-tumour immune responses was identified. As a scavenging receptor, 
ACKR4 regulates the bioavailability of the CCR7 ligands, CCL19 and CCL21, and the 
CCR9 ligand, CCL25. These ligands have previously been shown to be critical for many 
aspects of immune homeostasis, as well as contributing to tumour cell growth and 
metastasis. However, the contribution of ACKR4 in regulating tumour-specific responses 
has been unclear. Using multiple orthotopic, transgenic and chemically-induced models 
of cancer, loss of ACKR4 resulted in inhibited tumour growth. In the absence of ACKR4, 
enhanced CCL21 levels were associated with enhanced tumour infiltration of IFN + 
CD8+ T cells. The reduced tumour growth seen was dependent on the enhanced CD8+ 
response, with depletion of CD8+ T cells restoring growth of Ackr4–/– tumours to wildtype 
levels. The enhanced CD8+ T cell response was not a result of altered priming in draining 
lymph nodes, although there was increased intratumoural proliferation of CD8+ T cells. 
Furthermore, ACKR4-deficient tumours showed increased retention of CD103+ DCs, 
with these cells previously being shown to be critical for effective recruitment of CD8+ 
T cells to tumours. Moreover, intratumoural administration of CCL21 into wildtype 
tumours also enhanced the accumulation of DCs, suggesting a direct role for the 
scavenging ability of ACKR4. These data support the notion that ACKR4, through its 
regulation of CCL21 bioavailability, controls DC migration in tumours thus regulating 
the development of anti-tumour immune responses. Furthermore, multiple 
immunotherapies show increased efficacy in the absence of ACKR4, suggesting ACKR4 
may be useful as a potential novel target for immunotherapy. 
 
In the second part of this thesis, the role of CCR2 on memory CD4+ T cells was explored. 




of memory CD4+ T cells, despite correlations with improved disease outcomes. 
Furthermore, how these cells migrate to inflammatory sites is still largely unknown. In 
this project, CCR2 was identified as being enriched on antigen-specific memory CD4+ T 
cells in response to infection with the extracellular bacteria Streptococcus pneumoniae 
and infection with influenza A virus. Competitive co-transfer of wildtype and CCR2-
deficient TCR-transgenic CD4+ T cells showed enhanced contraction of Ccr2–/– cells, 
suggesting a cell-intrinsic role for CCR2 in CD4+ T cell maintenance. CCR2-deficient 
effector cells were unaffected in their ability to secrete cytokines or enter into effector 
sites. Moreover, despite being numerically reduced at memory timepoints compared with 
CCR2-sufficent cells, they were equally capable of expanding upon secondary challenge. 
These data highlight CCR2 as an important regulator of CD4+ T cell memory 
maintenance.  
 
Taken together, this project has furthered our understanding of the complexity of cell 
migration in dictating immune responses. The identification of CCR2 as a mediator of 
memory CD4+ T cell generation may allow further investigation into how these cells are 
induced and maintained. In ACKR4, a novel level of post-transcriptional regulation of 
intratumoural DC trafficking has been identified, with this having the potential to be a 































Chapter 1 – Introduction 
 
1.1 Chemokine-mediated control of immune responses 
 
1.1.1 Cell migration in the immune system 
The immune system is an integral component of our body’s ability to protect itself from 
invading pathogens, destroy mutated or non-functioning cells and repair damaged tissues. 
It achieves these functions through coordination of multiple cell types with specific roles, 
with each response tailored to the specific threat being faced. Classically, cells of the 
immune system have been divided into two arms: innate cells, which recognise pathogens 
relatively non-specifically and provide an immediate source of protection; and adaptive 
cells, which possess antigen-specific receptors and enable targeted destruction of the 
threat. However, interplay between these groups of cells is critical for effective immune-
mediated control.  
 
A key feature of cells of the immune system is their ability to migrate to different sites, 
and this is critical for their development and function. During homeostasis, cells 
recirculate throughout blood, lymphatics and tissues to survey for signs of damage or 
foreign insult. When a threat is identified, immune responses require controlled migration 
of cells to distinct niches to facilitate priming, as well as migration of effector cells from 
secondary lymphoid organs (SLOs) to peripheral sites to eliminate the danger and initiate 
repair. This migration is tightly controlled both spatially and temporally, and is facilitated 
to a large degree by the chemokine system. 
 
1.1.2  Chemokine system overview 
Chemokines are a family of structurally-related low molecular weight cytokines that 
guide the migration of cells through binding to cognate chemokine receptors. These 
chemokine receptors are differentially expressed in immune cells (as well as on many 
cells of non-haematopoietic origin), which enables selective migration of cells expressing 
a receptor towards areas of production of the specific chemokines to which the receptor 
binds. Chemokine receptors are a family of seven transmembrane-domain G protein-
coupled receptors (GPCRs), with the N-terminus and extracellular loops responsible for 




conserved DRY motif, which enables coupling to G proteins, initiating downstream 
signalling cascades that induce cell polarisation and remodelling of the cytoskeleton that 
ultimately result in directional cell migration. Furthermore, receptors can become 
desensitised or internalised in response to chemokine signalling, which acts to regulate 
the magnitude of the response, with receptors being either degraded or recycled back to 
the surface for subsequent reengagement. 
 
Chemokine receptors can be subdivided depending on the structural class of chemokines 
to which they bind, with these classes being determined by the N-terminal cysteine motif 
present in the chemokine. On this basis, there are four subfamilies of chemokine 
receptors: CC, CXC, XC, and CX3C, where X is a non-conserved residue adjacent to the 
cysteine (C) residue (Table 1.1). However, there is promiscuity in the chemokine system, 
with multiple chemokines capable of binding to the same receptor, and an individual 
chemokine capable of binding multiple receptors. In addition to these subfamilies are a 
family of atypical chemokine receptors (ACKRs), which are defined by the absence of 
the canonical DRY motif and consequently lack classical G-protein mediated signalling1. 
Thus, these atypical chemokine receptors do not induce cell migration, but upon ligand 
binding can internalise, transcytose or degrade the chemokines, providing a further level 
of regulation of this system2. In Chapter 3, the role of an atypical chemokine receptor in 
regulating anti-tumour responses will be described, whilst Chapter 4 assesses the 
chemokine-mediated regulation of CD4+ T cell memory in infectious immunity. 
 
1.2   Immune responses to tumours 
 
1.2.1 Tumour initiation and progression 
Tumours are masses of cells that have arisen from uncontrolled cell proliferation. In 
healthy tissues, cell growth and division is tightly regulated by a number of different 
signals and checkpoints, with cells displaying defects being eliminated through apoptosis. 
However, cancerous cells can develop from an accumulation of mutations in genes 
involved in regulating these processes, so called oncogenes, which promote cell growth 
and division, and tumour suppressor genes, which regulate cell division and promote 
DNA repair. There are a number of features that define a successful tumour (Figure 1.1), 




sustaining an energy-intensive cellular mass. Furthermore, tumour cells can gain the 
ability to migrate from their original site, which can range from invasion of surrounding 
tissues without further dissemination, through to cells breaking away from the primary 
tumour and entering the bloodstream or lymphatics, where they can metastasize to distant 
sites. Metastatic disease requires both the initial ability to escape the primary tumour, 
often through an epithelial-mesenchymal transition, as well as the ability to adapt to and 
colonise the secondary site, without which metastatic cells may remain dormant and not 
form macrometastases3. Once tumours have successfully metastasized, treatment can be 
much more difficult, with patient prognosis generally poorer. 
 
1.2.2 The tumour microenvironment (TME) 
Whilst the initial focus in cancer research was on tumour cell-intrinsic characteristics, 
over the last decade, there has been increased recognition that the TME is a key 
contributor to the development of malignant tumours. In carcinomas, which are 
neoplastic lesions derived from epithelial cells, the tumour parenchyma consists of the 
epithelial cell mass, with the surrounding stroma including fibroblasts, blood and 
lymphatic endothelial cells, pericytes, mesenchymal stem cells and infiltrating immune 
cells. These components can each contribute to tumour progression, and have been the 
focus of intense research to determine novel potential therapeutic targets. In particular, 
much attention has been placed on cells of the immune system, which have been 
identified in most if not all solid tumours and can drive an inflammatory environment. 
Tumour-infiltrating immune cells are a heterogeneous population of both myeloid and 
lymphoid-lineage cells, which can have either anti-tumourigenic or pro-tumourigenic 
roles.  
 
Pro-tumourigenic responses typically involve creation of an immunosuppressive or 
tolerogenic environment, mediated in part by cytokines such as transforming growth 
factor  (TGF ), IL-4 and IL-10, among others4. This environment invokes the 
development of M2-polarised macrophages, myeloid-derived suppressor cells (MDSCs) 
and Foxp3+ CD4+ Treg cells, which can all act to suppress T cell responses to the tumour, 
as well as promoting angiogenesis and tissue-remodelling to support tumour growth and 
survival.  The presence of Treg cells in tumours is often associated with poor prognosis, 




sequestration of IL-2 from effector T cells, or competition for antigen-presenting cell 
(APC) costimulation through CTLA-4 expression5-9. Recently, neutrophils have been 
identified as a key facilitator of metastatic spread, by inducing leaky vasculature, 
supporting a premetastatic niche and limiting anti-tumour responses through production 
of soluble mediators such as matrix metalloproteinase 9 and inducible nitric oxide 
synthesis10-13. 
 
On the other hand, anti-tumourigenic responses are generally Type 1 responses, with 
CD8+ cytotoxic T cells and natural killer (NK) cells both capable of targeting and 
destroying tumour cells. CD8+ T cells act in an antigen-specific manner, predominantly 
recognising neoantigens created through tumour mutations or oncogenic viral epitopes, 
although tissue-specific differentiation antigens and cancer-testis antigens can also act as 
targets14. CD8+ T cells become activated upon cognate recognition of their antigen 
presented in the context of MHC class I by APCs, and can differentiate into cytotoxic T 
cells capable of inducing tumour cell death through provision of IFN , Fas ligand (FasL), 
TRAIL and cytolytic effector proteins, perforins and granzymes. The presence of CD8+ 
T cells and their effector proteins is correlated with improved patient prognoses in a range 
of different cancers15-17. NK cells are part of the innate immune response, and so their 
recognition of tumours is not antigen-specific. Rather, activation of NK cells is mediated 
through a balance of activating and inhibitory receptors, which can detect perturbations 
in normal cell health18,19. A major target for their inhibitory receptors are MHC class I 
molecules, which are expressed on normal cells, but can be downregulated on tumours 
cells to avoid antigen-presentation to CD8+ T cells. Other important NK receptors are 
TIGIT, CD96 and CD226, which regulate a number of ligands altered in response to 
cellular stress. NK cell cytotoxic mechanisms are similar to those of CD8+ T cells, with 
perforin/granzyme cytolytic complexes and IFN  being the predominant mediators. 
These anti-tumour responses are also orchestrated through provision of cytokines such as 
IFN  from TH1-polarised CD4+ T cells, with CD4+ T cells also purported to have direct 
cytotoxicity in certain scenarios20. In addition, a wide range of other cells have been 







1.2.3 Cancer immunoediting 
There is now great evidence for the immune system actively shaping tumour progression, 
with initial crucial experiments showing that tumours grown in immunodeficient animals 
were more immunogenic upon subsequent transfer into immunocompetent hosts24,25. 
This influence of the immune system is referred to as the cancer immunoediting 
hypothesis, in which there are three distinct phases of tumour-immune interactions; 
elimination, equilibrium and escape (Figure 1.2). The elimination phase consists of the 
immune system detecting and destroying cancerous cells, prior to the development of 
malignancy or clinical disease. Evidence for this phase comes from early experiments 
demonstrating increased incidence of tumours in immunodeficient animals compared 
with wildtype controls, and has been further supported by models lacking specific cellular 
or molecular immune components26,27. The elimination phase relies on appropriate 
recognition of early tumours through mechanisms which are not fully understood, but 
requires integration of signals from both the innate and adaptive arms of the immune 
system. The next phase is known as equilibrium, in which tumour growth is controlled, 
but not entirely eliminated by the immune system. This stable coexistence of tumour cells 
and immune cells relies on the adaptive immune response, and was first demonstrated in 
a fibrosarcoma model induced by the chemical carcinogen 3-methylcholanthrene (MCA). 
Deletion of CD4+ and CD8+ T cells approximately 200 days post-MCA injection induced 
stable tumours to grow progressively, indicating a constant underlying immune response 
that controls tumour growth without eradicating the tumour28. This active immune 
response towards the tumour can also promote emergence of antigen-loss tumour 
variants, thus providing selective pressure for tumours to evolve towards a less 
immunogenic phenotype29. A loss in adaptive control can lead to the last phase of escape, 
in which tumours can successfully evade immune detection and progressively develop 
into malignant and often metastatic disease. 
 
1.2.4 Mechanisms of immune evasion by tumours 
There are a number of mechanisms by which tumours can escape immune control; one 
major issue is lack of sufficient quantity or quality of antigen able to be recognised as 
foreign by CD8+ T cells, which is perhaps unsurprising given tumours arise from host 
cells. The frequency of predicted neoantigens is positively correlated with cytolytic gene 
signatures in a range of human tumour types30. However, even in tumours with strong 




epitopes which can be presented on class I or II MHC, and thus cannot be recognised by 
CD4+ or CD8+ T cells31,32. Another hindrance to effective recognition is the 
downregulation of MHC class I molecules on some tumour cells, preventing antigen 
presentation to CD8+ T cells33. However, this can be circumvented by NK cells as lack 
of engagement with MHC class I molecules induces their cytolytic activity. As eluded to 
above, lack of immunogenic antigen can also be a result of Darwinian selection from 
antigen-loss during an ongoing immune response, with variants that have lost this 
antigen, perhaps due to the inherent genomic instability of the tumour, able to become 
dominant and cause progressive outgrowth34. 
 
Another barrier to developing effective anti-tumour immunity is through sequestration of 
CD8+ T cells from the tumour parenchyma. A pioneering study by Naito and colleagues 
found that the presence of CD8+ T cells in the tumour bed was significantly associated 
with improved survival in human colorectal cancer, compared with CD8+ localisation in 
the stroma or at the parenchyma-stroma interface, and this has since been supported in a 
range of other cancers and tumour models15,35,36. The TME has been shown to selectively 
favour entry of immune cells such as MDSCs and Treg cells, whilst preventing CD8+ T 
cell entry37. The vascular endothelium of certain tumours can induce apoptosis in CD8+ 
T cells through high expression of FasL, whereas Treg cells are protected through higher 
endogenous expression of the anti-apoptotic protein c-FLIP. FasL expression on the 
vasculature can be induced by tumour-derived VEGF, PGE2 and IL-10, although these 
cytokines can also be expressed by infiltrating immunosuppressive immune cells38. 
Similarly, expression of the endothelin B receptor on tumour vasculature can prevent T 
cell adhesion to the endothelium, inhibiting T cell entry and correlating with poor patient 
prognoses39. Cancer-associated fibroblasts (CAFs) can also exclude T cell entry into the 
parenchyma, in part through deposition of extracellular matrix that acts as a physical 
barrier40. Furthermore, CAFs can produce the chemokine CXCL12 which binds to 
tumour cells and prevents T cell colocalisation, through an as yet undescribed 
mechanism41. 
 
In addition to T cell entry to the tumour being prevented, T cell effector function in 
tumour settings is often dampened. The expression of cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4) on T cells correlates with reduced anti-tumour activity, with CTLA-




outcompeting CD28 for binding to their mutual ligands CD80 and CD8642-44. 
Intracellular stores of CTLA-4 can accumulate at the immunological synapse in response 
to TCR stimulation and act to inhibit signalling and induce anergy45,46. Furthermore, cells 
expressing CTLA-4 can strip CD80/CD86 expression from cells in trans through trans-
endocytosis, resulting in degradation of these molecules and thus impaired 
costimulation7. 
 
PD-1 expression can also affect T cell effector function, and can be upregulated on CD8+ 
T cells after prolonged antigen stimulation. Although initially believed to inhibit TCR 
signalling, recent evidence indicates PD-1 ligation actually induces dephosphorylation of 
CD28, thus attenuating downstream signalling and hence CD8+ T cell function47,48. Both 
PD-L1 and PD-L2 act as ligands for PD-1, and can be expressed by cancer cells as well 
as infiltrating immune cells such as DCs and monocytes49-51. PD-L1 expression is also 
upregulated in response to IFN  produced by infiltrating CD4+ and CD8+ T cells, and 
thus acts as a homeostatic negative feedback loop to induce T cell exhaustion and 
diminished function in cells for which persistent antigen exists, presumably as a 
safeguard to prevent autoimmunity52,53. However, this mechanism can be exploited by 
tumour cells to avoid cytolytic destruction, with PD-1 expression correlating with poorer 
prognoses in many human cancers54,55. Furthermore, PD-L1 has also been shown to 
promote the differentiation and suppressive function of inducible Treg (iTreg) cells 
through dampening of the Akt-mTOR pathway56. In addition to PD-1, other markers of 
T cell exhaustion have been identified including TIM-3 and LAG-357,58. 
 
The TME itself can act as a potent site for T cell proliferation, with Batf3-dependent DCs 
capable of cross-presenting antigen to CD8+ T cells and inducing clonal expansion in 
situ21,59,60. However, production of indole 2,3-dioxygenase (IDO) by cancer cells, DCs 
and myeloid cells, which catabolises tryptophan to generate kynurenine, can inhibit this 
proliferation as well as promoting the generation of Treg cells61,62. The TME can also 
promote T cell apoptosis, with production of the pro-death molecules FasL, TRAIL and 
TNF  by infiltrating myeloid cells. Furthermore, accumulation of adenosine through 
breakdown of ATP by ectonucleotidases CD39 and CD73 can both promote tumour cell 





Given the multitude of different mechanisms mediating tumour escape from immune 
control, the lack of effective immune responses to tumours is perhaps not surprising. 
However, these mechanisms have provided potential targets for therapeutic treatment of 
cancers, through enhancing the immune system’s capability to target tumour cells. 
 
1.2.5 Immunotherapy 
For many years, the gold standards in cancer treatment have consisted of targeting the 
hyperproliferative nature of the tumour through non-specific destruction using 
chemotherapy or radiotherapy. However, as greater understanding of the role of the 
immune system in regulating cancer was gained, more specific targets have emerged, 
including several of the immune checkpoint inhibitors. The first of these drugs targeting 
immune control of tumours to be FDA-approved was ipilimumab (Bristol Myers Squibb), 
a monoclonal antibody targeting CTLA-4. Clinical trials in patients with previously 
treated advanced metastatic melanoma demonstrated increased survival in patients 
receiving anti-CTLA-4 plus a peptide vaccine or anti-CTLA-4 alone, compared with only 
the peptide vaccine66. Since then, pooled analysis of multiple clinical trials using 
ipilimumab in metastatic melanoma have demonstrated an overall three-year survival rate 
of 22% of all patients, after which survival curves plateau, indicating durable responses 
in these surviving patients67. 
 
It is proposed that anti-CTLA-4 treatment prevents CTLA-4 engagement with 
CD80/CD86, thus allowing CD28-mediated costimulation of effector T cells. Detailed 
analysis of TILs in mouse tumour models using mass cytometry showed that anti-CTLA-
4 treatment predominantly induces the expansion of ICOS+ Tbet+ PD-1+ TH1-like CD4, 
as well as distinct CD8+ populations68. However, there are also controversial reports 
regarding effects of anti-CTLA4 on the Treg compartment, which express increased 
levels of CTLA-4 compared with effector T cells69. Treg-specific deletion of CTLA-4 
reduces the suppressive capacity of these cells, resulting in impaired control of anti-
tumour T cell responses and hence reduced tumour growth8. Conversely, there is 
evidence that anti-CTLA-4 treatment expands the Treg compartment through an increase 
in proliferation70,71. More recently, it was reported that despite the expansion of Treg cells 
in the lymph nodes (LNs) in response to anti-CTLA-4 treatment, there is a selective 




This, coupled with anti-CTLA-4-induced expansion of effector T cells, resulted in an 
increased Teffector/Treg ratio, driving tumour rejection. Furthermore, optimal 
enhancement of effector T cell function is only seen when CTLA-4 is blocked in both the 
Treg and non-Treg populations, demonstrating CTLA-4 acts on both compartments to 
suppress T cell activity73. 
 
The success of anti-CTLA-4 treatment has encouraged clinical trials targeting other 
checkpoint inhibitors, with monoclonal antibodies targeting PD-1 (pembrolizumab, 
Merck; nivolumab, Bristol Myers Squibb) being approved for advanced melanoma in 
2014. Pembrolizumab treatment showed significantly increased overall survival rates at 
12 and 24 months compared with ipilimumab in metastatic melanoma, as well as reduced 
toxicities and adverse events74. Anti-PD-1 treatment has been shown to induce the 
expansion of PD-1+ TIM-3+ CD8+ T cell subsets specifically, leading to enhanced 
proliferation and cytokine production by these cells68. Antibodies targeting PD-L1 
(atezolizumab, Genentech) have also been recently approved for treatment of NSCLC 
and urothelial carcinoma after promising results in clinical trials75,76.  
 
Given that CTLA-4 and PD-1 work with distinct mechanisms to impair tumour-directed 
immune responses, it is perhaps not surprising that combination of anti-CTLA-4 and anti-
PD-1 treatments leads to increased patient survival77-79. In a phase III trial, combination 
of nivolumab and ipilimumab in previously untreated melanoma resulted in median 
progression-free survival of 11.5 months, compared with 6.9 months and 2.9 months for 
nivolumab or ipilimumab alone, respectively80. However, combination immunotherapy 
also leads to significant increases in toxicity, with significantly more patients 
experiencing adverse events when treated with both nivolumab and ipilimumab, 
compared with either therapy alone. 
 
Despite these remarkable advances, the percentage of patients with durable clinical 
responses is still limited, and large proportions of patients remain unresponsive to 
immunotherapy, or develop resistance. Studies comparing responsive and unresponsive 
patients have shed some light on factors that dictate whether anti-tumour responses will 
be induced in response to therapy. Mutational load is a significant prognostic factor for 
responsiveness to anti-PD-1 and anti-CTLA-4 therapy, with high mutational burden 




constituent of antigen presentation through MHC class I, are also significantly increased 
in metastatic melanoma patients non-responsive to anti-CTLA-4 or anti-PD-1 treatment 
and are correlated with lower survival, highlighting the importance of CD8+ T cell 
responses in these therapies83. Another major prognostic factor for anti-PD-1/PD-L1 
responsiveness is the extent of immune infiltration in the tumours prior to therapy. On 
this basis, tumours can be subdivided into three categories: an immune-inflamed 
phenotype, in which CD4+ and CD8+ T cells can be found within the tumour parenchyma; 
an immune-excluded tumour, in which T cells are found within the stroma surrounding 
the tumour but are physically separated from contact with tumour cells; and the immune-
desert tumour, which lack T cells within the entire TME14,75. Patients with an immune-
inflamed phenotype display the greatest proportion of clinical responses to anti-PD-1/PD-
L1 therapy, suggesting that T cell exhaustion is a major contributor to tumour escape in 
these patients84. However, not all patients with a parenchymal infiltrate are responsive, 
suggesting the existence of alternate mechanisms of immunosuppression. In patients with 
an immune-excluded phenotype, anti-PD-1 treatment can induce T cell activation and 
proliferation, however these T cells still cannot enter into the tumour parenchyma and so 
tumour regression is rare85. In these patients, therapies targeted at overcoming this 
exclusion and enhancing T cell migration are likely to be beneficial. Tumours that 
completely lack a T cell infiltrate may be a result of a paucity in priming, perhaps due to 
defective antigen presentation or lack of tumour antigen able to be recognised as foreign. 
In these scenarios, tumour vaccination strategies or adoptive transfer of ex vivo-expanded 
lymphocytes may be of interest therapeutically. 
 
1.3 Chemokine-mediated control of anti-tumour immune responses 
 
1.3.1 The chemokine system in the TME 
Tumour-directed immune responses, whether protumourigenic or antitumourigenic, rely 
on coordinated migration of immune cells into the TME and this is mediated to a large 
extent by the chemokines expressed within the tumour milieu. A prominent chemokine 
receptor mediating intratumoural recruitment of CD8+ T cells, TH1 cells and NK cells is 
CXCR3, which induces migration towards its ligands CXCL9 and CXCL1086. 
Expression of CXCR3 ligands is correlated with enhanced T cell infiltration and 




of CXCL10 stimulated CD8+ T cell infiltration and enhanced tumour regression91,92. 
Moreover, CXCR3 was essential for CD8+ T cell intratumoural migration in vivo, with 
loss of this receptor abrogating migration to the same extent as pertussis toxin 
pretreatment, an inhibitor of most chemokine signalling through G i protein blockade93. 
CXCL9 and CXCL10 can be secreted by tumour cells and infiltrating macrophages94. 
More recently, it was shown that the predominant source of CXCL9 and CXCL10 in 
tumours was CD103+ DCs, which were both sufficient and essential for intratumoural 
recruitment of adoptive transferred CD8+ T cells95. These CCR5+ DCs are recruited into 
the tumour through expression of CCL4 by transformed cells96. 
 
CCR5 and CCR2 have also been linked with intratumoural T cell accumulation and 
enhanced survival, suggesting potential redundancies in CD8+ T cell trafficking 
mechanisms97. Transgenic expression of CCL5, a ligand for CCR5, in xenografted 
tumours can overcome collagen-mediated exclusion of T cells in an ex vivo assay40. 
However, despite CCR5 and CCR2 being functional on CD8+ T cells and their ligands 
being expressed within the tumour parenchyma, deletion of these receptors had no effect 
on intratumoural homing or extravasation from blood vessels in B16-OVA bearing 
mice93. This may be due in part to post-translational modification of chemokines in the 
TME, as CCL2 can be nitrated in response to reactive nitrogen species produced by 
tumour cells. Nitrated-CCL2 can induce recruitment of myeloid cells such as MDSCs but 
not effector T cells, perhaps owing to the higher expression of CCR2 on myeloid cells, 
providing another means of immune evasion by tumour cells98. Indeed, recruitment of 
myeloid cells through CCL2 is a major contributor to immunosuppression, with 
neutralising antibodies or small molecule inhibitors to CCL2 showing anti-tumour 
activity in preclinical models of prostrate and breast cancer99,100. CCR2 is also used by 
Treg cells to traffic from draining LNs into mouse tumour models and CCR2+ Treg cells 
are enriched in human oral squamous cell carcinoma patients101. Moreover, Treg cells 
can also traffic through CXCR3, CCR4 and CCR10, thus showing diverse mechanisms 
of recruitment into different tumour types102-104. Other chemokine receptors have also 
been implicated in regulation of both tumour-directed immune responses as well as 
tumour cells themselves, and three receptors of key interest to this study are discussed 






CCR7 is a key facilitator of homeostatic immune trafficking, and binds to the chemokines 
CCL19 and CCL21. CCR7 is highly expressed by naïve and central memory T cells and 
allows their entry into LNs and Peyer’s patches (PP) through interaction with CCL21, 
which is constitutively expressed on the luminal surface of high endothelial venules 
(HEV), specialised vasculature controlling immune cell entry into these SLO105. Inside 
LNs, CCL19 and CCL21 are expressed by follicular reticular cells, which promotes naïve 
T cell motility and guides their ability to scan for cognate antigen presented by dendritic 
cells106,107. CCR7 is also essential for dendritic cell migration, with CCR7 upregulated 
concomitantly with DC maturation in response to antigen processing and required for 
homing to lymphatic vessels and subsequently LN entry108,109. CCR7 is also required for 
a number of other homeostatic functions of immune cells110.  
 
In tumour settings, the presence of CCR7-expressing T cells is associated with favourable 
prognosis in colorectal carcinoma and prostate cancer111,112. In mice, overexpression of 
CCL19 in a breast cancer cell line was shown to induce an immune response dependent 
on CD4+ T cells and NK cells, resulting in inhibition of tumour growth113. Similarly, 
intratumoural injection of CCL21 into two murine lung cancer models led to enhanced 
recruitment of CD8+ T cells and DCs and inhibition of tumour growth, with 40% of mice 
exhibiting complete tumour regression114. Enhanced CD8+ T cell responses and inhibited 
tumour growth were also identified in other murine cancer models in response to CCL21 
delivery115-117. Mechanistically in the L1C2 lung carcinoma model, the anti-tumour 
effects of CCL21 were partially dependent on IFN , CXCL9 and CXCL10, with 
neutralisation of these proteins reversing tumour inhibition118. Conversely, it has been 
reported that CCL21 can promote tumour growth in the B16 melanoma model, with 
overexpression of CCL21 inducing a tolerogenic environment and increasing infiltration 
of Treg cells, along with inducing development of lymphatic vessels reminiscent to that 
found in LNs119. In the same study, knockdown of CCL21 by B16 cells reduced tumour 
growth and was associated with enhanced infiltration of T cells and higher IFN  levels. 
The reasons for these conflicting reports on the role of CCL21 in tumours are unclear and 
require more research, but emphasise the importance of the TME context in dictating 





The CCR7 axis can also regulate tumour growth independently of its effects on the 
immune system. Activation of PI3K/Akt signalling downstream of CCR7 promotes 
survival of cancer cells in head and neck tumours120. CCR7 contributes to the 
maintenance of stem-like cells in breast cancer, with deletion of this receptor resulting in 
reduced tumour growth in the MMTV-PyMT transgenic model of breast cancer121. CCR7 
is also important for metastatic spread, with its expression on tumour cells promoting 
metastasis to regional LNs due to the high levels of CCL19 and CCL21 expressed in 
these sites122-125. CCR7 can promote lymphangiogenesis or the development of new 
lymphatic vessels, in part through induction of VEGF-C, which also helps to facilitate 
metastatic dissemination of tumour cells from the primary tumour126. Furthermore, 
signalling through CCR7 can inhibit anoikis or detachment-induced cell death, which can 
prevent metastatic spread127. Thus, the CCR7 axis has clear tumour-promoting roles but 
also predominantly promotes anti-tumourigenic immune responses, and the overarching 
balance of these effects in cancer is still not fully understood. 
 
1.3.3 CCR9 
CCR9 is expressed by a subset of T cells, plasmablasts and plasmacytoid dendritic cells 
(pDCs) and is essential for homing of these cells from the peripheral blood to the small 
intestine, the predominant site of expression of its ligand, CCL25128-130. Neutralisation or 
ablation of CCR9 on CD8+ T cells inhibited their ability to migrate to the small intestinal 
mucosa but did not affect migration to lung, liver or LNs131,132. Thus, CCR9 plays a 
pivotal role in controlling migration of leukocytes to the intestine, which is an essential 
form of immune surveillance needed to counteract potential threats posed by commensals 
and ingested pathogens. 
 
CCR9 has been reported to be overexpressed in many different cancer models133-135. 
CCR9-bearing tumour cells preferentially migrate to the intestine in mouse tumour 
models, and CCR9 was strongly expressed in human melanoma metastases found in the 
small intestine, but not in other locations136,137. It was recently shown that CCR9/CCL25 
interaction could promote survival of lung carcinoma cells by inhibiting apoptosis 
through activation of Akt signalling138. However, the functions of CCR9 in tumour 







The atypical chemokine receptor ACKR4 (formerly known as CCX-CKR, CCRL1) acts 
as a scavenging receptor for the ligands CCL19, CCL21, and CCL25 both in vitro and in 
vivo139,140. Upon ligand binding, ACKR4 rapidly internalises and subsequently degrades 
chemokines and thus acts to regulate the bioavailability of its ligands. ACKR4 is highly 
expressed by lymphatic endothelial cells (LECs) and cortical thymic epithelial cells but 
has been shown to be widely expressed in many tissues, including the heart, lungs and 
intestine141-144. ACKR4 has been shown to regulate many CCR7-dependent processes 
such as DC migration and T cell priming, likely through its scavenging of CCR7 ligands. 
ACKR4-deficient mice display reduced trafficking of DCs from skin to draining LNs at 
both steady state and in response to inflammation141. Further analysis showed that 
ACKR4 was specifically expressed by lymphatic endothelial cells (LECs)s on the ceiling 
of the subcapsular sinus of LNs, where it was required for establishment of a chemokine 
gradient across the sinus, thus promoting DC entry into the LN through the floor of the 
sinus144. Furthermore, ACKR4-deficient mice immunized with MOG35-55/CFA in a 
mouse model of multiple sclerosis showed enhanced CD4+ T cell priming in the spleen 
and a TH17-biased response, which correlated with earlier disease onset and enhanced 
disease severity140. 
 
In tumour settings, little is known about the function of ACKR4. In a breast cancer 
xenograft model, which thus lacks an intact adaptive immune system, overexpression of 
ACKR4 on human breast cancer cell lines reduced tumour growth and metastasis to the 
lung145. This was also accompanied by reduced proliferation and invasion capability in 
vitro, although the mechanism behind these phenotypes remains unclear. Furthermore, 
we have shown that overexpression of ACKR4 in an orthotopic mouse breast cancer 
model also reduced tumour growth in vivo but conversely enhanced spontaneous and 
haematogenous metastasis to the lung146. Interestingly, this was not correlated with 
altered abundance of chemokine ligands but instead was associated with enhanced 
epithelial-to-mesenchymal transition, potentially mediated through altered regulation of 
TGF- 1 as a result of transgenic expression of ACKR4 in these cell lines. In analyses of 
human breast and cervical cancer specimens, ACKR4 expression has been correlated 
with improved survival and reduced LN metastasis145,147,148. These correlations were 




polyclonal antibody against ACKR4, with one report showing that 50-70% of this 
staining was found in the cytoplasm147. Given that the known function of ACKR4 is to 
scavenge its chemokine ligands from extracellular spaces, the specificity of this antibody 
and the functional significance of cytoplasmic sources of ACKR4 is uncertain. A separate 
study found that ACKR4 expression in hepatocellular carcinoma was inversely correlated 
with tumour stage and overall survival149. Manipulation of ACKR4 expression in 
hepatocellular carcinoma cell lines showed that ACKR4  was inversely correlated with 
tumour growth in vivo in nude mice, as well as being inversely correlated with CCL19 
and CCL21 levels in the tumour, indicating a potential chemokine scavenging role in 
tumour settings. Furthermore, in vitro analysis indicated that when ACKR4 expression 
was reduced in these cell lines, there was greater Akt phosphorylation and nuclear 
accumulation of -catenin. 
 
While the above reports provide some evidence for a role of ACKR4 in cancer, the studies 
to date are very limited in number and the mechanism of action of this receptor in 
regulating tumour growth is unclear. Furthermore, only one mechanistic study was 
performed in mice with a fully-intact immune system, and this was studying the effect of 
overexpression of ACKR4 on cancer cells, with unaltered ACKR4 in the host146. Since 
ACKR4 that is endogenously expressed by the host is known to markedly influence 
immune responses at homeostasis as well as in non-tumour settings, it is highly likely 
that modulation of host ACKR4 would also impact on anti-tumour responses, however 
investigation of the role of host ACKR4 has not yet been reported to date. Thus, the role 
of ACKR4 in regulating tumour progression and mediating anti-tumour immune 
responses will be analysed in Chapter 3. 
 
1.4   Immune responses to infectious diseases 
 
1.4.1 Tailored immune responses to infectious pathogens 
Over the course of a lifetime, a human body will be exposed to a diverse array of 
infectious pathogens, including bacteria, viruses and fungi. Successful protective 
immunity to these pathogens requires coordination of elements of both the innate and 
adaptive immune response. Typically, a pathogen threat will be rapidly recognised by 




which recognise conserved features of pathogens, known as pathogen-associated 
molecular patterns (PAMPs), although danger-associated molecular patterns (DAMPs) 
and other disruptions to tissue homeostasis can also stimulate immunity150,151,152. This 
leads to DC maturation, where cells express high levels of MHC class II presenting 
antigen, and distinct cytokines depending on the PRR-induced signalling pathway 
engaged. Given that pathogens have a number of different modes of infection, there is a 
subsequent requirement for diversity in the immune response needed to eliminate the 
pathogen (Table 1.2). Infection with pathogens which are predominantly intracellular, 
including viruses such as influenza and some bacteria, induces a Type 1 response, with 
IFN  production by CD4+ T helper 1 (TH1) cells coordinating clearance of infected cells 
through cytolytic destruction by CD8+ T cells. Type 2 responses are generated towards 
macroscopic parasites as well as both toxic and inert compounds, including allergens. 
Removal of these insults involve tissue-wide changes, with TH2 cells, mast cells and 
eosinophils often required, along with mucus secretion and muscle contractility153. Type 
17 responses are induced in response to infection with extracellular pathogens, including 
bacteria such as Streptococcus pneumoniae and many fungi154,155. Production of 
cytokines such as IL-17A and IL-17F by TH17 cells drives recruitment of neutrophils 
which can phagocytose these pathogens, as well as inducing the release of anti-microbial 
compounds such as -defensins and S100 peptides156,157. Furthermore, in each of these 
responses, antibody production by B cells is tailored to the secretion of specific isotypes 
with the help of CD4+ T follicular helper (TFH) cells158. Other CD4+ T cells such as TH9 
and TH22 cells can also contribute to distinct facets of these responses. Thus, considerable 
diversity is required in the immune response in order to successfully eliminate infectious 
pathogens, with CD4+ TH cells playing key roles in coordinating these responses. 
 
1.4.2 Memory response to infectious pathogens 
A defining feature of the adaptive immune response is the ability to mount responses with 
enhanced quality and efficiency upon secondary exposure, known as memory. Following 
a primary infection, the large pools of effector T and B lymphocytes generated in the 
response contract, leaving behind a small population of memory lymphocytes159,160. 
These memory lymphocytes can reside at the site of the infection or in SLOs, or circulate 




differentiated lymphocytes can reactivate and expand more readily, leading to enhanced 
elimination of the pathogen and improved protection.  
 
Memory B cells can provide long-lasting protection against pathogens, with different 
subsets of memory B cells contributing different functions161. Long-lived plasma cells 
can secrete antibody constitutively, which may provide protection if the neutralising 
antibody is present at sufficiently high concentrations. Furthermore, reactivation of 
memory B cells in response to antigen allows more efficient production of isotype-
switched, high affinity antibody compared with that from naïve B cells. 
 
In response to viral and other intracellular pathogens, CD8+ T cell memory is critical for 
improved protection. In addition to mounting cell-mediated cytotoxicity with enhanced 
efficiency, populations of memory CD8+ T cells can also act as innate-like sensors of 
pathogens. IL-12 and IL-18, released in response to pathogen invasion, can stimulate 
these memory CD8+ T cells, leading to the release of IFN  in an antigen-independent 
manner162. Both of these functions of memory CD8+ T cells result in improved protection 
against infectious challenges, with pre-existing CD8+ T cells providing protection against 
otherwise lethal challenges163-165. 
 
CD4+ T cell memory is not as well understood as for CD8+ T cell memory, however pre-
existing memory CD4+ T cells are correlated with reduced viral load and improved 
protection in some models166-169. Memory CD4+ T cells specific for influenza infection 
promote production of inflammatory cytokines upon heterosubtypic infection with an 
independent influenza strain, which is associated with improved viral control170. 
Additionally, vaccination-induced protection against a mouse model of Herpes Simplex 
Virus (HSV)-2 infection was entirely dependent on viral-specific CD4+ T cells168. 
However, the mechanisms promoting generation and maintenance of memory CD4+ T 
cells are still mostly undefined. 
 
1.5   CD4+ T cells and their chemokine-mediated control 





Each TH subset is defined by their expression of distinct lineage-specific transcription 
factors, as well as the production of cytokines which shape the outcome of the immune 
response. The diversity of CD4+ T cells generated in response to a pathogen stems from 
the signals received during their priming in SLO. Depending on the affinity of the 
interaction, naïve T cells expressing a T cell receptor specific for an antigen-MHC class 
II complex expressed on a DC (signal 1) will reduce their motility and form prolonged 
interactions with the DC. Subsequently, costimulation by DC-expressed molecules such 
as CD80 and CD86 (signal 2) and cytokines to promote polarisation of the naïve T cell 
(signal 3) are also required for differentiation into an effector TH cell subset.  
 
Central to the role of CD4+ T cells in shaping the outcome of the immune response is 
their ability to migrate in a spatiotemporally controlled manner. The potentially large 
surface areas of the body exposed to antigen, combined with the rare clonal frequency of 
antigen-specific CD4+ T cells, necessitate this efficiency in migration. Precise control of 
cell migration ensures that CD4+ T cells encounter antigen when it is present, permits 
appropriate cross-talk with other immune cells, regulates homing to sites of peripheral 
inflammation, and is also critical for immune surveillance and memory maintenance. It 
is well recognised that the various functional states of CD4+ T cells (e.g. naïve, effector, 
memory) have profoundly distinct migratory patterns and that the effector subsets of 
CD4+ T cells that shape adaptive immune responses all have distinguishable and in some 
cases defining homing characteristics (Figure 1.3). The profiles of TH subsets relevant to 
this project are discussed in more detail below. 
 
1.5.1 TH1 cells 
TH1 cells promote cell-mediated immunity and are critical for protection against 
intracellular pathogens. They are also important for clearance of cancerous cells, but can 
contribute to pathology in cases of transplantation or autoimmunity. These roles are 
predominantly mediated through TH1 production of the cytokine IFN , as well as TNF  
and IL-2. IFN  is essential for control against numerous pathogens, through both direct 
effects on the pathogen itself as well as more broadly stimulating a concerted immune 
response by numerous cell types171. TH1 cell differentiation is first induced by TCR 
engagement in the presence of IFN  or type I IFNs, which leads to expression of the 




IL-12 then acts via STAT4 to further stimulate expression of T-bet, which drives IFN  
production to create a feed-forward loop which stabilises the TH1 differentiation program.  
 
TH1 cells can assist in many facets of type 1 immunity against infectious pathogens. A 
critical role for these cells is in promoting the priming and expansion of antiviral CD8+ 
T cells. In the absence of CD4+ T cells, CD8+ T cells fail to expand or persist as 
effectively in response to HSV or vaccinia virus, although robust type I IFN signalling 
bypasses this requirement for CD4+ help172,173. Furthermore, CD4+ T cells are critical for 
effective generation of CD8+ T cell memory in response to infections, in part through 
reducing susceptibility of CD8+ T cells to TRAIL-mediated apoptosis and through 
provision of CD40L174-177. TH1 cells are also critical for promoting formation of CD8+ 
tissue resident memory (TRM) cells, with CD4+-derived IFN  required for localisation of 
CD8+ T cells to the airways after influenza infection, where they receive signals 
promoting their retention and memory formation178. IFN  produced by TH1 cells can also 
induce class switching of B cells to produce IgG2a antibody, a potent neutralising 
antibody for viruses, although this role is largely fulfilled by the specialised TFH subset 
of CD4+ T cells158,179. 
 
The canonical chemokine receptor expressed by TH1 cells is CXCR3. The CXCR3 axis 
is a prototypical inflammatory axis, with CXCR3 absent on naïve T cells and the ligands 
CXCL9 and CXCL10 (and CXCL11 in humans) only induced upon exposure of cells to 
inflammatory stimuli180. These ligands can be produced by a broad range of cell types, 
with fibroblasts, leukocytes and keratinocytes all reported sources of expression. CXCR3 
is essential for the peripheral localisation of TH1 cells in a multitude of diseases, with 
deletion of CXCR3 broadly inhibiting TH1 migration in infections, autoimmune diseases 
and many cancers181.  Furthermore, the CXCR3 axis is important for amplifying the 
effector response, with IFN  inducing the expression of the CXCR3 ligands, which in 
turn recruits in more TH1 cells and CD8+ T cells expressing IFN 181. Indeed, in HSV 
infection, CD4+ T cells are essential for CD8+ migration to the vaginal mucosa and TH1-
derived IFN  is critically required for this182. TH1 cells at the infection site produce IFN  
which upregulates expression of CXCL9 and CXCL10 by local epithelial cells, thereby 





Another chemokine receptor classically associated with TH1 cells is CCR5, which binds 
to CCL3, CCL4 and CCL5. CCR5 is also used by effector TH1 cells to migrate to 
peripheral sites to exert their function183-185. CCR5 expression on OT-II cells, which 
express a transgenic TCR specific for the ovalbumin peptide OVA323-339, is also required 
for optimal upregulation of CD40L on DCs and hence development of IFN + CD8+ cells, 
thus pointing to a role for CCR5 in promoting cross-presentation by DCs to induce CTL 
responses184.  
 
Although CXCR3 and CCR5 are often coexpressed by TH1 cells, they do not appear to 
have redundant functions. In chronic hepatitis C infection, CCR5 ligands are expressed 
in vessels within the portal triad, whereas CXCR3 ligands are expressed on the sinusoidal 
epithelium, suggesting these receptors may instead control different aspects of TH1 
trafficking186. Furthermore, during malarial infection with blood-stage Plasmodium 
yoelii, CXCR3 was equivalently expressed in TH1 cells that were IL-10+ or IL-10–, 
however CCR5 was preferentially expressed on IL-10+ TH1 cells187.  
 
1.5.2 TH17 cells 
TH17 cells were first described in 2005 as a lineage independent to TH1 and TH2, that 
were capable of producing the proinflammatory cytokines, IL-17A and IL-17F188,189. 
These cells are characterised by their expression of the master transcription factor, 
retinoic acid receptor-related orphan receptor- t (ROR t) and have since been described 
to secrete a diverse repertoire of cytokines, including IFN , GM-CSF, IL-10 and IL-22190. 
TH17 cells are critical for host defence against extracellular microorganisms and this 
protective role against both bacterial and fungal pathogens is primarily mediated through 
IL-17A and IL-17F, which bind to the heterodimeric IL-17 receptor, composed of IL-
17RA in complex with IL-17RC191. IL-17 can induce expression of a number of proteins 
with antimicrobial roles, including CXCL1 and CXCL2, which can induce the 
recruitment of neutrophils to phagocytose microbes192.  
 
The characteristic chemokine receptor expressed by TH17 cells is CCR6, which binds to 
the sole known chemokine ligand, CCL20. CCL20 can be upregulated in response to 
various inflammatory signals, but is also expressed under resting conditions in a diverse 




through CCR6193,194. Expression of CCR6 appears to be tightly coupled to the initial TH17 
differentiation program, as forced expression of ROR t in naïve T cells is sufficient to 
upregulate CCR6 and in mice with transgenic expression of ROR t and GFP under the 
CD4 promoter, the vast majority of GFP+ IL-17+ cells were also CCR6+ 195,196.  
 
TH17 cells are highly enriched in the intestinal tract, which given the abundance of 
microbes at this site, is in accordance with the demonstrated role of TH17 cells in 
protection against extracellular bacterial infection. CCR6 has been strongly implicated in 
TH17 cell recruitment to the intestine and as a consequence is suggested to be a driver of 
intestinal inflammation. CCL20 is abundantly expressed in the subepithelial dome of PP, 
as well as in isolated lymphoid follicles. Accordingly, transferred Ccr6–/– TH17 cells 
displayed impaired migration to PP, the small intestinal lamina propria and the peritoneal 
cavity195. Aside from CCR6, other chemokine receptors may contribute to intestinal 
homing of TH17 cells. TH17 cells from the large intestine have been shown to express 
CCR4 and CXCR5 and, although it is not clear if these are functional in mouse TH17 
cells, CCR4 is also expressed on human memory TH17 cells195,197. CCR9 is also enriched 
in TH17 cells in the small intestine, and along with 4 7 can be induced on in vitro-
generated TH17 cells by addition of retinoic acid (RA)198. RA-induced TH17 cells use 
these receptors to migrate to the small intestinal lamina propria, where epithelial cells 
produce the CCR9 ligand, CCL25.  
 
TH17 cells are also critical for controlling bacterial infection at other peripheral sites, 
particularly at other mucosal barrier sites such as the lung. Intranasal challenge with an 
array of extracellular bacteria including Klebsiella pneumoniae and Streptococcus 
pneumoniae induces TH17 cells, with IL-17 being a key mediator of bacterial clearance 
through induction of a neutrophilic response155,199,200. Similarly, fungal pulmonary 
infections such as with Aspergillus fumigatus or Pneumocystic carinii also induce potent 
TH17 responses. The trafficking receptors used by TH17 cells for migration to the lung 
are not well understood, although given that CCL20 is upregulated in response to 
pulmonary infection, it is likely that CCR6 plays a role here as well201. This is supported 
by studies of human TH17 cells, in which TH17 memory subsets with a CCR6+CCR4+ 




aureus. However, functional evidence identifying chemokine receptors involved in TH17 
homing to the lung is currently lacking. 
 
It is now clear that a spectrum of cellular phenotypes exist within the TH17 subset with 
differing capacities to promote inflammation. Populations of TH17 cells can co-express 
the anti-inflammatory cytokine IL-10 in addition to IL-17, with these cells having a less 
pathogenic profile and generated in response to mild insults and transient infection202. 
Conversely, TH17 cells can co-express proinflammatory cytokines such as IFN  and GM-
CSF, with these being termed pathogenic TH17 cells and being main contributors to 
autoimmune-associated pathology203. Furthermore, TH17 cells can lose IL-17 expression 
completely and become exTH17 cells. Pioneering work by the Stockinger laboratory used 
an IL-17 fate-mapper mouse that permanently marks cells and their progeny with eYFP 
if IL-17A is expressed. This showed a sequential change in cytokine production by 
differentiated TH17 cells in experimental autoimmune encephalomyelitis (EAE) that 
transitions from IL-17+ IFN – to IL-17+ IFN + and then to a IL-17– IFN + profile 204. Loss 
of IL-17 expression by TH17 cells in EAE was concomitant with downregulation of 
CCR6 and CCR6– eYFP+ cells had substantially higher levels of Ifng mRNA than CCR6+ 
eYFP+ cells, suggesting pathogenic TH17 cells may not use CCR6 for their trafficking. 
Indeed, we have recently demonstrated that there is a temporal switch in TH17 trafficking 
programs during EAE, with CCR6 only required for migration of TH17 cells during the 
initial stages of pathogenesis205. As disease progresses, CCR2-expressing TH17 cells 
emerge from the SLO, with this being the critical migratory receptor for homing of 
encephalitogenic TH17 to the CNS. Furthermore, production of the pathogenic cytokines 
GM-CSF and IFN  by TH17 cells primarily emanated from cells with a CCR6–CCR2+ 
phenotype. Expression of CCR2 by TH17 cells does not appear to be limited to 
autoimmune disease, as TH17 cells generated in response to chronic S. pneumoniae 
nasopharyngeal infection displayed similar temporal upregulation of CCR2, with CCR6–
CCR2+ cells again being the predominant source of GM-CSF and IFN . Whether CCR2 
is important for TH17 trafficking in situations of transient infection remains to be 
determined. 
 




Upon antigen clearance, CD4+ effector T cells rapidly contract, with approximately 90% 
of cells dying within 1-2 weeks. However, memory CD4+ T cells persist long-term and 
are critical for the rapid response to subsequent antigen encounter. The precise 
mechanisms by which CD4+ memory T cells develop and function is still not well 
described, however significant advances to improve our understanding have been made 
in recent years. CD4+ memory T cells are a heterogenous population and have been 
divided into at least 3 categories based on their migratory patterns. The first division of 
function of memory T cells was first described by Sallusto and colleagues in 1999 on the 
basis of CCR7 expression206. Central memory (TCM) cells are defined as CCR7+ CD62Lhi 
CD4+ T cells that preferentially produce IL-2 upon restimulation and cross HEVs to 
recirculate from blood through SLOs (Figure 1.4)207. Conversely, effector memory (TEM) 
cells were described as CCR7–CD62Llo and migrate to inflamed peripheral tissues for 
immunosurveillance and enter LNs via afferent lymph. Upon antigen engagement, these 
cells preferentially produce effector cytokines such as IFN  and IL-4. More recently, 
CD11ahi CD69+ resident memory (TRM) that permanently reside in previously-infected 
peripheral tissues and are restricted from accessing the circulation were described, with 
these cells being critical for protective immunity upon rechallenge at the site of the 
primary infection208,209. These subsets of CD4+ T cells, and the chemokine receptors that 
control their functions, will be described here. 
 
1.5.3.1 TCM 
TCM cells are mainly restricted to recirculating through the blood and lymphoid organs, 
where they rely on Ag-presenting APCs in SLOs for their reactivation. Because of this, 
TCM cells are the slowest of the memory cell subsets to respond to antigen and take days 
to expand. However, TCM cells have a unique role in that they produce high levels of IL-
2 and display enhanced proliferative capacity, giving rise to multiple effector subsets that 
can then emigrate from SLO to traffic to peripheral sites. The expression of CCR7 by 
TCM is critical for this recirculation, and along with CD62L expression allows trafficking 
patterns akin to naïve T cells.  
 
TCM can also express CXCR5, with Ag-specific CD4+ TCM cells (CCR7+CD62Lhi) at 60 
days post infection with L. monocytogenes displaying a characteristic CXCR5+ T-betlo 




efficiently produced IL-2 but secreted less IFN  than TEM, supporting their status as TCM 
cells. Perhaps surprisingly given their expression of CXCR5, these cells were excluded 
from follicles and localised to the paracortex upon adoptive transfer, which suggests that 
other migratory cues, possibly including CCR7, confine them to T cell areas. However, 
CXCR5+ TFH cells can also persist into memory in the absence of continued antigen, 
where they drive enhanced secondary responses and can provide more efficient B cell 
help than TFH cells in the primary response211,212.  
 
Other chemokine receptors have also been reported to be expressed by human CD4+ TCM 
cells and correlate to the differentiation capability of those TCM cells, suggesting reduced 
multipotency and perhaps partial differentiation213. CXCR3+ TCM cells secrete low levels 
of IFN  and were able to generate fully differentiated TH1 cells in vitro, while CCR4+ 
TCM cells secreted low levels of IL-4 but not IL-5 and gave rise to TH2 cells. In contrast, 
CXCR5+ TCM that were CXCR3– and CCR4– were not polarised and relied on exogenous 
cytokines to divert them to a TH1 or TH2 phenotype. Evidently, there is much to learn 
about the further classification of diversity within TCM cells based on their chemokine 
receptor expression. Furthermore, the precise role of these chemokine receptors in 
guiding TCM cells to specific SLO niches supportive of their function is also largely 
unexplored. 
 
1.5.3.2 TEM  
Under steady state conditions, TEM circulate through the blood and peripheral tissues. 
CD4+ TEM are generally thought to be excluded from entering HEV due to low expression 
of CCR7 and CD62L, but can migrate into reactive LN through CD62P where they can 
enhance naïve T cell priming through provision of CD40L to DCs214. Due to their 
efficient expression of effector cytokines, TEM provide an earlier response to secondary 
infections than TCM and can be recruited to the site of infection to respond within hours 
to days. TEM are thought to arise from T effector cells that have survived the contraction 
phase, although it is not clear at which point memory fate determination is conferred. 
Certainly, the markers used to define CD8+ memory precursors such as CD127 and 
KLRG1 do not apply to CD4+ memory215. It is also not clear if all TH subsets equally 
form memory, with most reports describing TH1-like memory cells, although TH2 and 





Very little is known about the migration patterns and cues used by CD4+ TEM to migrate 
through the periphery. However, it is clear there are substantial differences compared to 
memory CD8+ T cells. For example, in skin following cutaneous HSV infection, CD4+ 
memory T cells are confined to the dermis, while CD8+ memory T cells populate the 
epidermis208. Similarly, intravaginal HSV infection permits localisation of memory CD4+ 
T cells to the lamina propria and memory CD8+ T cells to the epithelium of the genital 
tract. In HSV infection, memory CD4+ T cell trafficking to the skin is transient and these 
cells exit the tissue and recirculate. Chemokine receptor expression on TEM has been 
reported. In response to EAE immunisation, memory CD4+ T cells express higher levels 
of CXCR3 and CCR5 than effector T cells217. Transfer of these TEM into Tcr –/– mice 
given EAE induced greater disease severity than transfer of effector T cells, which was 
associated with enhanced trafficking to the CNS, suggesting TEM migration was mediated 
through these axes.  We have recently shown that IL-17-producing CD4+ memory cells 
are present in the lung after S. pneumoniae infection and these cells express high levels 
of both CCR6 and CCR2, with the proportion of CCR2+ CCR6– TH17 cells preferentially 
increasing upon rechallenge205. Furthermore, TEM from human PBMCs have also been 
reported to express CCR10, CCR5, CXCR3, CCR6 and CCR4, suggesting diverse 
trafficking within the TEM population that may follow similar classification to TH cells218. 
This was partially supported by analysis of TEM from human cord blood, in which 
CXCR3+ TEM cells preferentially produced IFN , and CCR6+ TEM cells displayed a 
transcriptional profile biased to a TH17 phenotype, although they could not robustly 
secrete IL-17219. Taken together, it is clear that the signals controlling tissue niche 
occupancy and recirculation for memory CD4+ T cells are not well understood and there 




TRM are the most recently discovered subset of memory cells with parabiosis experiments 
first definitively revealing CD8+ TRM in 2009 and CD4+ TRM in 2011208,209. The essential 
defining property of these cells is that they are resident in peripheral tissues and do not 
recirculate through the blood or lymph, although the factors promoting their residence 




responses upon reencounter of antigen and due to their peripheral location can have the 
shortest response time of all memory subsets. CD4+ TRM generated in response to L. 
major infection in the skin are essential for optimal protection against secondary parasite 
challenge as they enhance recruitment of circulating memory cells through production of 
CXCL9 and CXCL10220. A recent study also demonstrated that CD4+ TRM resident in the 
spinal cord and dorsal root ganglia (DRG) in response to HSV-2 infection facilitate 
protection through production of IFN  which enhances vascular permeability thus 
allowing access of antiviral antibodies to the brain169. Again, CD4+ TRM are much less 
well described than their CD8+ counterparts, although they generally express a CD44hi 
CD62Llo CD11ahi CD69+ phenotype168,209,221. In contrast to CD8+ TRM, CD103 is not 
considered a marker of CD4+ TRM in neither mice nor humans 222-225. 
 
CD4+ TRM generated in the genital tract in response to intravaginal HSV-2 immunisation 
do not express CCR7, in support of their restriction from entering lymphatic 
circulation168. However, chemokine signalling is required to maintain their residency in 
the vaginal parenchyma, as treatment with pertussis toxin results in expulsion into the 
lumen. Furthermore, neutralisation of CCL5 reduces the numbers of TRM in the vagina 
and accordingly reduces the protection observed in the presence of these cells. TRM in 
this model express the CCL5 receptors CCR1 and CCR5 as well as CXCR3, although 
neutralisation of the CXCR3 ligand CXCL9 does not affect CD4+ TRM residency. CD4+ 
TRM are also generated in the spinal cord and dorsal root ganglia (DRG) in response to 
HSV-1 infection, with the ligands for CXCR3, CCR5 and CCR2 expressed in DRG169. 




CCR2 is defined as an inflammatory chemokine receptor, with its ligands generally being 
absent at homeostasis but induced upon inflammation226. CCR2 binds to the ligands 
CCL2, CCL7, CCL8 (in humans), CCL12 (in mice), CCL13 and CCL16 (in humans). 
CCR2 is known mostly for its roles in guiding monocyte trafficking in response to 
infection and is used to subclassify monocytes, with high expression of CCR2 found on 
inflammatory monocytes and low CCR2 expression on resident monocytes227. 




with Ccr2–/– mice displaying reduced monocyte frequencies in the blood but enhanced 
levels in the bone marrow228. Furthermore, CCR2 is used by monocytes to migrate into 
inflamed tissues in infection and autoimmune models, with loss of CCR2 in infection 
models resulting in impaired pathogen control229-233. 
 
On T cells, CCR2 has been reported to be expressed within subpopulations of Treg cells, 
with this axis being required for their migration into tumours and arthritic joints101,234. In 
an islet allograft model, CCR2 was expressed on Treg cells and used for their migration 
between the allograft and the draining lymph nodes, with loss of CCR2 resulting in 
impaired migration and suboptimal suppression235. As mentioned earlier, CCR2 has also 
been shown to be induced on TH17 cells in EAE, with this receptor being critical for 
migration of the pathogenic GM-CSF-secreting TH17 subset into the CNS205. Indeed, T 
cell-intrinsic loss of CCR2 reduced disease severity, highlighting the importance of this 
axis in mediating disease. CCR2 was also shown to be expressed on IL-17-secreting cells 
in the lung during persistent infection with S. pneumoniae, although whether this receptor 
was required functionally for TH17 cells in infection was not determined205. Expression 
of CCR2 on other T cell subsets has been reported, although the functional significance 
of this receptor remains unclear236,237. 
 
1.6 The research project 
The ability of immune cells to migrate to peripheral sites as well as within distinct 
lymphoid niches is critical for execution of their effector functions. The chemokine 
system plays a critical role in this migration, with spatiotemporal regulation of chemokine 
receptor expression allowing exquisite specificity and control. However, many open 
questions remain about how expression of certain chemokine receptors affects overall 
immune function. 
 
1.6.1 ACKR4 in solid tumours 
Recently approved immunotherapies have emphasised the potency of the immune 
system’s ability to eradicate tumours, but many patients remain unresponsive or develop 
resistance to current drugs and novel targets are needed to improve efficacy. The 
CCR7/CCL19/CCL21 axis is critical for many homeostatic functions of the immune 




CCR7 and CCR9 axes have also been implicated to have pro-tumourigenic tumour-
intrinsic functions. ACKR4, an atypical chemokine receptor, regulates the bioavailability 
of the ligands of CCR7 and CCR9, and has been shown to influence multiple CCR7-
mediated processes. However, the function of ACKR4 in tumour settings is largely 
unstudied, particularly regarding how it may influence the immune response to cancer. 
This has led to the following hypothesis, tested in Chapter 3: 
 
Hypothesis: ACKR4 regulates the immune response to solid tumours. 
 
This will be addressed with the following aims: 
Aim 1.1: To investigate the effect of ACKR4 deletion in solid tumour models. 
Aim 1.2: To investigate if ACKR4 influences the immune response to solid tumours. 
 
1.6.2 CCR2 in CD4+ T cells 
Memory CD4+ T cells are critical for protection in a number of infectious models as well 
as correlating with protection in human disease. However, relatively little is known about 
the establishment and maintenance of memory CD4+ T cells. Furthermore, the migratory 
cues that guide memory CD4+ T cells to and within effector sites are not well understood. 
Previous work from our laboratory has identified CCR2 as being enriched on TH17 cells 
at memory timepoints after S. pneumoniae infection, although its function on these cells 
is unknown. Additionally, CCR2 has been reported to be expressed on other CD4+ T cell 
subsets but it is unclear if it contributes to their migration and function in inflammatory 
sites. This has led to the following hypothesis, tested in Chapter 4: 
 
Hypothesis:  CCR2 regulates migration of memory CD4+ T cells in infection. 
 
This will be addressed with the following aims: 
Aim 2.1: To determine the spatiotemporal expression of CCR2 on TH17 cells in response 
to S. pneumoniae infection. 
Aim 2.2: To determine the function of CCR2 on TH17 cells in S. pneumoniae infection. 








Figure 1.1: Hallmarks of cancer. 
In order for an aberrant cellular mass to successfully form a malignant tumour, it must 
acquire certain characteristics. Although these functional characteristics are common 
amongst multiple distinct tumour types, the mutations and mechanisms by which they 
are gained are diverse. The uncontrolled proliferation that defines tumour cells is 
accompanied by dysregulation of growth suppressors, cell cycle checkpoints, and cell 
death pathways. This proliferative cell mass requires high energy input, with 
dysregulation of metabolic pathways and an enhanced reliance on glycolysis, as well as 
induction of new blood vessels to support the growing mass. Successful tumours are also 
able to evade immune-mediated killing, either through exclusion of cytotoxic cells from 
the tumour microenvironment or through recruitment of tolerogenic cells. Furthermore, 
the inflammation generated in response to tumours can also support tumour progression 
through induction of growth factors and enhancing mutagenesis. Lastly, tumour cells can 
acquire metastatic capability and migrate to secondary sites, where they may successfully 
















Figure 1.2: Cancer immunoediting. 
The cancer immunoediting hypothesis consists of three phases of tumour cell–immune 
cell interactions. The elimination phase is when tumour cells are recognised and 
destroyed by a range of innate and adaptive lymphocytes, leading to host protection. In 
the equilibrium phase, an ongoing immune response is able to control but not completely 
eliminate the tumour.  In the escape phase, tumours are able to overcome immune-
mediated control and progress into malignant and in some cases metastatic tumours. In 
all cases, the presence of a tumour-directed immune response exerts a selective pressure, 
favouring the emergence of tumour antigen-loss variants that may arise as a result of 









Figure 1.3: CD4+ T cell subsets are distinguished by distinct chemokine receptor 
expression and differentiation cues. 
Upon cognate interactions with peptide:MHC II complexes presented by DCs, priming 
of naïve CD4+ T cells is influenced by the local cytokine milieu. This leads to expression 
of distinct transcription factors that can induce subset-specific transcriptional profiles, 
which encompass expression of effector cytokines as well as chemokine receptors that 
are tailored to enable optimal responses to the initial antigen. The key subsets of TH cells 
that have been described are shown, along with the cytokines and transcription factors 
that drive/maintain their development (black text); characteristic cytokines that they 












Figure 1.4: Trafficking of CD4+ T memory cells. 
Long-lived CD4+ memory T cells are classified into three subsets based on their 
patterns of recirculation. TCM cells are mainly found in the blood and SLO, with 
expression of CCR7 and CD62L enabling their migration into SLO through HEVs. TEM 
recirculate through peripheral tissues and can reenter LNs through the afferent lymph. 
TRM permanently reside in peripheral tissues after infection and are restricted from 
reentering the circulation. The ontogeny of the different memory subsets is still unclear 
and markers of memory precursors in the effector phase of the response has not yet 
been reported, unlike that of CD8+ T cells. At which stage memory fate is conferred 
remains to be determined. Chemokine receptor alterations between these memory 
subsets are depicted. Arrows indicate differentiation/transdifferentiation of T cell 

























Chapter 2 – Materials and Methods 
 
2.1 Mice 
C57Bl/6J and B6.SJL Ptprca (Ly5.1) mice were purchased from the Animal Resource 
Centre (Western Australia), bred at the University of Adelaide animal house or bred at 
QIMR Berghofer animal house (Queensland). OT-I mice were purchased from the Walter 
and Eliza Hall Institute (Victoria). Ccr2–/–, OT-II, MMTV-PyMT and Ackr4–/– mice were 
sourced from Prof. Christian Engwerda (QIMR Berghofer), Dr Kerrilyn Diener 
(University of Adelaide), Dr Marina Kochetkova (University of Adelaide) and Prof. Rob 
Nibbs (University of Glasgow), respectively, with these mice bred at the University of 
Adelaide animal house. In addition, Ackr4–/– mice were bred at QIMR Berghofer animal 
house. Ccr2–/– OT-II mice were generated by crossing Ccr2–/– mice to OT-II mice, and 
were bred at the University of Adelaide animal house. OT-II x Ly5.1 mice were generated 
by crossing OT-II mice to Ly5.1 mice, and were bred at the University of Adelaide animal 
house. OT-I x Ly5.1 mice were generated by crossing OT-I mice to Ly5.1 mice, and were 
bred at the University of Adelaide animal house. MMTV-PyMT x Ackr4–/– mice were 
generated by crossing MMTV-PyMT males to Ackr4–/– females, and were bred at the 
University of Adelaide animal house. Mice were housed under specific pathogen-free 
conditions. Experiments used age-matched and gender-matched mice between 6 and 15 
weeks of age. Mice were humanely euthanized by CO2 asphyxiation. All experiments 
were conducted with the approval of the University of Adelaide Animal Ethics 
Committee or QIMR Animal Ethics Committee. 
 
2.2 In vivo techniques 
2.2.1 Primary tumour growth 
Cell lines were harvested, washed twice and resuspended in PBS. Cells were kept on ice 
until injection. C57Bl/6J mice were anaesthetised by isofluorane (Henry Schein Animal 
Health) inhalation and 10-20 l was injected into the fourth mammary gland (E0771) or 
subcutaneously in the ventral flank (B16F10, MC38) using a 50 l glass syringe 
(Hamilton Company, NV, USA). Tumour sizes were measured every 2 days from day 7 
using digital callipers (Mitutoyo, Japan), with tumour size calculated as the multiple of 




tumour diameter exceeded 15mm or tumours became ulcerated. For antibody treatments, 
mice were injected intraperitoneally with antibodies listed in Table 2.3. 
 
2.2.2 Haematogenous metastasis 
Cell lines were harvested, washed twice and resuspended in PBS. Cells were kept on ice 
until injection. C57Bl/6J mice were restrained and injected with 100-200 l of cells into 
the tail vein. Mice were monitored for signs of distress and weight loss, and lung 
metastases visually counted with use of a dissection microscope. These experiments were 
performed by Prof. Mark Smyth. 
 
2.2.3 MCA induction 
Male C57Bl/6J mice were injected subcutaneously in the hind flank with the indicated 
dose of 3-methylcholanthrene (MCA) dissolved in 100 l of sterile corn oil. Mice were 
monitored for the development of fibrosarcoma for over 200 days. These experiments 
were performed by Prof. Mark Smyth. 
 
2.2.4 CCL21 administration 
Female C57Bl/6J mice were injected into contralateral sides of the fourth mammary 
gland with 105 E0771 cells. Beginning on day 7, mice were anesthetised and tumours 
were injected every 2 days. The left hand side tumour was injected with 3 g CCL21 or 
MCPala 241,242, with the right hand side tumour injected with PBS.  
 
2.2.5 Adoptive transfers 
Splenocytes and inguinal LN were harvested from naïve congenic OT-I or OT-II mice. 
For naïve OT-I transfers, the percentage of naïve CD8+ T cells in single cell suspensions 
was determined by flow cytometry and 5x106 unpurified naïve CD8+ T cells were 
transferred. For naïve OT-II cell transfers, CD4+ T cells were purified using EasySepTM 
Mouse Naïve CD4+ T cell Isolation Kit (Stem Cell Technologies) as per the 
manufacturer’s instructions. Purity was determined to be at least 85% pure by flow 
cytometry prior to transfer, with the number of cells transferred indicated in text. Mice 
were placed under a heat lamp, restrained and injected with 100-200 l of cell suspension 





2.2.6 Intravascular labelling 
3 g of fluorescently labelled antibody was diluted in sterile PBS (Table 2.3). Mice were 
placed under a heat lamp, restrained and 200 l of diluted antibody injected into the tail 
vein. Mice were culled by CO2 asphyxiation 5 min after injection.  
 
2.2.7 Streptococcus pneumoniae infection  
D39 stocks were concentrated to 3.33x108 cfu/ml by centrifugation at 13,000rpm for 5 
min. Female C57Bl6/J mice were anesthetised with pentobarbitone (Ilium) and 30 l of 
bacteria was administered intranasally. Mice were allowed to recover on a 37°C heatpad. 
Mice were monitored every 4 hours for the first 72 hours, and subsequently once daily 
for signs of distress, and culled according to ethical guidelines. To measure bacterial load, 
the nasal wash and lung were collected as described (Sections 2.3.4, 2.3.6). Nasal tissue 
was harvested by cutting the upper palate from nose to below the eye, removing the nose 
and skin. Lung and nasal tissue were homogenised in 1ml PBS in a ceramic bead tube on 
a Precellys 24 homogeniser (Bertin Technologies). Lysates and nasal wash were 
subsequently serially diluted in serum broth, plated in duplicate on blood agar plus 
gentamycin and incubated for at least 16 hours at 37°C, 5% CO2. Some experiments 
performed in collaboration with Dr. Richard Harvey. 
 
2.2.8 Influenza infection 
Influenza viral stocks were diluted in sterile PBS to 313 TCID50/ml (X31-OVA323-339; 
PR/8-OVA323-339) or 228 TCID50/ml (X31). Female C57Bl6/J mice were anesthetised 
with pentobarbitone (Ilium) and 32 l of virus was administered intranasally. Mice were 
allowed to recover on a 37°C heat pad and given wet food and soft bedding. Mice were 
weighed daily and monitored for signs of distress, with mice culled if weight loss 
exceeded 20% of their original weight.  
 
2.2.9 Bone marrow chimeras 
Ly5.1 mice were lethally irradiated with 1000 Rads. The next morning, bone marrow was 
isolated from the femur and tibia of 8-16 week old donor mice of the indicated genotypes 
and red blood cells were lysed with sterile MRCLB (Section 2.7.2). 4-5x106 total bone 
marrow cells were injected into the tail vein of irradiated mice and allowed to reconstitute 




the acute phase of reconstitution. Irradiation was performed in collaboration with Dr. 
Josef Nguyen. 
 
2.3 Cell isolation 
2.3.1 Lymphoid organs 
Spleens were prepared by mechanical disruption through a 70 m filter (BD Biosciences), 
incubated in MRCLB for 5 min at 37°C and washed in PBS. Inguinal and mediastinal 
LN were digested for 15 min in 200 l digestion medium (Section 2.7.3) at 37°C, passed 
through a 70 m filter (BD Biosciences) and washed in PBS. All cells were centrifuged 
at 300 x g for 4-10 min. 
 
2.3.2 Tumours 
Tumours were excised, manually minced into small pieces and incubated in digestion 
medium for 40-120 min at 37°C, with mixing every 20 min. Tumour homogenates were 
passed through a 70 m filter (BD Biosciences), washed in PBS, incubated in MRCLB 
for 5 min at 37°C and washed again in PBS.  
 
2.3.3 Mammary glands 
The fourth (inguinal) pair of mammary glands were manually minced into small pieces 
and digested in mammary gland digestion medium (Section 2.7.4) for 3.5 hr at 37°C with 
agitation. Suspensions were then washed in DMEM, resuspended in a solution of 6U/ml 
Dispase II (Sigma-Aldrich) and 300U/ml DNase I (Sigma-Aldrich) and incubated for 15 
min at 37°C. After vigorous pipetting, cells were washed with DMEM supplemented with 
2% FBS, incubated in MRCLB for 5 min at 37°C and washed again in PBS. 
 
2.3.4 Lungs 
Immediately following asphyxiation, the chest cavity was opened and mice were perfused 
with PBS through the left ventricle. Lung lobes were harvested, manually minced into 
small pieces and incubated in digestion medium for 40-60 min at 37°C, with mixing every 
20 min. Lung homogenates were passed through a 70 m filter (BD Biosciences), washed 






2.3.5 Peripheral blood 
Immediately following asphyxiation, the chest cavity was opened through the ribs 
without cutting into the peritoneum. The right ventricle was cut and blood was collected 
into heparin-coated Vacutainer tubes (BD Biosciences). Blood was incubated in MRCLB 
for 10 min at 37°C and washed twice in PBS. 
 
2.3.6 Nasal wash 
The chest cavity was opened and the trachea exposed, with a small incision made part 
way into the trachea. A syringe fitted with an Insyte Autoguard Catheter (BD 
Biosciences) was inserted into the tracheal opening directed away from the lung, with 
500 l of PBS injected and collected through the nostrils.  
 
2.3.7 Bronchiolar alveolar lavage 
The chest cavity was opened and the trachea exposed, with a small incision made part 
way into the trachea. A syringe fitted with an Insyte Autoguard Catheter (BD 
Biosciences) was inserted into the tracheal opening directed towards the lung, with three 
sequential washes of 1ml PBS collected. 
 
2.4 Ex vivo techniques 
2.3.1 Flow cytometry 
Single cell suspensions were plated into round-bottom 96-well trays (Corning) at 2x106 
cells per well, with the exception of tumour suspensions in which 8x105-1x106 cells were 
plated. For intracellular cytokine staining, cells were first incubated in 50 l of 
restimulation medium for 4 hr at 37°C, 5% CO2. After centrifugation at 400 x g for 2 
min, cells were resuspended in 50 l of FACS buffer containing a 1:1000 dilution of 
LIVE/DEADTM Fixable Near-IR Stain (ThermoFisher Scientific) plus 10 g mouse 
gamma globulin (m g) (Rockland) and incubated for 5 min at room temperature in the 
dark, to exclude dead cells and block Fc receptors. To this, 10 l of a cocktail of antibodies 
was added (Table 2.1). If an unlabelled antibody was included in the stain, this was 
incubated for 20-60 min at 4°C, washed once in FACS buffer, stained with secondary 
antibody preadsorbed with m g and normal mouse serum (NMS) for 20 min at 4°C, 
washed once in FACS buffer and blocked with rat gamma globulin for 15 min at 4°C. 




and washed with FACS buffer. For biotinylated antibodies, this was followed by 
incubation with fluorescently-conjugated streptavidin for 15 min at 4°C. For intracellular 
cytokine staining or transcription factor staining, the BD Cytofix/CytoPermTM kit (BD 
Biosciences) or the Foxp3/Transcription Factor Staining Buffer Set (ThermoFisher 
Scientific) were used respectively according to the manufacturer’s instructions. All stains 
were washed and resuspended in 1% PFA (Section 2.7.7) and stored at 4°C in the dark. 
Flow cytometry data was acquired on a LSR II, FACSAria, or LSRFortessa (all BD 
Biosciences) and analysed using FlowJo software (BD Biosciences). 
 
2.3.2 RNA isolation and qPCR 
Mammary gland cells were isolated and stained as described above and sorted on a 
FACSAria. Total RNA was extracted from sorted cells using the RNeasy Micro Kit 
(Qiagen) with on-column DNase treatment, and reverse-transcribed into cDNA using the 
Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science). qPCR was 
conducted using LightCycler480 SYBR Green I Master mix (Roche Applied Science) on 
a LightCycler480 instrument (Roche Applied Science). All procedures were carried out 
as per the manufacturer’s instructions. Cycle threshold (CT) values were determined by 
the second derivative method and relative gene expression was calculated using the 
formula 2-[CT(target)–CT(reference)], where the reference gene was Rplp0. The melting curve of 
each product was also analysed to confirm the specificity of the product. Primer 
sequences used for qPCR are listed in Table 2.5. 
 
2.3.3 ELISA 
Supernatants from digested tumours were collected, protease inhibitors (Sigma) added 
and stored at -80°C. Capture antibodies were diluted in ELISA coating buffer (Section 
2.7.8), applied to 96-well high binding plates (Corning) and incubated overnight at 4°C. 
All further incubations were at RT and all washes performed in PBS/Tween (Section 
2.7.11). The next day, wells were washed 4 times and blocked with 200 l ELISA 
blocking buffer (Section 2.7.9)  for 2 hr. Plates were washed 4 times and protein 
standards and samples diluted in ELISA diluent (Section 2.7.10) were added and 
incubated for 2 hr. Plates were washed 4 times and detection antibodies diluted in ELISA 
diluent were added and incubated for 1 hr. Plates were washed 4 times and incubated 




washed 6 times, developed with TMB (ThermoFisher Scientific), stopped with 1M 




Tail tips from weaned pups were digested overnight at 55°C in tail tip lysis buffer, heat 
shocked at 95°C for 5 min, centrifuged and stored at 4°C. PCR was conducted using 
MyTaq (Bioline) according to the manufacturer’s instructions, using 0.5 l of tail tip 
DNA per reaction. Annealing temperatures for CCR2, PyMT and ACKR4 were 60 C. 
Primers used for PCR are listed in Table 2.5. PCR products were separated on 1.5% 
agarose gel and visualised using GelRed (Life Technologies) in a ChemiDoc imager 
(Bio-Rad).  
 
2.5 Tissue culture 
2.5.1 E0771 cells and derivatives 
The murine mammary carcinoma cell line E0771 and its derivate of E0771-OVA were 
kindly provided by Prof. Mark Smyth and A/Prof. Phil Darcy (Peter MacCallum Cancer 
Centre), respectively. Cells were maintained in DMEM (Gibco) supplemented with 10% 
foetal bovine serum (FBS), 1mM sodium pyruvate (Gibco) and 1x 
penicillin/streptomycin (Gibco) and cultured at 37°C in 5% CO2. Cells were passaged 
every 2-3 days by rinsing the flasks with sterile PBS and dissociating cells with 
trypsin/EDTA in PBS for approximately 3 min at 37°C. 
 
2.5.2 B16F10 cells  
The murine melanoma cell line B16F10 was kindly provided by Prof. Mark Smyth. Cells 
were maintained in RPMI 1640 (Gibco) supplemented with 10% FBS and 1x 
penicillin/streptomycin (Gibco) and cultured at 37°C in 5% CO2. Cells were passaged 
every 2-3 days by rinsing the flasks with sterile PBS and dissociating cells with 
trypsin/EDTA in PBS for approximately 5 min at 37°C. 
 
2.5.3 Other cell lines 
The murine prostrate carcinoma cell line RM-1, murine carcinoma cell line MC38 and 




Smyth. Cells were maintained in complete DMEM or RPMI 1640 and cultured at 37°C 
in 5% CO2. Cells were passaged every 2-3 days by rinsing the flasks with sterile PBS and 
dissociating cells with trypsin/EDTA in PBS for approximately 5 min at 37°C. 
 
2.6. In vitro techniques 
2.6.1 Generation of genetically modified Streptococcus pneumoniae strains 
S. pneumoniae strains expressing OVASIINFEKL and OVA323-339 were constructed by 
inserting these sequences into the surface protein, pneumococcal surface protein A 
(PspA), analogous to that described previously243. Mutants were constructed in the D39 
background using the complete transformation medium (CTM) method and the Janus 
cassette244-246. The Janus cassette was inserted in pspA of a D39 derivative with a rpsL 
mutation to generate D39rpsL-pspA::Janus. Insertion of the Janus cassette suppresses the 
rpsL StrepR phenotype and confers kanamycin resistance. Primers for generation of these 
mutants are listed in Table 2.5. The construct to insert the Janus into pspA was generated 
by overlap-extension PCR using primers TTM051(D39)F and RHPspA(J)R for the upper 
flanking product, primers RHPspA(J)F and TTM059 for the lower flanking product, and 
primers JanusF and JanusR for the Janus cassette. The KanR/StrepS 
D39rpsLΔpspA::Janus strain was then transformed with a pspA construct containing 
either the OVASIINFEKL or OVA323-339 epitope nucleotide sequence. These constructs were 
generated by overlap-extension PCR using primers TM051(D39)F and OTIR, and OTIF 
and TTM059 for OVASIINFEKL and primers TM051(D39)F and OTIIR, and TTM059 for 
OVA323-339. Successful transformants were selected by plating on blood agar with 
streptomycin. The inserted sequence was confirmed by DNA sequencing, and PspA 
expression confirmed by Western blot analysis. Generation of these strains were 
performed by Dr. Richard Harvey. 
 
2.6.2 Generation of Streptococcus pneumoniae stocks 
Stocks of the genetically modified S. pneumoniae strains were generated from a streak 
plate and inoculated into 10ml of serum broth for 3-6 hr at 37°C, 5% CO2 without 
agitation. Once the OD600 reached 0.20-0.22, bacteria was aliquoted and stored in -80°C 
without additives. A frozen aliquot was thawed to determine bacterial titre, with serial 
dilutions in serum broth plated in duplicate on blood agar with gentamycin and incubated 




2.6.3 Generation of influenza A virus stocks 
X31 stocks were kindly provided by Dr. Mohammed Alsharifi (University of Adelaide). 
X31-OVA323-339 and PR/8-OVA323-339 were generated by Dr. Paul Thomas (St. Jude 
Children’s Research Hospital, USA) and an aliquot was kindly provided by Dr Katherine 
Kedzierska (Doherty Institute, Victoria). Stocks of influenza A virus were made by 
inoculating approximately 105 PFU in the allantoic cavity of 10-day old embryonated 
chicken eggs, which were subsequently incubated for 48 hours at 37°C. The allantoic 
fluid was collected, clarified through centrifugation and aliquoted for storage at -80°C. 
The absence of bacterial contamination was confirmed by plating virus stocks on to LB 
agar plates in the absence of antibiotic selection. 
 
2.6.4 Quantification of influenza A viral titre 
The concentration of influenza A virus stocks were determined by analysing the 50% 
tissue culture infectious dose (TCID50) on Madin-Darby Canine Kidney (MDCK) cells. 
5x104 MDCK cells were plated into a round-bottom 96-well tray in DMEM 
supplemented with 1% FBS, 1x penicillin/streptomycin (Gibco) and 2mM L-glutamine 
(Gibco) and incubated overnight at 37°C, 5% CO2. The following day, medium was 
replaced with 100 l of DMEM supplemented with 1% FBS, 1x penicillin/streptomycin, 
2mM L-glutamine and 0.08% trypsin. 100 l of serial dilutions of viral stocks were made 
across the plate in replicates of 7 and incubated for 72 hr at 37°C, 5% CO2. 50 l of 0.6% 
packed chicken red blood cells in saline were added to each well and allowed to 
agglutinate for 30 min at room temperature. TCID50 was determined using the Spearman 
and Karber algorithm (Hierholzer & Killington, Virol Methods Manual 96). Viral 
concentrations are listed in Table 2.6. 
 
2.7 General reagents 
2.7.1 PBS 
1x PBS was either purchased from University of Adelaide Technical Services Unit (TSU) 
or prepared by diluting 20x PBS (TSU) with MilliQ water. 
 
2.7.2 MRCLB 
255mM NH4Cl (AnalaR) solution and 170mM TRIS (pH 7.65) were mixed at a 9:1 ratio 





2.7.3 Digestion medium 
DMEM (Gibco) was supplemented with 5% FBS, 2.5mM CaCl2, 10mM HEPES (Gibco), 
1x penicillin/streptomycin (Gibco), 30U/ml DNase I (Sigma-Aldrich) and 1mg/ml 
collagenase IA (Sigma-Aldrich). 
 
2.7.4 Mammary gland digestion medium 
DMEM (Gibco) was supplemented with 2% FBS, 1x penicillin/streptomycin (Gibco) and 
1x collagenase/hyaluronidase (StemCell Technologies). 
 
2.7.5 Restimulation medium 
1x Incomplete IMDM powder (Gibco) was reconstituted according to the manufacturer’s 
instructions and supplemented with 10% FCS, 200mM L-glutamine, 1x 
penicillin/streptomycin and 54pM -mercaptoethanol (Sigma). For restimulation, 
20ng/ml phorbol-12-myristate 13-acetate (PMA; Sigma-Alrich), 1nM ionomycin (Life 
Technologies) and GolgiStop (1:1500 dilution; BD Biosciences) were added.  
 
2.7.6 FACS buffer 
PBS was supplemented with 2% FBS and 0.04% NaN3 and stored at 4°C. 
 
2.7.7 Paraformaldehyde 
4% (w/v) paraformaldehyde (PFA) was prepared by dissolving PFA in PBS at 55°C with 
stirring overnight, and diluted to 1% PFA in PBS. These solutions were stored at 4°C for 
short-term storage or -20°C for long-term storage. 
 
2.7.8 ELISA Coating buffer  
3.03g of Na2CO3 and 6.0g of NaHCO3 were resuspended in 1L of MilliQ water and pH 
was adjusted to 9.6. 
 
2.7.9 ELISA Blocking buffer  






2.7.10 ELISA Diluent  
PBS was supplemented with 1% BSA. 
 
2.7.11 PBS/Tween 
PBS was supplemented with 0.05% (v/v) polyoxyethylene-sorbitan monolaurate (Tween 
20; Sigma-Aldrich) and mixed thoroughly at RT. 
 
2.7.12 Tail Tip Lysis Buffer (TTLB) 
100mM Tris-HCl pH 8.5, 5mM EDTA, 0.2% SDS, 200nM NaCl and 100ug/ml 
proteinase K (Roche). 
 
2.7.13 Serum broth 
Nutrient broth was obtained from TSU and supplemented with 5% horse serum and 
5 g/ml gentamycin. 
 
2.7.14 Blood agar 
Oxoid blood agar base (TSU) with 5% horse blood and 5 g/ml gentamycin. 
 
2.7.15 Antibodies and staining reagents 
Antibodies, streptavidin conjugates and tetramers used in flow cytometry, ELISA and in 
vivo studies are listed in Tables 2.1-2.4. 
 
2.7.16 Oligonucleotides  
Primers used for genotyping and quantitative PCR (qPCR) are listed in Table 2.5. All 
primers were purchased from Sigma-Aldrich and stocks were reconstituted with 
nuclease-free water to 100 M, and further diluted to a working concentration of 20 M. 
 
2.8 Statistical analysis 
All statistical analyses were performed using GraphPad Prism version 7.0 for Mac OS X 
or version 7.02 for Windows. An unpaired t-test was used when comparing two sets of 
unpaired, continuous data with a normal distribution and similar standard deviations. An 
unpaired t-test with Welch’s correction was used when comparing two sets of unpaired, 




used when comparing two sets of paired, continuous data with a normal distribution. A 
Wilcoxon matched-pairs signed rank test was used when comparing two sets of paired, 
continuous data with a non-normal distribution. A Mann-Whitney test was used when 
comparing two sets of discrete quantitative data with a non-normal distribution. A one-
way ANOVA was used when comparing three or more groups of continuous data with 
approximately normal distribution, with one dependent and one independent variable. A 
two-way ANOVA was used when comparing three or more groups of continuous data 
with approximately normal distribution, with one dependent and two independent 





















The role of ACKR4 in regulating  









The atypical chemokine receptor ACKR4 has previously been shown to regulate the 
bioavailability of the CCR7 ligands, CCL19 and CCL21, as well as the CCR9 ligand, 
CCL25139,193. The CCR7 and CCR9 axes have critical roles in directing many 
homeostatic immune functions, and accordingly ACKR4 has been implicated as a 
regulator of some of these pathways140,141,144.  In tumour settings, CCR7 has emerged as 
an important axis controlling the anti-tumour immune response, as well as intrinsically 
in tumour cell metastasis and survival.  However, there have been very limited reports on 
how ACKR4 may influence tumour progression, and its role in regulating tumour-
directed immune responses is unknown. In this chapter, the importance of ACKR4 in 
regulating anti-tumour immune responses was assessed in multiple murine tumour 
models. 
 
3.2 ACKR4 promotes tumour growth in a range of in vivo tumour 
models 
To begin to dissect a potential role for ACKR4 in tumour biology, ACKR4-deficient mice 
were utilised140. Previous reports have highlighted the importance of CCR7 and its 
ligands in breast cancer121,122,247, and we and others have reported that over-expression of 
ACKR4 in orthotopic or xenograft breast cancer models results in reduced tumour growth 
145-147. Thus, the role of ACKR4 in regulating the immune response to breast cancer was 
studied. For this, the E0771 mammary carcinoma cell line, syngeneic to C57Bl/6 (B6) 
mice, was injected orthotopically into wildtype (WT) and ACKR4-deficient mice. The 
E0771 model displays a triple negative, basal-like phenotype, which is associated with 
poor prognosis and reduced treatment options in human patients248,249.  In this model, 
ACKR4-deficiency is restricted to the host. E0771 tumour growth was significantly 
reduced in ACKR4-deficient animals (mean size at day 21 42.8 5.1mm2 in Ackr4–/– 
versus 63.2 8.1mm2 in WT mice), as measured by tumour size over time (Fig. 3.1 A). 
Similarly, the weight of tumours in Ackr4–/– mice at day 21 was significantly reduced 
(236.2 30.2 mg) compared with tumours grown in WT mice (444.9 90.5 mg) (Fig. 3.1 




transgenic model of breast cancer was used, in which the Polyoma virus middle T antigen 
is driven by the mouse mammary tumour virus long terminal repeat250. This model more 
faithfully recapitulates the stepwise progression of human breast cancer, as well as many 
morphological features and expression of biomarkers251,252. MMTV-PyMT mice on a B6 
background were crossed with Ackr4–/– mice to generate PyMT+ Ackr4–/– mice and the 
development of tumours was assessed. Palpable tumours were detected with median 
onset of 81 days in PyMT+ B6 mice, but were significantly delayed in PyMT+ Ackr4–/– 
mice with median onset of 88 days (Fig. 3.1 C). Furthermore, the total combined weight 
of mammary glands at twenty weeks of age was significantly reduced in PyMT+ Ackr4–
/– mice (882.6  58.0mg) compared with PyMT+ B6 mice (1095  58.7mg), indicative of 
reduced tumour burden (Fig. 3.1 D). ACKR4 expression has also been reported in the 
skin253, and so to determine if ACKR4 may also play a role in regulation of tumour 
growth in other cancer types, a fibrosarcoma model was used, in which tumours are 
induced with 3-methylcholanthrene (MCA). With both high (300 g) and medium (25 g) 
dose MCA treatments, Ackr4–/– mice showed significantly increased survival compared 
with WT mice (Fig. 3.1 E, F).  
 
To assess a potential role for ACKR4 in regulating metastatic disease, lung colonisation 
capability was measured in haematogenous metastases experiments. In these 
experiments, B16F10 melanoma cells, 3LL lung carcinoma cells and RM1 prostrate cells 
were used, which are all syngeneic to C57Bl/6 mice. Two different doses of each cell line 
were injected intravenously into the tail vein of WT and Ackr4–/– mice (Fig. 3.2). In both 
doses of each cell line, lung colonisation was significantly reduced in Ackr4–/– mice. 
Thus, in multiple models of primary tumour growth and lung metastasis, loss of host 
ACKR4 reduces tumour progression. 
 
3.3 ACKR4 controls chemokine abundance within the mammary 
gland and TME 
Given that a known biological role for ACKR4 is to regulate the bioavailability of its 
ligands CCL19, CCL21 and CCL25, the reduced tumour growth in ACKR4-deficient 
mice may be a result of dysregulation of these chemokines. To test if chemokine 
abundance at the site of tumour inoculation was altered by deletion of ACKR4, naïve 




of CCL19 and CCL25 in mammary glands were below the limits of detection in both WT 
and Ackr4–/– mice. However, the level of CCL21 protein was significantly increased in 
Ackr4-/- glands (11.5 1.0 pg/mg) compared with WT glands (3.44 0.1 pg/mg), indicating 
that loss of ACKR4 leads to increased abundance of CCL21, consistent with its known 
role as a scavenger of CCL21140. To assess whether this difference was maintained or 
disrupted in a tumour setting, end-point E0771 tumours were harvested and similarly 
analysed (Fig. 3.3 B). CCL19 levels in E0771 tumours were again below the limit of 
detection, whilst CCL25 levels were low and unaltered between tumours in WT and 
Ackr4–/– mice. The concentration of CCL21 was significantly increased in tumours from 
Ackr4–/– mice (30.5 8.1 pg/mg) compared with tumours from WT mice (5.52 2.2 
pg/mg), again indicating that ACKR4 is important for normal regulation of CCL21 
abundance. Furthermore, although the concentration of CCL21 in tumours from WT mice 
was similar to that of in naïve WT mammary glands, in Ackr4–/– mice CCL21 levels were 
further increased in tumours compared with naïve mammary glands, indicating that the 
tumour leads to increased abundance of CCL21, which is only apparent in the absence of 
ACKR4. These data suggest that the reduced tumour growth in Ackr4–/– mice may 
potentially be a result of altered CCL21 abundance in these animals. 
 
The hyperabundance of CCL21 within the mammary gland of ACKR4-deficient mice 
implies that one or more cell types within the mammary gland may express ACKR4 and 
act to control CCL21 abundance at this site.  Although ACKR4 transcript has been 
detected in a wide range of tissues143, analysis of mammary glands has not been reported 
to date. Currently, no antibodies with high specificity against murine ACKR4 exist, with 
commercially available clones displaying reactivity to Ackr4–/– mice (Cameron Bastow, 
personal communication). As an alternate approach, major cell populations from 
mammary glands were sorted and ACKR4 transcript detected by quantitative PCR (Fig. 
3.4). Resident immune cells, including myeloid cells,  CD4+ and CD8+ T cells, were 
sorted on the basis of CD45 expression. Of the CD45– non-immune compartment, the 
luminal and basal epithelial cell populations were distinguished by differential expression 
of CD24 and CD49f254, while a subpopulation of the remaining CD24– CD49f– stromal 
cells expressed CD140  and gp38, indicative of a fibroblast phenotype. Abundant 




mammary glands, with no or minimal expression detected within the other compartments 
(Fig. 3.4). 
 
3.4 ACKR4-deficient tumours have altered composition of tumour-
infiltrating immune cells. 
The increased CCL21 levels within Ackr4–/– tumours led to the hypothesis that CCL21 
dysregulation may enhance the tumour-directed immune response. This is because one 
of the main functions of CCL21 is to recruit CCR7-expressing immune cells and thus 
altered CCL21 abundance may influence the extent of immune cell infiltration of 
tumours. It was hypothesised that these changes in immune cell infiltration may lead to 
more effective anti-tumour immunity, which would explain the reduced tumour growth 
in Ackr4–/– mice. Furthermore, unpublished data taken from melanoma tumours with 
artificially reduced expression of ACKR4 suggested that when ACKR4 expression is 
reduced, enhanced CD8+ T cell-dependent anti-tumour immune responses result (C.E. 
Whyte et al., data not shown). To begin to address this, E0771 tumours from WT and 
Ackr4–/– mice were harvested and infiltrating immune cells were analysed by flow 
cytometry. A large proportion of the immune infiltrate in E0771 tumours from WT mice 
were myeloid cells (Fig. 3.5), with monocytic CD11b+ Ly6C+ Ly6G– cells making up 
approximately 30% of the tumour infiltrate, and being marginally but significantly 
increased in number in tumours from Ackr4–/– mice (Fig. 3.5 C). These cells have a 
heterogeneous phenotype, likely consisting of monocytes at various stages of maturation, 
as well as monocytic MDSCs, a class of immature monocytes that develop in tumour 
settings with the capacity to suppress T cell responses255. Granulocytic CD11b+ Ly6C+ 
Ly6G+ myeloid cells, which may encompass granulocytic MDSCs as well as anti-
tumourigenic neutrophils, were unaltered in Ackr4–/– mice, as were CD11b+ Ly6Clo 
F4/80+ macrophages (Fig. 3.5 A, B). A range of innate lymphocytes have been reported 
to influence tumour growth, including NK cells and CD1d-restricted natural killer T 
(NKT) cells, with subsets of these cells capable of expressing CCR7256,257. Intratumoural 
accumulation of NK1.1+ CD3– NK cells was unaltered in Ackr4–/– mice, as were NK1.1+ 
CD3+ NKT cells (Fig. 3.6 A-C). Only a proportion of NKT cells express NK1.1 and type 
I iNKT cells are more reliably detected by their capacity to bind CD1d- GalCer 
tetramers258, although frequency of CD3+ tetramer+ type I NKT cells were also unaffected 




Although ACKR4 expression is generally restricted to the non-haematopoietic 
compartment, we have recently reported the expression of ACKR4 on recently activated 
B cells, with this receptor important in controlling their correct localisation and 
proliferation259. In line with this, an increased frequency of B cells in tumours from 
Ackr4–/– mice was detected compared with WT tumours, although the overall frequency 
within the tumour remained relatively low (Fig. 3.7 B). Foxp3+ CD4+ Treg cells are a 
major contributor to suppression of anti-tumour responses and are enriched within most 
mouse and human tumours260. However, frequencies of intratumoral Treg cells were 
unaltered between WT and Ackr4–/– mice. Foxp3– effector CD4+ cells were also 
equivalent in number between WT and Ackr4–/– mice, however there was a significant 
increase in percentage of activated CD44hi CD8+ T cells in tumours from Ackr4–/– mice.  
 
3.5 Ackr4–/– develop an enhanced anti-tumour CD8+ T cell response 
CD8+ T cells are one of the most critical cell types for executing anti-tumour immunity, 
and are capable of specifically recognising and killing tumour cells. Thus, to test if the 
increased number of CD8+ T cells in tumours from Ackr4–/– mice were responsible for 
the reduced tumour growth, CD8+ depletion experiments were performed (Fig. 3.8 A). 
Depleting antibody towards CD8  was administered intraperitoneally on two consecutive 
days, with E0771 inoculation into the fourth mammary fat pad on the second day. 
Depleting antibody was subsequently administered every seven days to eliminate newly 
generated CD8+ T cells. Depletion of CD8+ T cells in WT mice did not affect tumour 
growth, suggesting that although CD8+ T cells are present within WT tumours, they are 
ineffective at controlling tumour growth (Fig. 3.8 B, C). However, depletion of CD8+ T 
cells in Ackr4–/– mice significantly increased tumour burden to a similar size as tumours 
in WT mice, suggesting that enhanced CD8+ responses in Ackr4–/– mice are responsible 
for the reduced tumour growth in these mice. 
 
Intratumoural CD8+ T cells were characterised further to see if there were any differences 
in the quality or phenotype of CD8+ T cells generated, in addition to the increased 
quantity seen in Ackr4–/– mice. Upon ex vivo PMA restimulation, there was a higher 
frequency of IFN -production from CD8+ T cells taken from Ackr4–/– mice compared 
with WT mice, consistent with increased anti-tumour activity (Fig. 3.9 A). The 




Ackr4–/– mice, indicating a similar ability to secrete cytotoxic granules (Fig. 3.9 B). 
Expression of PD-1 was significantly enhanced in CD8+ T cells from Ackr4–/– mice, 
indicative of enhanced exhaustion of these cells (Fig. 3.9 C). However, expression of 
other exhaustion markers such as TIM-3 and LAG-3 were unaltered (Fig. 3.9 D, F). 
Furthermore, PD-1+ TIM-3+ and PD-1+ LAG-3+ CD8+ T cell frequencies were also 
unaltered (Fig. 3.9 E, G), with these cells having been described as more highly 
exhausted subsets, compared with cells positive for single markers261,262. CTLA-4, 
another checkpoint inhibitor and target for immunotherapy, was not detected on CD8+ T 
cells in this model (Fig. 3.9 H). 
 
CD8+ T cells are reported to lack expression of ACKR4, and the altered CD8 response in 
ACKR4-deficient mice is almost certainly cell-extrinsic. To assess whether the enhanced 
response generated in Ackr4–/– mice was a result of increased CD8+ T cell proliferation, 
expression of Ki67, a marker of proliferating or recently divided cells, was measured 
(Fig. 3.10)263. There was a significant increase in geometric MFI of Ki67 among tumour-
infiltrating CD8+ T cells, and a trend towards increased frequency of Ki67+ CD8+ T cells 
(p=0.077). Conversely, there was a significant reduction in Ki67 expression by CD8+ T 
cells in the draining lymph node (Fig 3.10 D-F). This is consistent with previous reports 
indicating reduced T cell priming in Ackr4–/– LN140,144. Taken together, these data suggest 
that the enhanced anti-tumour CD8+ T cell response in Ackr4–/– mice may be a result of 
enhanced intratumoural proliferation of CD8+ T cells, rather than a result of enhanced 
priming in draining lymph nodes. However, these data were obtained from advanced 
tumours where there is already a robust CD8+ T cell presence in Ackr4–/– mice, rather 
from an earlier time-point in which the response is being generated. Furthermore, the 
bulk of the CD8+ T cells present in the dLN are irrelevant for the tumour antigen, making 
conclusions about tumour-specific responses difficult in this model.  
 
3.6 Priming of tumour-specific CD8+ T cells is unaltered in Ackr4–/– 
mice. 
 
To address these issues, a variant of the E0771 cell line expressing the model antigen 
ovalbumin (OVA) was used, with endogenous CD8+ T cells specific for the 
immunodominant SIINFEKL peptide analysed with the use of a class I MHC H-2Kb-




tumour size between WT and Ackr4–/– mice becoming apparent.  At this time, there was 
already a substantial increase in OVA-specific CD8+ T cells in tumours from Ackr4–/– 
mice, however there was no difference in cell frequency or number of these cells in the 
dLN (Fig. 3.11). This indicates that the alterations leading to the enhanced CD8+ T cell 
response in Ackr4–/– mice may occur outside of priming in the draining lymph nodes. 
 
Although priming of anti-tumour CD8+ T cells is thought to predominantly occur within 
SLO, priming of naïve CD8+ T cells within tumours has also been reported. Tumours 
were able to support activation of naïve tumour-specific CD8+ T cells in splenectomised 
mice with in utero-ablated LNs, with these CD8+ T cells acquiring normal effector 
functions such as IFN  production and cytotoxic capacity59. Furthermore, naïve CD8+ T 
cell entry into tumours has been reported to occur in a CCR7-dependent manner with 
adhesion and intravasation through CCL21-coated PNAd+ LN-like vasculature264. Thus, 
whether the increased levels of intratumoural CCL21 in Ackr4–/– mice could support 
naïve T cell recruitment and thus potentially in situ priming was tested. Congenically-
labelled OT-I cells, which are specific for the OVASIINFEKL peptide in the context of H-
2Kb, were adoptively transferred into WT or Ackr4–/– recipients 10 days after inoculation 
with the parental E0771 cell line. In this model, the transferred CD8+ T cells are not 
specific for tumour-derived antigen and so entry into the tumour only occurs in an 
antigen-independent manner. 24 hours after transfer, mice were injected intravenously 
with fluorescently labelled antibody against CD8  in order to label cells within the 
vasculature. Although naïve OT-I cells were found to be present both within tumour 
vasculature as well as in the tumour parenchyma by this time, there was no difference in 
total number of naïve OT-I cells or parenchymal naïve OT-I cells between tumors from 
WT and Ackr4–/– mice (Fig. 3.12 C, D). Furthermore, there was also no difference in the 
ratio of naïve OT-I cells present within the parenchyma versus the vasculature of WT or 
Ackr4–/– tumours. One possibility for this lack of difference is that the specialised 
vasculature required to support naïve T cell entry had not yet developed at this early stage 
of tumour growth, and so in a separate experiment naïve OT-I cells were transferred into 
mice with tumours inoculated 16 days prior. However, there was again no difference in 
total number or ratio of naïve OT-I recruitment in these mice (Fig. 3.12 F-H), indicating 




enhanced intratumoural recruitment of naïve CD8+ T cells, at least under the conditions 
investigated. 
 
3.7 DCs are enhanced within tumours of Ackr4–/– mice. 
Given that priming in the dLN as well as intratumoural priming of naïve T cells did not 
appear to account for the enhanced CD8+ T cell response in Ackr4–/– mice, the loss of 
ACKR4 appears to be affecting CD8+ T cells after they have been activated. Although 
naïve CD8+ T cells express high levels of CCR7, upon activation they downregulate this 
receptor265, making a direct role for CCL21 in recruiting activated CD8+ T cells unlikely. 
However, DCs also rely on CCR7-mediated signalling and play critical roles in 
controlling the magnitude of anti-tumour CD8+ T cell responses. In their canonical role, 
DCs take up tumour-derived antigen and upregulate CCR7 to migrate to CCL21-
expressing lymphatic vessels, where they can egress from tissue and migrate to dLN to 
prime T cells. However, recent reports have demonstrated that subsets of DCs also have 
important roles within the tumour microenvironment, with intratumoural CD103+ DCs 
being critical for the cytotoxic activity of transferred tumour-specific CD8+ T cells21. 
Furthermore, CD103+ DCs have been reported to be the predominant source of CXCL9 
and CXCL10 in tumours, thus mediating recruitment of activated CD8+ T cells into the 
tumour95. The classification of DCs based on their functional capacity, transcriptional 
ontogeny and surface marker expression has recently been updated with unsupervised 
analysis of high-parameter flow and mass cytometric data, allowing more clear 
delineations between subsets to become apparent266. Within conventional DCs (cDCs), 
cDC1s are marked by their expression of XCR1 and their potent ability to cross-present 
antigen to prime CD8+ T cell responses, while CD172a+ cDC2s are considered to be more 
important for the generation of CD4+ T cell help266,267. CD103+ DCs in the skin have been 
described as a sub-population of cDC1s, consistent with their ability to cross-present 
antigen and prime CD8+ T cell responses, although it is not entirely clear from previous 
reports whether the CD103+ DCs described in tumours are synonymous with XCR1+ 
cDC1s. Indeed, some cDC2s have been reported to express low levels of XCR1268. To 
assess whether disrupted CCL21 gradients within Ackr4–/– tumours would affect DC 
migration, the presence of Ly6C– MHC-II+ CD11c+ DCs were analysed within E0771 
tumours. Total DCs were significantly increased in both number and frequency within 




abundant than cDC1s, although both subsets were significantly increased within tumours 
from Ackr4–/– mice (Fig. 3.13). Furthermore, CD103+ DCs were also augmented in 
tumours from Ackr4–/– mice compared with WT mice. A recent report has indicated that 
CD103+ Ly6C+ myeloid-derived cells can also potently activate anti-tumour CD8+ T 
cells269. However, these cells were unaltered between tumours from WT and Ackr4–/– 
mice. 
 
The frequencies of DC subsets were also analysed in the dLN, where migratory DCs can 
be distinguished from resident DCs based on their increased expression of MHC-II, 
which is upregulated upon their activation in tissues (Fig. 3.14). Total migratory DCs or 
resident DCs were not altered in number or frequency in Ackr4–/– dLN, with migratory 
cDC1s and cDC2s also being unchanged. However, CD103+ migratory DCs were 
reduced in Ackr4–/– dLNs, which along with their enhanced presence in tumours from 
Ackr4–/– mice is suggestive of decreased egress from tumours.  
 
3.8 CCL21 promotes intratumoural DC accumulation 
To assess whether the enhanced retention of DCs within the tumour was a direct result of 
excess CCL21 seen in Ackr4–/– tumours, which presumably disrupts homeostatic CCL21 
distribution, it was tested whether exogenous administration of CCL21 into tumours in 
WT mice would phenocopy this result. To test this, E0771 tumours were established in 
contralateral sides of the fourth mammary gland. From day 7, at which point tumours had 
just become palpable, 3ug of CCL21 or MCPala, a non-functional control peptide, were 
injected intratumourally into the left tumour, with the PBS vehicle control injected into 
the right tumour241,242. In CCL21-treated tumours, levels of CCL21 were similar or 
slightly enhanced compared with tumours taken from Ackr4–/– mice (Fig 3.15 B, Fig. 3.3 
B). Intratumoural administration of CCL21 did not lead to a systemic increase in 
chemokine abundance, as measured in the serum (Fig. 3.15 C). Paired analysis of 
tumours weights at day 17 showed no difference between CCL21-treated tumours and 
PBS-treated tumours, nor the corresponding MCPala controls. However, in tumours where 
sufficient numbers of cells could be obtained to perform robust flow cytometric analysis, 
the frequency of DCs within CCL21-treated tumours was significantly increased over the 
PBS control, but not in mice treated with MCPala (Fig. 3.15 D). This shows that disrupted 




tumours, but this alone did not lead a reduction in tumour growth. This may be due to 
other alterations in Ackr4–/– mice that were not mimicked by intratumoural CCL21 
administration in WT mice, or due to the altered kinetics of CCL21 disruption, with 
CCL21 levels and DC retention unaltered until tumours were already established.  
 
3.9 ACKR4 deficiency improves responsiveness to immunotherapies 
The presence of CD8+ T cells within the tumour parenchyma has been reported to be 
conducive to responsiveness to immunotherapies that enhance the quality of CD8+ T cell 
responses. Given that there is an increase in CD8+ T cells within tumours from Ackr4-/- 
mice, it was tested whether loss of ACKR4 would increase the efficacy of these 
immunotherapies. To assess this, WT or Ackr4–/– mice given E0771 tumours were treated 
with an agonistic antibody targeting CD137. CD137, also known as 4-1BB or TNFRS9, 
is a potent costimulatory molecule for T cells and NK cells, with stimulation of this 
receptor leading to inhibited tumour growth in a variety of models270,271. The efficacy of 
this therapy in the E0771 model has not been previously reported, and WT mice treated 
with anti-CD137 showed significantly reduced tumour growth (mean tumour size 
82.04mm2 ± 18.34 at day 26) compared with the control group (156.89mm2 ± 7.8). 
However, tumour growth was even more strongly inhibited in Ackr4-/- mice (103.08mm2 
± 4.95 in control vs 17.25mm2 ± 7.65 in anti-CD137), indicating enhanced efficacy in the 
absence of ACKR4. 
 
To extend these findings, responsiveness to anti-PD-1 and anti-CTLA-4 combination 
therapy was tested in the B16F10 melanoma model, a widely-used tumour model for 
immunotherapy. As previously reported, combination of anti-PD-1 and anti-CTLA-4 
reduced B16F10 tumour growth in WT mice (Fig 3.17 A). There was a modest reduction 
in tumour growth in Ackr4–/– mice treated with control antibody, but this was further 
reduced when treated with the dual therapy, with the extent of inhibition induced by the 
therapy significantly increased in Ackr4–/– animals compared with their WT counterparts. 
Similar results were seen with the immunogenic MC38 colon carcinoma model, with 
Ackr4–/– animals displaying minimal tumour burden when treated with anti-PD-1 (Fig. 
3.17 B). Indeed, 4 out of 5 mice in this group displayed complete tumour regression, with 






The findings in this chapter establish ACKR4 as an important regulator of anti-tumour 
immunity. In the mammary gland, ACKR4 is expressed by luminal epithelial cells where 
it acts to control local bioavailability of CCL21. Loss of ACKR4 is protective, with 
reduced tumour growth seen in multiple orthotopic and transgenic models of cancer. This 
reduction in growth is the result of an increased tumour-directed CD8+ T cell response, 
with enhanced accumulation of CD8+ T cells and increased production of IFN . Priming 
of CD8+ T cells in Ackr4–/– mice is unaffected, suggesting the enhanced response is a 
result of increased recruitment or proliferation of activated CD8+ T cells within the TME. 
Furthermore, ACKR4 regulates intratumoural DC numbers, with loss of ACKR4 
promoting DC retention within tumours due to dysregulation of the CCL21/CCR7 axis. 
Loss of ACKR4 also enhances the efficacy of immunotherapies against CD137, PD-1 
and CTLA-4. This work reveals a previously unappreciated level of regulation of tumour-
directed immune responses, and provides a possible novel target for enhancing the 








Figure 3.1: Loss of ACKR4 inhibits tumour growth in vivo. 
(A) Growth curves and (B) weights of E0771 mammary tumours injected into WT or 
Ackr4–/– mice in the fourth mammary fat pad. Data are pooled from three independent 
experiments; n=16 WT mice, 21 Ackr4–/–mice, (A) two-way ANOVA, (B) unpaired t-
test. (C) Day of tumour onset for MMTV-PyMT B6 (Ackr4+/+) and Ackr4–/–mice; Mantel-
Cox test. (D) Total weight of mammary glands in MMTV-PyMT B6 and Ackr4–/–at 20 
weeks of age; unpaired t-test. (E-F) Survival curve of WT and Ackr4–/–mice inoculated 
with (E) 25μg or (F) 300μg methylcholanthrine (MCA) in the hind flank; Mantel-Cox 
test. Mean ± SEM. * p≤0.05, *** p≤0.001. (E-F) Experiment designed and executed by 




















Figure 3.2: Loss of ACKR4 inhibits haematogenous metastasis in vivo. 
WT or Ackr4–/– mice were injected with (A) B16F10 melanoma, (B) 3LL lung carcinoma 
or (C) RM1 prostrate cells intravenously at the indicated doses and the number of lung 
metastases were counted; n=5-6 mice, Mann-Whitney test. Mean ± SEM. * p≤0.05, ** 




















Figure 3.3: Loss of ACKR4 alters chemokine abundance in the mammary gland. 
Concentrations of CCL19, CCL21 and CCL25 as detected by sequential ELISA. (A) 
Chemokine abundance in naïve mammary glands of virgin 12-week old female mice. 
n=7. (B) Chemokine abundance in endpoint E0771 tumours. n=6. Data representative of 














Figure 3.4: ACKR4 is expressed by luminal epithelial cells in the mouse mammary 
gland. 
Immune, stromal and epithelial cell populations were sorted from the fourth mammary 
glands from naïve virgin 12-week old female mice. (A) Representative gating strategy of 
luminal epithelial cells (CD45– CD24hi CD49fint), basal epithelial cells (CD45– CD24int 
CD49fhi) and fibroblasts (CD45– CD24lo CD49flo CD140 +), pre-gated CD45–. (B) 
Relative expression of Ackr4 in sorted cell populations. n=7, pooled from two 







Figure 3.5: Myeloid cell accumulation in tumours of WT and Ackr4–/– mice. 
WT or Ackr4–/– mice were injected with E0771 mammary carcinoma cells into the fourth 
mammary gland, with tumours analysed 21 days post-inoculation. (A) Representative 
flow cytometry of myeloid cells in tumours, pre-gated on live CD45+ cells. (B) 
Macrophage-like (CD45+CD11b+F4/80+Ly6Clo) cell frequency and number. (C) 
Monocyte (CD45+CD11b+Ly6C+Ly6G-) cell frequency and number. (D) Neutrophil-like 
(CD45+CD11b+Ly6C+Ly6G+) cell frequency and number. Mean ± SEM. n= 5-6 mice, 











Figure 3.6: NK cell and NKT cell accumulation in tumours is unaltered in  
Ackr4–/– mice. 
WT or Ackr4–/– mice were injected with E0771 mammary carcinoma cells into the fourth 
mammary gland, with tumours analysed 21 days post-inoculation. (A) Representative 
flow cytometry of NK cells and NK1.1+ CD3+ cells in tumours, pre-gated on live CD45+ 
cells. (B) CD45+ NK1.1+ CD3+ cell frequency and number. (C) NK cell (CD45+ NK1.1+ 
CD3-) frequency and number. (D) Representative flow cytometry of CD1d-restricted 
iNKT cells in tumours, pre-gated on live CD45+ cells. (E) CD1d-restricted iNKT cell 
(CD45+ CD3+ CD1d- GalCer+) frequency and number. n= 5-6 mice, representative of 
















Figure 3.7: Adaptive lymphocyte accumulation in tumours is altered in Ackr4–/– 
mice. 
WT or Ackr4–/– mice were injected with E0771 mammary carcinoma cells into the fourth 
mammary gland, with tumours analysed 21 days post-inoculation. (A) Representative 
flow cytometry of B cells in tumours, pre-gated on live CD45+ cells. (B) B cell frequency 
and number. (C) Representative flow cytometry of Treg cells in tumours, pre-gated on 
live CD45+ cells. (D) Treg cell frequency and number. (E) Representative flow cytometry 
of activated CD4+ and CD8+ T cells in tumours, pre-gated on live CD45+ cells. (F) CD44hi 
CD4+ T cell frequency and number. (G) CD44hi CD8+ T cell frequency and number. 
n=11-13 mice, unpaired t-test. Data is pooled from two independent experiments. Mean 
























Figure 3.8: CD8+ T cells control tumour growth in ACKR4-deficient mice. 
WT or Ackr4–/– mice were injected with E0771 mammary carcinoma cells into the fourth 
mammary gland and treated with antibody to deplete CD8+ T cells on days -1, 0, 7 and 
14. (A) Schematic of experiment. (B) Tumour growth curves; two-way ANOVA. (C) 
Tumour weights at day 21; one-way ANOVA. n= 9 (WT + control), 10 (WT + -CD8), 
14 (Ackr4–/– + control; Ackr4–/– + -CD8) mice, pooled from two independent 














Figure 3.9: Characterisation of CD8+ T cell response in ACKR4-deficient mice. 
WT or Ackr4–/– mice were injected with E0771 mammary carcinoma cells into the fourth 
mammary gland, with tumours analysed 18 days post-inoculation. (A) Representative 
flow cytometry and frequency of IFN -producing CD8+ T cells. (B) Representative flow 
cytometry and frequency of granzyme B (GzmB)-producing CD8+ T cells. (C) 
Representative flow cytometry, frequency and geometric mean fluorescent intensity 
(gMFI) of PD-1 on CD8+ T cells. (D) Representative flow cytometry, frequency and 
gMFI of TIM-3 on CD8+ T cells. (E) Frequency of PD-1+ TIM-3+ CD8+ T cells. (F) 
Representative flow cytometry, frequency and gMFI of LAG-3 on CD8+ T cells. (G) 
Frequency of PD-1+ LAG-3+ CD8+ T cells. (F) Representative flow cytometry, frequency 
and gMFI of CTLA-4 on CD8+ T cells. (A-C) Representative of at least two experiments, 
n=6-10, unpaired t-test. (D-H) Data from a single experiment, n=10. Mean ± SEM. * 


















Figure 3.10: Assessment of intratumoural CD8+ T cell proliferation in ACKR4-
deficient mice. 
WT or Ackr4–/– mice were injected with E0771 mammary carcinoma cells into the fourth 
mammary gland, with tumours analysed 18 days post-inoculation. (A) Representative 
flow cytometry of Ki67 expression on intratumoural CD8+ T cells. (B) Frequency of 
Ki67+ CD8+ T cells in the tumour. (C) Geometric mean fluorescent intensity (gMFI) of 
Ki67 on intratumoural CD8+ T cells. (D) Representative flow cytometry of Ki67 
expression on CD8+ T cells from the draining lymph node (dLN). (E) Frequency of Ki67+ 
CD8+ T cells in the dLN. (C) gMFI of Ki67 on CD8+ T cells in dLN. n=10, unpaired t-







Figure 3.11: ACKR4 deficiency does not affect tumour-specific CD8+ T cell priming. 
WT or Ackr4–/– mice were injected with 5x105 E0771-OVA mammary carcinoma cells 
into the fourth mammary gland with tumours harvested at day 11. (A) Representative 
gating strategy of endogenous OVA-specific CD8+ T cells in the tumour, pre-gated on 
live, CD45+ cells. (B) Frequency and number of OVA-specific CD8+ T cells in the 
tumour. (C) Frequency and number of OVA-specific CD8+ T cells in the draining LN 











Figure 3.12: ACKR4 deficiency does not affect intratumoural recruitment of naïve 
CD8+ T cells. 
WT or Ackr4–/– mice were injected with E0771 mammary carcinoma cells into the fourth 
mammary gland. Congenic OT-I cells were adoptively transferred at d10 (C-E) or d16 
(F-H), and tumours were harvested 24 hours later. Intravascular labelling of CD8+ T cells 
was performed 5 minutes prior to harvest.  (A) Schematic of experiment. (B) 
Representative gating strategy of intratumoural OT-I cells. (C,F) Number of total 
intratumoural naïve OT-I cells. (D, G) Number of parenchymal naïve OT-I cells. (E, H) 















Figure 3.13: Loss of ACKR4 promotes intratumoural DC accumulation. 
WT or Ackr4–/– mice were injected with E0771 mammary carcinoma cells into the fourth 
mammary gland, with tumours analysed 18 days post-inoculation. (A) Representative 
gating strategy of intratumoural DCs, pre-gated on live, CD45+ cells. (B) Frequency and 
number of DCs (MHC-II+ CD11c+ Ly6C–) in the tumour. (C) Frequency and number of 
CD103+ DCs in the tumour. (D) Frequency and number of XCR1+ cDC1s in the tumour. 
(E) Frequency and number of CD172a+ cDC2s in the tumour (F) Representative gating 
strategy of CD103+ myeloid cells, pre-gated on live, CD45+ cells. (G) Frequency and 
number of Ly6C+ CD103+ CD11c+ cells in the tumour. (B) Pooled from two independent 
experiments. (C-G) Representative of at least two independent experiments. n= 6-10 
















Figure 3.14: CD103+ migratory DCs are reduced in ACKR4-deficient lymph nodes. 
WT or Ackr4–/– mice were injected with E0771 mammary carcinoma cells into the fourth 
mammary gland, with tumours analysed 18 days post-inoculation. (A) Representative 
gating strategy of resident and migratory DCs, pre-gated on live, CD45+ cells. (B) 
Frequency and number of migratory DCs (MHC-IIhi CD11c+) in draining inguinal LNs 
(dLN). (C) Frequency and number of resident DCs (MHC-II+ CD11c+) in dLN.  (D) 
Frequency and number of migratory XCR1+ cDC1s in dLN. (E) Frequency and number 
of migratory CD172a+ cDC2s in dLN. (F) Frequency and number of CD103+ migratory 
DCs cells in dLN. Representative of two independent experiments. n= 6-10 mice, 










Figure 3.15: Intratumoural administration of CCL21 promotes DC retention. 
WT mice were injected with E0771 mammary carcinoma cells in the left and right side 
of the fourth mammary gland (m.g.). From day 7, tumours in the left m.g. were injected 
with 3µg MCPala or CCL21, while the right m.g. was injected with PBS. (A) Schematic 
of experiment. (B) CCL21 concentration in the tumour as measured by ELISA. (C) 
CCL21 concentration in serum of treated mice as measured by ELISA. (D) Tumour 
weight at day 21. (E) Frequency of intratumoural DCs. n= 6-7 mice; paired t-test. Data 




















Figure 3.16: ACKR4 deficiency improves response to agonistic anti-CD137 therapy. 
Tumour growth in WT or Ackr4–/– mice injected with E0771 mammary carcinoma cells 
and administered 100 g anti-CD137 (clone 3H3) or rat IgG every 3 days from day 10. 
n=7-9. Mean ± SEM. Experiment conceptualised in collaboration with and executed by 














Figure 3.17: ACKR4 deficiency improves response to anti-PD-1 and anti-CTLA4 
therapy. 
(A) Tumour growth curves from WT or Ackr4–/– mice injected with B16F10 melanoma 
cells and administered 4 doses of 250 g anti-PD-1 (clone RMP1-14) and 250 g anti-
CTLA-4 (clone UC10-4F10) or 500 g control hamster IgG every 3 days from day 6. 
Representative of two independent experiments, n=4-6 mice. (B) Tumour growth curves 
from WT or Ackr4–/– mice injected with MC38 colon adenocarcinoma cells and 
administered 4 doses of 250 g anti-PD-1 (clone RMP1-14) or 250 g rat IgG every 3 
days from day 6. From a single experiment, n=5 mice. Mean ± SEM. Experiment 




















The role of CCR2 in regulating  









One of the hallmark features of the adaptive immune system is its ability to mount 
enhanced responses upon secondary reencounter of an antigenic stimulus. The 
significance of memory CD8+ T cells and B cells in protective immunity is well 
established, however relatively little is understood about the role of memory CD4+ T 
cells, despite correlations with improved pathogen control168,272. The generation and 
maintenance of CD4+ T cell memory is largely unknown, and despite early 
subclassification of memory CD4+ T cells on the basis of their expression of the 
chemokine receptor CCR7, little progress has been made regarding how these subsets 
migrate. We have previously shown that the majority of memory TH17 cells generated in 
response to infection with the extracellular bacteria S. pneumoniae express the 
inflammatory chemokine receptor CCR2, however the functional significance of this 
receptor on these cells is unclear. Thus, in this chapter the role of CCR2 on memory CD4+ 
T cells in infectious immunity was studied. 
 
4.2 Development of an antigen-specific Streptococcus pneumoniae 
infection model. 
Our previous work has shown that IL-17-producing CD4+ cells present in the lung up to 
84 days post-primary infection with S. pneumoniae express high levels of CCR2205.  In 
order to study the functional consequences of CCR2 expression, a transgenic S. 
pneumoniae infection model was first developed in which antigen-specific CD4+ T cells 
could specifically be tracked. Because the immunodominant CD4+ T cell epitopes of S. 
pneumoniae in mouse models are unknown, the OT-II TCR transgenic system was 
utilised, wherein CD4+ T cells from the OT-II transgenic mouse are specific for the 
OVA323-339 peptide presented in the context of the MHC-II molecule, H-2b 273. The 
sequence for OVA323-339 was inserted into the pneumococcal surface protein A (PspA) of 
D39 (D39-OVA323-339), an encapsulated serotype 2 strain274. This approach has 
previously been used in a whole killed cell vaccine to induce robust immunity in 
DO11.10Rag-/- mice, which are similar to OT-II mice but recognise OVA323-339 in the 




the OVASIINFEKL epitope being specifically recognised by transgenic CD8+ OT-I cells, 
but in this case acting as an irrelevant genetically-modified control. To confirm that 
insertion of these sequences did not affect the virulence of the strains, CD45.2+ C57Bl/6 
(henceforth referred to as B6) mice were infected intranasally with D39-OVA323-339, D39-
OVASIINFEKL or the unmodified parental D39 strain of S. pneumoniae. At 7 days post-
infection, there was a significant reduction in bacterial burden in the nasal wash for both 
genetically-modified strains compared to the parental strain, however colonisation in the 
nasal tissue was unchanged, indicating the genetic manipulation reduced virulence (Fig. 
4.1 A). To confirm that the inserted peptide sequence was presented to T cells and could 
induce an antigen-specific response, congenically-marked OT-II cells were adoptively 
transferred into Ly5.1 hosts which were subsequently challenged intranasally with either 
D39-OVA323-339 or D39-OVASIINFEKL (Fig. 4.1 B). Challenge with D39-OVA323-339 
induced more than a 10-fold increase in OT-II cell frequency in the lung and spleen and 
more than 4-fold increase in the mediastinal LN, as well as a significant increase in CD44 
expression compared with challenge using the control D39-OVASIINFEKL (Fig. 4.1 C, D).  
 
4.3 CCR2 is expressed on S. pneumoniae–specific memory CD4+ T cells 
To assess the kinetics of CCR2 expression on the antigen-specific CD4+ T cells generated 
in response to S. pneumoniae, OT-II cells were transferred into Ly5.1 hosts and analysed 
at different time-points after infection. Bacterial burden in the nasal wash was highest 7 
days post-infection and then decreased over time (Fig. 4.2 B). CCR2 was not expressed 
by naïve CD4+ T cells, but was upregulated on OT-II cells after infection. In the spleen, 
CCR2 expression on OT-II cells peaked on day 14, and was expressed on approximately 
13% of OT-II cells 28 days post-infection. Conversely, expression of CCR2 increased 
over time on OT-II cells in the mediastinal LN (medLN) and lung, with approximately 
21% of OT-II cells in the medLN and 36% of OT-II cells in the lung expressing CCR2 
on day 28 (Fig 4.2 C-F).  
 
CD44hi CD4+ T cells at memory time-points have classically been subdivided into 
circulating (TCM) or effector (TEM) memory T cells on the basis of their expression of 
CD62L (and CCR7)206. More recently, CD4+ tissue-resident memory (TRM) cells, which 
remain in tissues and are excluded from circulation, have been identified and shown to 




proportion of OT-II cells entering each memory compartment was assessed 28 days post-
infection with S. pneumoniae (Fig. 4.3). In the spleen, a large proportion of OT-II cells 
formed CD44hi CD62Lhi TCM cells, whilst a smaller proportion formed CD44hi CD62Llo 
TEM cells, and there were virtually no CD11ahi CD69hi TRM-like cells. In the lung, OT-II 
cells predominantly had a TEM surface phenotype, although TCM cells were also apparent. 
Furthermore, approximately 20% of OT-II cells expressed TRM-like markers, suggesting 
they may be resident in the tissue. In the spleen, CCR2 was expressed at low levels on 
TCM cells, but was greatly enriched on TEM cells (Fig. 4.3 D). This expression was 
mirrored on TCM and TEM cells in the lung, while TRM-like OT-II cells expressed similar 
levels of CCR2 to TEM cells. To confirm that CCR2 expression was not solely a feature 
of this specific TCR transgenic system, endogenous memory CD4+ T cells were also 
analysed, with these cells present in the lung as a result of exposure to various antigens 
over the course of the mouse’s lifetime. Similar patterns of CCR2 expression were 
obtained, confirming that CCR2 is expressed by memory CD4+ T cells regardless of the 
specificity of their TCR (Fig. 4.3 F, G).  
 
4.4 Ccr2-/- OT-II cells show enhanced contraction after S. pneumoniae 
infection 
In order to assess the functional significance of CCR2 on CD4+ T cells, a competitive 
cotransfer system was used. Congenically disparate WT (CD45.1.2+) and Ccr2-/- 
(CD45.2+) OT-II cells were mixed at a 1:1 ratio and transferred into Ly5.1 (CD45.1+) 
hosts, which were then infected with S. pneumoniae (Fig 4.4). On days 7 and 14 post-
infection, similar ratios of Ccr2-/- to WT OT-II cells were maintained, however by day 
28 the WT OT-II cells outnumbered the Ccr2-/- OT-II cells in spleen, medLN and lungs, 
with at least a 3-fold increase in the spleen (Fig 4.4 C-E). This was also reflected in the 
ratio of Ccr2-/- to WT OT-II cells decreasing at the memory time-point (Fig. 4.4 F-H), 
suggesting that there is an accelerated contraction of CD4+ T cells in the absence of CCR2 
expression.  
 
Exposure to inflammatory cues is critical for appropriate differentiation and cytokine 
production by T cells. To determine if the lack of ability to migrate through CCR2 by 
memory CD4+ T cells also affected their functional output, the ability of WT and Ccr2-/- 




S. pneumoniae infection has been reported to induce both TH1- and TH17-responses, 
although TH17 cells, through their secretion of IL-17, appear to be the critical TH subset 
required for protection against rechallenge154,155,275. A low proportion of OT-II cells in 
the spleen expressed IL-17 or IFN . This was somewhat enriched in the medLN and lung, 
with a higher frequency of IL-17-expressing cells than IFN -expressing cells. However, 
Ccr2-/- OT-II cells were unimpaired in their ability to secrete effector cytokines upon 
restimulation compared with WT OT-II cells. 
 
Given that TCM, TEM and TRM-like cells expressed different levels of CCR2, it was 
assessed whether CCR2-deficiency differentially affected formation of these memory 
subsets. In the spleen, despite TEM expressing significantly more CCR2 than TCM, the 
frequency of TEM and TCM subsets of Ccr2-/- OT-II cells were equivalent to that of WT 
OT-II cells, although the total numbers of Ccr2-/- cells were reduced (Fig. 4.6 A, B). In 
the lung, there was a trend towards a reduction of TCM cells in the Ccr2-/- OT-II 
compartment compared with WT OT-II, and a significant increase in formation of TEM 
and TRM-like cells (Fig. 4.6 C-E). However, the total numbers of Ccr2-/- TCM and TEM 
OT-II cells were still significantly reduced in the lung (Fig. 4.6 F, G). This suggests that 
although Ccr2-/- TCM and TEM OT-II cells both underwent enhanced contraction compared 
with WT OT-II memory cells, this was more pronounced in the TCM compartment. 
Furthermore, the Ccr2-/- TRM-like OT-II cells appeared to be protected from this effect 
and were present at comparable numbers to their WT counterparts (Fig. 4.6 H), although 
their frequency was significantly increased due to the contraction of the TCM and TEM 
compartments.  
 
4.5 CCR2-deficiency does not affect effector responses by OT-II cells 
in S. pneumoniae infection 
To assess whether the enhanced contraction of the Ccr2-/- OT-II cells might be explained 
by a difference in the effector phase of the response, cytokine production by OT-II cells 
was measured at early time-points post-infection. Similarly to the memory response, 
production of IL-17 and IFN  at 7 days post-infection was unimpaired in Ccr2-/- 
compared to WT OT-II cells in the spleen, medLN and lung (Fig. 4.7 A, C, E). On day 
14, at which point there is minimal difference in the numbers of WT and Ccr2-/- OT-II 




towards decreased production of IFN  in the lung by Ccr2-/- OT-II cells (significance 
value of p=0.06) (Fig. 4.7 B, D, F). 
 
CCR2 has previously been shown to be required for entry of T cells to sites of 
inflammation205,276. The equal numbers of WT and Ccr2-/- OT-II cells present in the lung 
at 7 days post-infection suggest that CCR2 is not required for CD4+ T cell entry into the 
lung in response to S. pneumoniae infection, but to test this more directly, the ratio of 
Ccr2-/- OT-II cells to WT OT-II cells was compared between the peripheral blood (PB) 
and the lung (Fig. 4.8). If CCR2 was required for entry in the lung, then an increased 
ratio would be expected in the PB versus the lung. At 7 days post-infection, the ratio was 
comparable between PB and lung, suggesting entry into the lung is CCR2-independent. 
Furthermore, on day 14 the ratio of Ccr2-/- to WT OT-II cells was higher in the lung than 
in the PB. This indicates that the Ccr2-/- OT-II cells may contract more rapidly in the 
circulation than in the lung tissue, or are diverted elsewhere.  
 
4.6 CCR2 is expressed on influenza-specific TH1 cells 
Previous publications have reported CCR2 expression on diverse subsets of CD4+ T cells 
in both human and mouse234,236,237,277. As described above, CCR2 is expressed on CD4+ 
T cells in response to S. pneumoniae, which induces a mixed type 1/type 17 response, 
although a greater proportion of OT-II cells expressed IL-17 at memory timepoints. To 
test if CCR2 is also important for CD4+ T cells induced in a predominantly type 1 
infection, the influenza A virus model was used. Influenza induces a type 1 response 
through intracellular infection of lung epithelial cells278, with protection largely mediated 
through influenza-specific antibody and the cytolytic activity of CD8+ T cells.  In this 
model, TH1 cells are critical for enabling optimal CD8+ T cell priming and memory, with 
TFH cells mediating T-dependent humoural immune responses. 
 
To assess the endogenous CD4+ T cell response to influenza, the A/HKX31 (referred to 
henceforth as X31) was used. This is a recombinant influenza A virus expressing the 
H3N2 surface proteins and is considered to be of low pathogenicity in mice, despite 
inducing weight-loss following infection279. B6 mice were infected intranasally with 7.3 
TCID50 of X31, and analysed 7 to 10 days post-infection (Fig. 4.9 A). To detect X31-




peptides that have previously been shown to be immunodominant class II-restricted 
epitopes in B6 mice following influenza infection280. A small proportion of CD4+ T cells 
in the lung and spleen of immunised mice expressed IFN  in response to stimulation, 
with no IFN  detected in the absence of these peptides (Fig. 4.9 B).  However, low cell 
yields prevented robust analysis of IFN  production by CD4+ T cells in the medLN, PB 
and bronchoalveolar lavage (BAL), and so CD44hi CD4+ T cells were also measured as 
a surrogate, since the patterns of CCR2 expression on CD44hi and IFN + CD4+ T cells 
were similar in the lung and spleen. CCR2 expression was induced on TH1 cells and 
activated CD4+ T cells on day 7 after influenza infection in spleen and lung, and further 
upregulated in these organs by day 10. The expression of CCR2 on HA211-225– and NP311-
325–specific CD4+ T cells was similar. On CD44hi CD4+ T cells isolated from the medLN, 
PB and BAL similarly upregulated CCR2 expression by day 10. A similar analysis was 
performed at day 28 to assess CCR2 on memory CD4+ T cells (data not shown), but IFN -
producing CD4+ T cells could not be reliably detected using this approach, likely due to 
the low frequency of these cells at memory timepoints. 
 
To circumvent this issue, the OT-II TCR transgenic system was again utilised. 
Congenically labelled OT-II cells were transferred intravenously into Ly5.1 hosts, and 
infected the following day with X31 that has been modified to express OVA323-339 (X31-
OVA323-339)281 (Fig. 4.10). The OT-II cells showed robust activation and expansion in 
this model. In the spleen, CCR2 was upregulated by day 7, but CCR2+ cells remained at 
a consistent frequency on days 14 and 28 post-infection. Conversely, in the medLN and 
lung, CCR2-expressing OT-II cells were further enriched at later time-points. This may 
reflect that OT-II cells increasingly upregulated CCR2 after infection, or that CCR2-
expressing cells had an increased propensity to survive the contraction phase.  
 
The ability of OT-II cells to form different memory subsets in response to influenza was 
then assessed. In both spleen and lung, TEM cells outnumbered TCM cells, although both 
subsets were present (Fig. 4.11 B-C). Similarly to S. pneumoniae infection, cells of a 
TRM-like phenotype were identified in the lung, but were not reliably detected in the 
spleen. In contrast to that observed in response to S. pneumoniae, CCR2 was expressed 





4.7 CCR2 is expressed on regulatory T cells 
Briefly, to determine whether CCR2 is expressed by regulatory CD4+ T cells in this 
model, CCR2 expression on the endogenous repertoire of Treg cells was measured. Treg 
cells can be categorised based on their ontogeny, with thymic-derived Tregs referred to 
as natural Treg (nTregs) and those generated in the periphery as induced Tregs 
(iTregs)282. CCR2 expression was highly expressed on both Treg subsets in the lung, and 
expressed at reduced levels in the spleen and medLN (Fig. 4.12 B). This is consistent 
with the higher expression of CCR2 on TH1 and TH17 cells in the lung, compared with in 
the secondary lymphoid organs. It was then assessed whether transferred OT-II cells 
could turn on Foxp3 and gain a regulatory phenotype in influenza infection. On day 7 
post-infection, Foxp3 expression was low in all tested organs, however on day 14, 
approximately 10-15% of OT-II cells in the spleen and medLN, but not the lung, 
upregulated Foxp3 expression (Fig. 4.12 D-E). Furthermore, when CCR2 expression was 
compared between OT-II cells that were Foxp3– and Foxp3+, CCR2 was significantly 
upregulated on those that had gained Foxp3 expression (Fig. 4.12 F-G). 
 
4.8 Ccr2-/- OT-II cells show enhanced contraction after influenza A 
infection 
To determine if, as observed in the response to S. pneumoniae, CCR2 on TH1 cells in 
influenza promotes maintenance into the memory phase, WT and Ccr2-/- OT-II cells were 
co-transferred into congenic recipients and infected with X31-OVA323-339. Similarly to S. 
pneumoniae infection, Ccr2-/- OT-II showed enhanced contraction compared with WT 
OT-II cells from day 14, despite being present at equivalent numbers on day 7 (Figure 
4.13). This was also reflected in the ratio of Ccr2-/-/WT OT-II cells, with an 
approximately 1:1 ratio on day 7, followed by a sharp skew in favour of the WT cells. 
This suggests that although the initial expansion of these cells was similar, Ccr2-/- OT-II 
cells had a reduced ability to survive or proliferate during the contraction phase. 
 
As above, the functional capacity of memory TH1 cells was analysed. At 28 days after 
infection, memory Ccr2-/- OT-II cells in the spleen and medLN had unimpaired 
production of IFN  (Fig. 4.14 A, B). However, there was a significant decrease in IFN  
production by Ccr2-/- OT-II cells taken from the lung (Fig. 4.14 C). Despite there being 




overall Ccr2-/- TEM numbers were reduced compared with WT TEM, in line with the 
enhanced contraction seen by Ccr2-/-  OT-II cells (Fig. 4.14 D). Although not statistically 
significant, the frequency of Ccr2-/- OT-II cells with a TRM-like phenotype trended 
towards an increase (p=0.08) compared with that of WT OT-II cells, despite their 
numbers being slightly, but significantly reduced (Fig. 4.14 E). These data are similar to 
those obtained in the S. pneumoniae model, in which TRM-like cells appeared to be 
somewhat protected from the enhanced contraction seen in the circulating populations.  
 
4.9 CCR2 is not required for initial TH1 effector responses in 
influenza. 
To assess whether CCR2 had a cell-intrinsic role in the initial effector phase of the TH1 
response to influenza, mixed bone marrow (BM) chimeras were generated. This was 
possible since the endogenous influenza-specific CD4+ T cells could be analysed with 
peptide restimulation, unlike the S. pneumoniae model. BM from Ly5.1 mice and Ccr2-
/- mice were mixed at a 1:1 ratio and transferred into lethally irradiated Ly5.1 hosts and 
the immune system was allowed to reconstitute for 8 weeks prior to experimentation (Fig. 
4.15, green). To control for any possible congenic biases as has been previously reported 
for B cells283, control chimeras were performed in which a 1:1 ratio of BM from Ly5.1 
and B6 was transferred (Fig. 4.15, black). In all experiments, no differences were seen in 
the control chimeras, suggesting there is no congenic bias on CD4+ T cells in this model. 
Seven days after infection with X31, the generation of influenza-specific TH1 cells was 
assessed through ex vivo stimulation with the peptides HA211-225 and NP311-325.  In the 
medLN and spleen, equal frequencies of IFN -producing CD4+ T cells were detected in 
the Ccr2-/- and Ly5.1 compartments, regardless of which peptide was used for stimulation 
(Fig. 4.15 B-E). The critical lineage-defining transcription factor for TH1 cells is T-bet, 
with this being critical for their appropriate differentiation and production of IFN  and 
other effector cytokines284. Ccr2-/- CD4+ T cells displayed upregulation of T-bet 
equivalent to Ly5.1 CD4+ T cells (Fig. 4.15 F-G). Expression of TNF  by activated Ccr2-
/- CD4+ T cells was also unaltered compared with WT. Furthermore, the formation of TFH 
cells, which are robustly induced in influenza to promote the humoural immune response, 





In these mixed BM chimeras, mice were injected with fluorescently-labelled antibody 
prior to being culled in order to distinguish between cells in the lung vasculature 
(intravascular, IV) versus those in the parenchyma (extravascular, EV). This allowed 
comparison of the frequency of CD45.2+ cells that were present in each compartment, 
which tested whether CCR2 had any role in CD4+ T cell migration into the lung 
parenchyma at this timepoint. Both HA211-225– and NP311-325–specific Ccr2-/- CD4+ T cells 
were equivalently represented in the IV and EV compartments, ruling out a role for CCR2 
in lung entry at this time-point (Fig. 4.16). Thus, CCR2 does not appear to play a role in 
the major effector functions or trafficking of TH1 cells in the initial response to influenza, 
and its function seems to be restricted to a later time-point, coinciding with its increased 
expression. 
 
4.10 Ccr2-/- OT-II cells display impaired cytokine production upon 
influenza rechallenge 
To assess if Ccr2-/- TH1 cells have deficient recall ability, WT and Ccr2-/- OT-II cells 
were co-transferred at a 1:1 ratio and infected with X31-OVA323-339 (Figure 4.17). 
Twenty eight days after the primary infection, mice were rechallenged with the 
heterotypic influenza A strain PR/8-OVA323-339. The internal proteins of X31 are derived 
from PR/8, meaning these residues will be recognised by memory CD4+ and CD8+ T 
cells, but PR/8 expresses surface H1N1 proteins instead of H3N2 in X31, limiting 
antibody-mediated secondary responses. In the lung, the number of CD44hi OT-II cells 
were increased seven days post-rechallenge, compared to mice that were not rechallenged 
(Figure 4.17 B). However, there was no detectable expansion of OT-II cells in the spleen 
or medLN in rechallenged mice compared with the control, indicating only OT-II cells 
in the lung were responding to the secondary infection. In the lung, WT and Ccr2-/- OT-
II cells showed no difference in their ability to expand upon secondary infection (Figure 
4.17 E). However, Ccr2-/- OT-II cells were significantly impaired in their ability to 
secrete IFN  compared with WT OT-II cells (Figure 4.17 F). 
 
4.11 Conclusion 
In this chapter, the role of CCR2 on CD4+ T cells was studied in two disparate infectious 
models. In response to both S. pneumoniae and influenza A infection, CCR2 was 




CCR2 was preferentially expressed on TEM and TRM-like S. pneumoniae–specific 
memory cells, whilst being consistently expressed among TCM, TEM and TRM-like cells in 
influenza infection. Cell-intrinsic loss of CCR2 led to enhanced contraction of CD4+ T 
cells after infection in both models, with TRM-like cells present in the lung being 
somewhat protected from this effect. The absence of CCR2 did not appear to affect initial 
cytokine production or entry into the inflamed lung, however it did lead to reduced IFN  
production by memory TH1 cells in influenza infection.  Despite the reduced numbers of 
Ccr2-/- CD4+ T cells in the memory response, these cells were equally capable of 
expanding upon secondary challenge in both models, although influenza-specific CD4+ 
T cells displayed inhibited ability to secrete IFN . Thus, these data suggest that CCR2 is 















Figure 4.1: Validation of antigen-specific S. pneumoniae model. 
Genetically modified D39 S. pneumoniae strains were generated through insertion of 
OVASIINFEKL or OVA323-339 peptides into the PspA protein. (A) WT B6 mice were 
infected with the unmodified parental strain D39, D39-OVASIINFEKL or D39-OVA323-339. 
Bacterial load in the nasal wash (left) and homogenised nasal tissue (right) was analysed 
seven days post-infection. n=5 mice, one-way ANOVA. Mean ± SEM (B-D) CD45.1.2+ 
OT-II cells were adoptively transferred into Ly5.1 hosts. Mice were subsequently 
infected with D39-OVASIINFEKL or D39-OVA323-339. (B) Schematic of experiment. (C) 
Representative gating of transferred OT-II cells in lung of D39-OVASIINFEKL challenged 
mice (left) or D39-OVA323-339 challenged mice 7 days post-infection (right). (D) Number 
of CD44hi OT-II cells in the indicated organs. n=2-4 mice, Mean ± SEM. * p ≤0.05. 


























Figure 4.2: CCR2 is expressed on antigen-specific CD4+ T cells in S. pneumoniae 
infection. 
CD45.1.2+ OT-II cells (105) were adoptively transferred into Ly5.1 hosts which were 
infected intranasally one day later with 107 CFU of D39-OVA323-339. (A) Schematic of 
experiment. (B) Bacterial load in the nasal wash. (C) Representative expression of CCR2 
on CD44hi or naïve OT-II cells post infection. (D-F) Quantification of CCR2 expression 
on CD44hi OT-II cells in the indicated organs. n=10-12 mice, one-way ANOVA. Pooled 














Figure 4.3: CCR2 is expressed on memory subsets after S. pneumoniae infection. 
CD45.1.2+ OT-II cells (105) were adoptively transferred into Ly5.1 hosts which were 
infected intranasally one day later with 107 CFU of D39-OVA323-339. Mice were analysed 
28 days post infection. (A) Representative gating of CD62Lhi CD44hi (TCM), cells 
CD62Llo CD44hi (TEM) cells and CD11ahi CD69+ (TRM-like) cells.  Cells were pregated 
on live CD4+ CD45.2+ cells. (B) Frequency of transferred OT-II cells with different 
memory phenotypes in the spleen. (C) Frequency of transferred OT-II cells with different 
memory phenotypes in the lung. (D) Frequency of CCR2 expression on memory OT-II 
cells in the spleen, unpaired t-test. (E) Frequency of CCR2 expression on memory OT-II 
cells in the lung, one-way ANOVA. (F) Frequency of CCR2 expression on endogenous 
memory CD4+ T cell subsets in the spleen, one-way ANOVA. (G) Frequency of CCR2 
expression on endogenous memory CD4+ T cell subsets in the lung. n=7-10 mice, one-




























Figure 4.4: CCR2-deficient OT-II cells contract more rapidly after S. pneumoniae 
infection. 
WT (CD45.1.2+) and Ccr2-/- (CD45.2+) OT-II cells were mixed at a 1:1 ratio and 2x105 
total cells were transferred into Ly5.1 hosts, which were subsequently infected with 107 
CFU of D39-OVA323-339. (A) Schematic of experiment. (B) Representative gating 
strategy of transferred OT-II cells, pre-gated on live cells. (C-E) Kinetic analysis of 
number of WT and Ccr2-/- OT-II cells in (C) spleen, (D) mediastinal LN and (E) lung 
after infection. (F-H) Ratio of Ccr2-/- OT-II to WT OT-II cells in the (F) spleen, (G) 
mediastinal LN and (H) lung after infection. n=12 mice, one-way ANOVA. Data pooled 





















Figure 4.5: CCR2 does not affect cytokine production by memory OT-II cells. 
WT (CD45.1.2+) and Ccr2-/- (CD45.2+) OT-II cells were mixed at a 1:1 ratio and 2x105 
total cells were transferred into Ly5.1 hosts, which were subsequently infected with 107 
CFU of D39-OVA323-339 and analysed 28 days post-infection. (A-C) Frequency of IL-17+ 
OT-II in the (A) spleen, (B) medLN and (C) lung. (D-F) Frequency of IFN + OT-II in 
the (D) spleen, (E) medLN and (F) lung. n=11 mice. Pooled from 2 independent 








Figure 4.6: Ccr2-/- TEM and TCM, but not TRM-like OT-II cells undergo enhanced 
contraction compared with WT OT-II cells. 
WT (CD45.1.2+) and Ccr2-/- (CD45.2+) OT-II cells were mixed at a 1:1 ratio and 2x105 
total cells were transferred into Ly5.1 hosts, which were subsequently infected with 107 
CFU of D39-OVA323-339 and analysed 28 days post-infection. (A) Frequency and number 
of CD62Lhi CD44hi (TCM) cells in the spleen. (B) Frequency and number of CD62Llo 
CD44hi (TEM) cells in the spleen. (C) Frequency and number of CD62Lhi CD44hi (TCM) 
cells in the lung. (D) Frequency and number of CD62Llo CD44hi (TEM) cells in the lung. 
(E) Frequency and number of CD11ahi CD69+ (TRM-like) cells in the lung. n=7-10 mice, 
Wilcoxon matched-pairs signed rank test. Pooled from 2 independent experiments. Mean 







Figure 4.7: CCR2 does not affect cytokine production by OT-II cells in the acute 
response to S. pneumoniae infection.  
WT (CD45.1.2+) and Ccr2-/- (CD45.2+) OT-II cells were mixed at a 1:1 ratio and 2x105 
total cells were transferred into Ly5.1 hosts, which were subsequently infected with 107 
CFU of D39-OVA323-339. (A-B) Frequency of IL-17+ and IFN + OT-II cells in the spleen 
at (A) 7 or (B) 14 days post-infection. (C-D) Frequency of IL-17+ and IFN + OT-II cells 
in the lung at (C) 7 or (D) 14 days post-infection. (E-F) Frequency of IL-17+ and IFN + 
OT-II cells in the medLN at (E) 7 or (F) 14 days post-infection. n=5-10 mice, Wilcoxon 
matched-pairs signed rank test. (A, C, E) Pooled from two similar experiments. (B, D, F) 















Figure 4.8: CCR2 is not required for OT-II entry into the lungs. 
WT (CD45.1.2+) and Ccr2-/- (CD45.2+) OT-II cells were mixed at a 1:1 ratio and 2x105 
total cells were transferred into Ly5.1 hosts, which were subsequently infected with 107 
CFU of D39-OVA323-339. Ratio of Ccr2-/- OT-II to WT OT-II cells in the peripheral blood 
versus the lung (A) 7 days or (B) 14 days post-infection. n=5 mice, paired t-test. Mean ± 








Figure 4.9: CCR2 is expressed on influenza-specific CD4+ T cells. 
WT mice were infected with 7.3 TCID50 X31 intranasally and endogenous influenza-
specific TH1 cells were analysed by ex vivo restimulation with HA211-225 or NP311-325 
peptide. (A) Schematic of experiment. (B) Representative gating strategy of IFN  
production by CD4+ T cells in the absence or presence of peptide restimulation. (C) 
Representative expression of CCR2 on IFN + or CD44hi CD4+ T cells from the lung on 
day 7 or 10 after influenza infection. (D-E) Frequency of CCR2 expression on CD44hi 
(black) or IFN + CD4+ T cells from (D) spleen or (E) lung after restimulation with HA211-
225 (grey) or NP311-325 (white) peptide. (F-H) Frequency of CCR2 expression on CD44hi 
CD4+ T cells from (F) mediastinal LN, (G) peripheral blood and (H) bronchoalveolar 
lavage. n=5 mice, unpaired t-test. Data representative of two similar experiments. Mean 










Figure 4.10: CCR2 is expressed on OT-II cells in response to influenza infection. 
WT (CD45.1.2+) OT-II cells (103) were transferred into Ly5.1 hosts, which were 
subsequently infected with 10 TCID50 X31-OVA323-339. (A) Schematic of experiment. 
(B) Representative gating strategy of transferred OT-II cells. (C) Representative 
expression of CCR2 on transferred OT-II cells or naïve CD4+ T cells in the lung after 
infection. (D-F) Frequency of CCR2 expression on CD44hi OT-II cells from (D) spleen, 
(E) mediastinal LN and (F) lung after infection. n=5 mice, one-way ANOVA. Mean ± 









Figure 4.11: CCR2 is expressed on memory CD4+ subsets after influenza infection. 
WT (CD45.1.2+) OT-II cells (103) were transferred into Ly5.1 hosts, which were 
subsequently infected with 10 TCID50 X31-OVA323-339. Mice were analysed 28 days post-
infection. (A) Representative gating strategy of CD62Lhi CD44hi (TCM), cells CD62Llo 
CD44hi (TEM) cells and CD11ahi CD69+ (TRM-like) cells.  (B) Memory phenotype of 
transferred OT-II cells in the spleen. (C) Memory phenotype of transferred OT-II cells in 
the lung. (D) Frequency of CCR2 expression on memory OT-II cells in the spleen. (E) 







Figure 4.12: Regulatory T cells express CCR2. 
WT (CD45.1.2+) OT-II cells were transferred into Ly5.1 hosts, which were then infected 
with X31-OVA323-339. (A) Representative gating strategy of host iTreg (CD4+ Foxp3+ 
Nrp1–) and nTreg (CD4+ Foxp3+ Nrp1+) cells from the lung 7 days post-infection, 
pregated CD4+. (B) Representative expression of CCR2 on iTreg (black line) and nTreg 
(shaded grey) from the lung. (C) Frequency of CCR2 expression on iTreg and nTreg from 
the indicated organs, seven days post-infection. (D) Representative gating strategy of 
Foxp3 expression by transferred OT-II cells. (E) Frequency of Foxp3 upregulation on 
transferred OT-II cells. (F) Frequency of CCR2 expression on Foxp3– and Foxp3+ OT-II 
cells in the spleen 14 days post-infection. (G) Frequency of CCR2 expression on Foxp3– 
and Foxp3+ OT-II cells in the mediastinal LN 14 days post-infection. n=5 mice, paired t-







Figure 4.13: CCR2-deficient OT-II cells contract more rapidly after influenza 
infection. 
WT (CD45.1.2+) and Ccr2-/- (CD45.2+) OT-II cells were mixed at a 1:1 ratio and 2x103 
total cells were transferred into Ly5.1 hosts, which were subsequently infected with 10 
TCID50 X31-OVA323-339. (A) Schematic of experiment. (B) Representative gating 
strategy of transferred OT-II cells, pre-gated on live cells. (C-E) Kinetic analysis of 
number of WT and Ccr2-/- OT-II cells in (C) spleen, (D) mediastinal LN and (E) lung 
after infection. (F-H) Ratio of Ccr2-/- OT-II to WT OT-II cells in the (F) spleen, (G) 
mediastinal LN and (H) lung after infection. n=10-15 mice (4-5 mice per experiment), 
one-way ANOVA. Pooled from three similar experiments. Mean ± SEM. * p≤0.05, ** 







Figure 4.14: CCR2 deficiency affects the memory phenotype of TH1 cells in response 
to influenza infection.  
WT (CD45.1.2+) and Ccr2-/- (CD45.2+) OT-II cells were mixed at a 1:1 ratio and 2x103 
total cells were transferred into Ly5.1 hosts, which were subsequently infected with 10 
TCID50 X31-OVA323-339. Mice were analysed at 28 days post-infection. (A-C) IFN  
production by WT and Ccr2-/- CD44hi OT-II cells in (A) spleen, (B) mediastinal LN and 
(C) lung after infection. (D) Frequency and number of CD44hi CD62Llo TEM cells among 
OT-II cells from the lung. (E) Frequency and number of CD11ahi CD69+ TRM-like cells 
among OT-II cells from the lung. n=10 mice, Wilcoxon matched-pairs signed rank test. 














Figure 4.15: CCR2 deficiency has no effect on the initial effector response to 
influenza infection.  
Bone marrow from Ly5.1 (CD45.1+) was mixed at a 1:1 ratio with either B6 (control 
chimera; black) or Ccr2-/- (experimental chimera; green) CD45.2+ bone marrow and 
transferred into irradiated Ly5.1 recipients. After 8 weeks to allow reconstitution, 
chimeric mice were infected with X31 and analysed 7 days post-infection. (A) Schematic 
of experiment. (B-E) Frequency of IFN + cells among congenic CD4+ T cells in the (B, 
C) mediastinal LN or (D, E) spleen after restimulation with (B, D) HA211-225 peptide or 
(C, E) NP311-325 peptide. (F) Frequency of T-bet expression among congenic IFN + CD4+ 
T cells in the spleen. (G) Geometric MFI of T-bet in congenic IFN + CD4+ T cells from 
the spleen. (H) Frequency of TNF + cells among congenic CD44hi CD4+ T cells in the 
spleen. (I) Frequency of PD1hi CXCR5hi TFH cells from congenic CD44hi CD4+ T cells 


















Figure 4.16: CCR2 deficiency does not affect TH1 cell entry into the lung 
parenchyma after influenza infection.  
Bone marrow from Ly5.1 (CD45.1+) was mixed at a 1:1 ratio with either B6 (control 
chimera; black) or Ccr2-/- (experimental chimera; green) CD45.2+ bone marrow and 
transferred into irradiated Ly5.1 recipients. After 8 weeks to allow reconstitution, 
chimera mice were infected with X31 and analysed 7 days post-infection. Intravascular 
CD4+ T cells were labelled five minutes prior to harvest. (A) Schematic of experiment. 
(B) Frequency of CD45.2+ cells among intravascular (IV) and extravascular (EV) IFN + 
CD4+ T cells in the lung in response to restimulation with HA211-225 peptide. (C) 
Frequency of CD45.2+ cells among intravascular (IV) and extravascular (EV) IFN + 
CD4+ T cells in the lung in response to restimulation with NP311-325 peptide. n=6-7 mice, 







Figure 4.17: CCR2 deficiency does not affect the recall response of OT-II cells upon 
influenza rechallenge. 
WT (CD45.1.2+) and Ccr2-/- (CD45.2+) OT-II cells were mixed at a 1:1 ratio and 2x103 
total cells were transferred into Ly5.1 hosts, which were subsequently infected with 10 
TCID50 X31-OVA323-339. At 28 days post-infection, mice were rechallenged with 10 
TCID50 PR/8-OVA323-339 and analysed seven days post-rechallenge. (A) Schematic of 
experiment. (B-D) Number of CD44hi OT-II cells in (B) spleen, (C) medLN or (D) lung 
in mice with or without rechallenge with PR/8-OVA323-339. (E) Fold expansion of CD44hi 
OT-II cells in rechallenged mice over CD44hi OT-II cells from non-rechallenged mice in 
the lung. (F) IFN  production by CD44hi OT-II cells after rechallenge in the lung. n=5 


























Chapter 5 – Discussion 
5.1 ACKR4 regulates anti-tumour immune responses 
5.1.1 Loss of ACKR4 enhances tumour-directed immune responses 
The data presented in Chapter 3 demonstrated a novel role for ACKR4 in restraining anti-
tumour immune responses. ACKR4 deficiency led to inhibition of tumour growth in 
numerous orthotopic, transgenic and chemically-induced models of cancer. This was 
dependent on the enhanced intratumoural recruitment of CD8+ T cells that occurred in 
the absence of ACKR4. Alterations in CD8+ T cell priming were not apparent, suggesting 
that loss of ACKR4 affected activated CD8+ T cells. This was associated with increased 
retention of CD103+ DCs at the tumour site, with these cells previously being shown to 
critically regulate the magnitude of anti-tumour CD8+ T cell responses. Furthermore, 
direct intratumoural administration of CCL21 into ACKR4-sufficient hosts also led to 
increased accumulation of DCs at the tumour site, implying that chemokine scavenging 
by ACKR4 is mechanistically involved in the control of intratumoural DC egress. 
Haematogenous metastatic colonisation in multiple tumour models was also significantly 
curtailed in ACKR4-deficient hosts, although due to time constraints, this was not 
investigated in more detail. Finally, in keeping with the observed effects on the anti-
tumour immune response, loss of ACKR4 enhanced responsiveness to multiple 
immunotherapies, suggesting targeting intratumoural DCs through ACKR4 may 
potentially be a novel therapeutic target.   
 
The findings presented here demonstrating that loss of ACKR4 is protective in cancer are 
somewhat in contrast to previously published reports. Although reports into ACKR4 in 
tumours are limited, ACKR4 expression has been inversely correlated with LN metastasis 
and positively correlated with improved survival in breast cancer, cervical squamous cell 
carcinoma and hepatocellular carcinoma145,148,149. Transgenic expression of ACKR4 in a 
human breast cancer cell line attenuated tumour growth and metastasis in mouse models 
in vivo145. Similarly, with transgenic expression or shRNA-mediated knockdown of 
ACKR4 in human HCC cell lines, ACKR4 expression was inversely correlated with 
tumour growth149. In those studies, CCL19, CCL21 or CCL25 levels were altered, 
suggesting that the effects of ACKR4 were mediated via chemokine scavenging, although 
the mechanism of how tumour growth was altered was not described. Given that previous 




proliferation120,126,127, it is likely that when ACKR4 expression is low, the lack of 
chemokine scavenging leads to higher levels of CCL19 and CCL21, which can promote 
tumour growth. However, in both of those studies, all mouse experiments were performed 
in nude mice, which lack T cells and thus the ability to mount T cell-dependent tumour-
directed immune responses. Thus, the relative contributions of the tumour-promoting 
functions of CCL21 and the immunomodulatory functions is undetermined. Given that 
in the data described in this thesis, loss of ACKR4 enhanced CD8+ T cell-mediated 
control of tumour growth, studying the role of ACKR4 in systems with an intact immune 
system is crucial for accurate assessment of the translatability of targeting ACKR4 in 
human disease. The only published report of ACKR4 in tumour models with an intact 
immune system came previously from our laboratory, in which transgenic expression of 
ACKR4 on 4T1.2 murine breast cancer cells was shown to reduce primary tumour 
growth, whilst enhancing both spontaneous and haematogenous metastasis to the lung146. 
However, this effect appeared to be independent of the host immune system, as 
inoculation of these cell lines into NK cell-depleted SCID mice, which lack both T and 
B cells, still led to accelerated growth of the ACKR4-overexpressing line.  In that model, 
enhanced metastasis was determined to be mediated through TGF -mediated enhanced 
epithelial-mesenchymal transition. These data emphasise that ACKR4 may have 
different roles depending on whether it is expressed by the host or on tumour cells. In 
most of the work described in Chapter 3, ACKR4 deletion is restricted to the host, with 
orthotopic injection of ACKR4-sufficient cells. However, inhibited tumour growth was 
still seen in the transgenic MMTV-PyMT model and the MCA-induced fibrosarcoma 
model in which tumours arise from Ackr4–/– cells. This suggests that at least in these 
models, any potential tumour-suppressive effects of tumour expression of ACKR4 as a 
result of the subsequent decreases in local chemokines are outweighed by its 
immunomodulatory role. Thus, these data are the first to establish a role for ACKR4 in 
regulating immune responses to cancer. 
 
5.1.2 ACKR4 is expressed by luminal epithelial cells 
This work also identified a novel source of expression of ACKR4 in the luminal epithelial 
cells of the murine mammary gland. In the absence of a highly specific antibody for 
mouse ACKR4, transcript of Ackr4 was identified by cell sorting of mammary gland 




ACKR4 protein is expressed by these cells, but protein expression could be assessed 
through binding of fluorescently-labelled CCL19 to these cells, combined with the 
appropriate Ackr4–/– and Ccr7–/– controls as previously described259. Furthermore, 
assuming sufficient cells can be isolated, ex vivo scavenging assays may assess whether 
luminal expression of ACKR4 is directly capable of scavenging its ligands, although the 
enhanced levels of CCL21 in the mammary gland reported here are highly suggestive 
that it is. Lastly, it would be of great interest to track ACKR4 expression over tumour 
development, to determine if ACKR4 is dysregulated as malignancy progresses. This 
could be performed in orthotopic models, in which the effect of the tumour milieu on 
luminal ACKR4 expression could be assessed, as well as in the MMTV-PyMT model, 
which appears to derive from oncogenic mutations to the luminal cells themselves285. The 
analysis of CCL21 concentration in the naïve mammary gland compared with E0771 
tumours suggests that it is likely that ACKR4 expression changes over the course of 
tumour progression. The results of the present study showed that in Ackr4–/– mice, CCL21 
was significantly increased in E0771 tumours compared to naïve mammary glands, 
suggesting CCL21 is upregulated in response to the tumour. However, no substantial 
difference was seen between CCL21 in naïve mammary glands and tumours in WT mice, 
indicating ACKR4 may be upregulated by host cells in the tumour setting.    
 
5.1.3 ACKR4 deficiency enhances anti-tumour CD8+ T cell responses 
The ligands of ACKR4 are critical in controlling numerous aspects of homeostatic 
lymphocyte trafficking.  Therefore, a thorough investigation of tumour-infiltrating 
immune cells in WT and Ackr4–/– mice was conducted. The proportions of infiltrating 
cell subsets were largely unaltered, although CD8+ T cells, B cells and Ly6G– monocytic 
cells were increased in Ackr4–/– tumours. The role of B cells in modulating anti-tumour 
responses is controversial, with both pro-tumourigenic and anti-tumourigenic responses 
being reported. Intratumoural B cell infiltrates have been shown to correlate with 
improved patient prognosis and greater survival in a range of cancers286-288, with mouse 
models suggesting that protection may largely be mediated through antibody 
responses289.  Conversely, B cell depletion in multiple mouse tumour models reduced 
tumour growth and led to greater therapeutic responses, suggestive of a regulatory 
function of B cells in those models290-292. Similarly, the function of Ly6G– monocytic 
cells is also difficult to address without further characterisation as these cells are a highly 




angiogenesis and tumour growth to CD103+ Ly6C+ cells which have been shown to cross-
prime CD8+ T cells in Batf3–/– mice269,293. Regardless, given that depletion of CD8+ T 
cells in Ackr4–/– mice reverted tumour growth to WT levels, the enhanced CD8+ T cell 
response appears to be the predominant mechanism of tumour inhibition in Ackr4-/- mice. 
Interestingly, depletion of CD8+ T cells did not alter the tumour course in WT mice, 
despite CD44hi CD8+ T cells being detected within the tumours by flow cytometry. Thus, 
although present, these cells are not contributing to a strong anti-tumour response, 
suggesting that in addition to CD8+ T cell numbers being enhanced in Ackr4–/– mice, 
CD8+ T cells in these mice are more capable of mediating anti-tumour responses.  This 
may be a consequence of a number different factors, which will now be discussed in turn. 
 
One possibility is that CD8+ T cells from Ackr4–/– mice are more effective at inducing 
tumour cell death. A major mechanism of CD8+ T cell mediated destruction is through 
the release of cytolytic granules containing the serine protease granzyme B, which can 
induce apoptosis in the target cell294, although the proportion of CD8+ T cells expressing 
granzyme B was not significantly altered between WT and Ackr4–/– mice. The cytokine 
IFN  is also critical for tumour control24,295,296, and this was significantly upregulated in 
CD8+ T cells in the tumours of Ackr4–/– mice compared with WT mice, indicating this 
may contribute to the enhanced control in these mice.  
 
Another hypothesis to explain why WT CD8+ T cells could not control tumour growth is 
due to their expression of immunosuppressive checkpoint molecules such as PD-1, TIM-
3 and LAG-3. These molecules are induced on subsets of exhausted T cells, and act to 
inhibit CD8+ T cell effector function297,298. Indeed, approximately 40% of all CD8+ T 
cells in WT tumours expressed these markers individually, with approximately 15% of 
cells being PD-1+ TIM-3+ or PD-1+ LAG-3+, reported to be the most highly exhausted 
subsets261,262. However, expression of these markers was comparable with CD8+ T cells 
taken from Ackr4–/– tumours with the exception of PD-1, which was more highly 
expressed in Ackr4–/– mice. Together, these data indicate that the enhanced CD8+ T cell 
response in Ackr4–/–  mice is unlikely to be the result of reduced exhaustion, and in fact 
a higher proportion of Ackr4–/– CD8+ T cell may display functional exhaustion as 
indicated by their increased PD-1 expression, perhaps owing to an enhanced activation 




response to anti-PD-1 or anti-PD-L1 therapy, which is a key future priority of this project, 
but was not performed due to time constraints. 
 
Another factor that may contribute to the inability of WT intratumoural CD8+ T cells to 
induce effective anti-tumour immunity is their localisation within the tumour. The 
presence of CD8+ T cells within the tumour parenchyma has been shown to correlate with 
greater immune responses compared with cells that accumulate peritumourally or in the 
surrounding stroma, likely since many of the cytotoxic functions of CD8+ T cells require 
direct cell contact with their target15,35,36. Thus, if CD8+ T cells in WT tumours are 
excluded from the tumour bed, they may not be effective at inducing tumour cell 
apoptosis. Determining whether dysregulation of chemokines in Ackr4–/– tumours also 
alters the spatial distribution of CD8+ T cells within tumours would also be important to 
establish in future experiments. 
 
Interestingly, the enhanced CD8+ T cell response in Ackr4–/– mice did not appear to be a 
result of enhanced priming of these cells. Expression of Ki67, a marker of recently-
proliferated cells, by CD8+ T cells in Ackr4–/– LN was significantly reduced compared 
with those in WT LN. This is consistent with previous reports demonstrating reduced 
intranodal priming of T cells in Ackr4–/– mice, and is likely to be a result of altered 
migration of DCs, as will be discussed later140,144. Analysis of the endogenous repertoire 
of CD8+ T cells with TCRs specific for the immunodominant SIINFEKL epitope of the 
OVA protein, expressed by E0771-OVA tumour cells, revealed no difference in the 
numbers or frequencies of these tumour-specific cells within the draining LN, despite 
increased numbers being present in the tumour. To gain a more precise understanding of 
the early proliferation of these cells, future experiments could measure incorporation of 
the thymidine analog BrdU into these cells after their activation, to determine if there are 
more subtle differences in their priming which were not detected in the present study.  
 
Another possible explanation for the enhanced CD8+ T cell presence in Ackr4–/– tumours 
that was investigated was whether there was enhanced recruitment of naïve CD8+ T cells 
into tumours. Naïve T cells abundantly express CCR7, and may be preferentially 
recruited in Ackr4–/– tumours due to the increased abundance of CCL21. Although 
intratumoural recruitment of naïve T cells may be surprising given their homeostatic 




entering peripheral tissues, including tumours59,299,300.  Furthermore, once inside tumours, 
naïve CD8+ T cells can be primed in situ and contribute to an effective anti-tumour 
response, with activated intratumoural tumour-specific CD8+ T cells reportedly generated 
even in splenectomised mice with in utero-ablated LNs264. In a subsequent study, naïve 
T cell entry into tumours was found to be dependent on CCR7 and occurred through 
PNAd-expressing vasculature, similar to the PNAd-expressing HEVs required for LN 
entry. HEV-like structures have been reported to spontaneously develop in many mouse 
and human tumours, suggesting this may be more common than previously 
considered264,301,302. Furthermore, the presence of HEVs in tumours have been correlated 
with increased expression of CCL19 and CCL21, as well as with improved patient 
survival301. Despite this evidence suggesting that increased CCL21 in E0771 tumours 
from Ackr4–/– mice may lead to enhanced recruitment of naïve CD8+ T cells, this was not 
apparent when naïve OT-I cells were adoptively-transferred into established E0771 
tumours at early or late stages of growth in this study. Although naïve T cells were 
detected within the tumour parenchyma of both WT and Ackr4–/– mice, there was no 
significant difference in naïve cell number. This experiment may have been hampered by 
the large number of transferred cells used, which potentially could have saturated the 
system through consumption of the CCL21 gradient through CCR7-mediated ligand 
internalisation. However, a large number of cells were required to be transferred in order 
to detect any transferred cells within the tumour, as the large majority of naïve cells home 
to the secondary lymphoid organs after transfer.  
 
Collectively, the data discussed above suggest that the defining changes in the CD8+ T 
cell response in Ackr4–/– mice occur after these cells have been activated. Although this 
work has not definitively clarified the precise mechanisms, there are a number of 
possibilities that will be explored in future work, including enhanced recruitment of 
activated CD8+ T cells into the tumour, enhanced survival in the tumour, or enhanced 
proliferation in the tumour. For the latter, the data presented here suggests this may at 
least be one mechanism, as there was an increase in Ki67 expression among tumour-
infiltrating CD8+ T cells in Ackr4–/– mice. This may be further assessed in future 
experiments through a short-term administration of BrdU to detect proliferating cells 
within the tumour. 
 




Many aspects of the generation of anti-tumour CD8+ T cell responses are controlled 
through DCs, including their recruitment and proliferation in tumours. Thus, the 
accumulation of DCs seen within Ackr4–/– tumours is highly likely to influence the extent 
of CD8+ T cell infiltration. The Batf3-dependent lineage of DCs, which encompasses the 
migratory CD103+ DCs and CD8 + LN-resident DCs appear to be the most prominent 
DC subsets influencing CD8+ T cell responses21,60. CD103+ DCs have been shown to be 
the predominant transporter of tumour-associated antigen to the draining lymph nodes, 
where they can cross-prime CD8+ T cells in addition to handing antigen to other DC 
subsets21. Depletion of this lineage using Zbtb46-DTR mice abrogated the tumour 
inhibition mediated by transfer of tumour-specific CTLs. Cross-presenting DCs, likely 
CD103+ DCs, have also been shown to prime CD8+ T cells directly within the tumour. In 
the B16-F1 model, the Tyr369 epitope is unable to be directly presented by tumour cells 
due to the absence of the appropriate class I MHC molecule59. However, in mice treated 
with FTY720 to prevent cell egress from LN, transferred Tyr369-specific CD8+ T cells 
were still capable of being activated in the tumour, indicating that intratumoral APCs 
could cross-present antigen to these cells.  
 
CD103+ DCs have also been recently shown to mediate CD8+ T cell recruitment to 
tumours. Despite CD8+ T cells expressing multiple functional chemokine receptors, 
recruitment of CD8+ T cells is predominantly mediated through CXCR3, the receptor for 
CXCL9 and CXCL10 (and CXCL11 in humans and some mouse strains)93. In a 
genetically-engineered melanoma model, intratumoural CD103+ DCs were shown to be 
the predominant source of CXCL10 in the tumour, with these cells being critical for 
intratumoural recruitment of transferred antigen-specific cells95. Similar results were 
seen in the MMTV-PyMT breast cancer model, although CD103+ DCs produced CXCL9 
more abundantly than CXCL10303. Collectively, it is clear that CD103+ DCs are critical 
in controlling the magnitude of the CD8+ T cell response. Thus, it is possible that the 
enhanced number of CD103+ DCs detected in Ackr4–/– tumours may be promoting 
increased recruitment of activated CD8+ T cells through secretion of CXCL9 and 






The increase in the number of CD103+ DCs in tumours from Ackr4–/– mice is coupled 
with a decrease in migratory CD103+ DC numbers in the LN. Given that CD103+ DCs 
are critical for antigen trafficking and cross-priming in the LN, the enhanced CD8+ T cell 
response in Ackr4–/– mice is perhaps surprising. Tumour-specific CD8+ T cells are still 
clearly being primed despite the decrease in migratory CD103+ DC at later time-points, 
and it would be of interest to examine  the CD103+ DC population in the tumour and LN 
to determine whether this deficit is also apparent at earlier time-points.  In addition to 
priming by CD103+ DCs, tumour-specific CD8+ T cells have been shown to be cross-
primed by CD169+ macrophages in LN through passive draining of antigen from dead 
tumour cells, suggesting DCs egressing from tumours may not be the sole determinant of 
CD8+ T cell priming in the LN304. It is also possible that there is a threshold of DC 
trafficking required to initiate CD8+ T cell priming, and the migration observed in 
ACKR4-deficient mice is sufficient to achieve optimal priming.  The increased number 
of these highly potent antigen-presenting cells would then contribute to the enhanced 
activation of the primed CD8+ T cells at the tumour site. 
 
ACKR4 appears to be regulating DC egress from tumours to LNs, as well as altering 
chemokine distribution at the tumour site. The altered CCL21 abundance in the tumour 
was mimicked experimentally through CCL21 administration directly into tumours of 
WT mice, which also led to increased accumulation of DCs in the tumour. It is well 
established that migratory DCs can use CCR7 to migrate to lymphatic vessels to egress 
from tissues108,305-307. Although all migratory DCs can express CCR7, in tumour models 
CD103+ DCs have been reported to express the highest levels of CCR7268,308. Thus, in 
Ackr4–/– mice, the disruption of a CCL21 gradient towards afferent lymphatics would 
impair CCR7-mediated DC egress. This is consistent with a previous report identifying 
a key role for ACKR4 in regulating DC egress from the skin253. In that study, ACKR4 
expressed by skin keratinocytes scavenged CCL19 and CCL21, and in mice lacking 
ACKR4 there was impaired egress of DC from skin to LN under both homeostatic and 
inflammatory conditions. As shown in this study, ACKR4 is also expressed by luminal 
epithelial cells in the mammary gland, and it is proposed that one of its main functions 
here is to scavenge CCL21 in order to maintain a functional chemokine gradient required 
for DC entry into the lymphatics through CCR7 (Figure 5.1). Lymphatic vessels in the 
mammary gland have been reported to express CCL21, and the distal location of ACKR4 




work in Ccr7–/– mice, migratory CD103+ and CD11b+ DCs in the LN were drastically 
reduced, although intriguingly there was no concomitant increase within B16 tumours268. 
The reasons for the discrepancy between the previous study and the data presented in this 
study is unclear, but one possible explanation is that active signalling through CCR7 on 
DCs may be required for both recruitment and retention in Ackr4–/– tumours, rather than 
simply a loss of CCR7-mediated migration to lymphatic vessels as a result of a disrupted 
chemotactic gradient. 
 
Another question posed by the data presented in this thesis is whether disruption of 
CCL21 alone in the mammary gland is sufficient to mimic the enhanced anti-tumour 
response seen in ACKR4-deficient mice.  In tumours treated with exogenous CCL21, 
there was a significant enhancement in intratumoural DCs. This supports the idea that 
ACKR4 is controlling egress of intratumoural DC via scavenging of CCL21. However, 
CCL21 administration alone did not lead to inhibited tumour growth, suggesting 
dysregulation of this chemokine in the mammary gland alone was not sufficient for an 
enhanced anti-tumour response and inhibited growth. However, this experiment did not 
completely replicate loss of ACKR4 in the mammary gland, as CCL21 was not 
administered until tumours were palpable at day 7. Thus, the initial priming of CD8+ T 
cells would not have been disturbed. Furthermore, although CCL21 appears to be the 
predominant chemokine that is altered in Ackr4–/– glands, the other ligands may also 
contribute to the defects seen, although this may be unlikely given the undetectable levels 
of CCL19 and equivalent levels of CCL25. Clearly, the experimental parameters tested 
with respect to administration of exogenous CCL21 should be expanded in future and 
further work will need to address the contribution of ACKR4 specifically in the 
mammary gland to the phenotype observed. 
 
Lastly, the enhanced CD8+ T cell response in Ackr4–/– mice was essential for control of 
E0771 tumours, but it remains to be seen whether CD8+ T cells are also responsible for 
the reduced tumour growth in the other tumour models used in this study. Particularly for 
haematogenous metastasis experiments, previous reports have demonstrated a high 
dependence on NK cells for immunity, whereas CD8+ T cells have varied 
contributions310-312. Although ACKR4 did not appear to influence NK cells in primary 
mammary gland responses, whether it may modulate NK cell-mediated metastasis 




chemokine levels and immune cell recruitment into the lung tumours should also be 
assessed. 
 
5.1.5 ACKR4 deficiency enhances immunotherapy responsiveness 
Since the loss of ACKR4 enhanced the magnitude of the anti-tumour CD8+ T cell 
response, it was assessed whether combining this with immunotherapies that enhance the 
activity of CD8+ T cells may lead to greater therapeutic responses. Monoclonal antibodies 
(mAb) directed towards PD-1 and CTLA-4 are FDA-approved and thus analysis of these 
immunotherapies in Ackr4–/– mice is of great interest.  However, the E0771 model is 
reportedly not responsive to anti-PD-1/anti-CTLA-4 treatment (Mark Smyth, personal 
communication) and so instead, a CD137 agonist was initially used in the E0771 model. 
Anti-CD137 treatment in tumours has been shown to protect CD8+ T cells from 
activation-induced cell death, as well as promoting their effector function through 
enhanced production of IFN , granzyme B and perforin313.  Administration of the 
agonistic anti-CD137 mAb in Ackr4–/– mice led to significantly reduced E0771 tumour 
growth compared with either ACKR4 deletion or anti-CD137 treatment alone. Thus, 
combining deletion of ACKR4 to enhance CD8+ T cell recruitment with anti-CD137 
treatment to enhance their survival and effector function had a synergistic effect. The 
B16F10 melanoma and MC38 colon carcinoma model were also utilized, since these are 
commonly used mouse models for assessing the efficacy of immunotherapy, and are 
known to be responsive to PD-1 and CTLA-4 treatment314-316.  As observed with anti-
CD137 in the E0771 model, the response to anti-PD-1 and anti-CTLA-4 treatment was 
significantly enhanced in Ackr4–/– mice compared with WT mice. Anti-PD-1 and anti-
CTLA-4 are thought to affect distinct populations of cells, with anti-PD-1 treatment 
predominantly increasing exhausted-like CD8+ T cell subsets, while anti-CTLA-4 
promotes expansion of CD4+ effectors, particularly TH1-like cells, in addition to 
exhausted-like CD8+ subsets68. In the absence of immunotherapy treatment, ACKR4 
deficiency led to a reduction in B16F10 growth, although this was not as pronounced as 
in the E0771 model. This may reflect that there is not as significant an increase in 
intratumoural CD8+ T cells in B16F10 tumours relative to E0771 tumours, with the 
B16F10 model generally considered to be a poorly immunogenic cell line317. 
Alternatively, it may suggest that the CD8+ T cells in this model are more exhausted or 




tumour growth was observed in Ackr4–/– mice treated with control antibody. In contrast 
to the B16F10 line, this is a highly immunogenic line which is particularly sensitive to 
checkpoint blockade, as evidenced by the robust inhibition of tumour growth in WT mice 
treated with anti-PD-1317. However, ACKR4 deficiency greatly enhanced the therapeutic 
response to anti-PD-1 treatment, with minimal tumour burden in endpoint tumours 
observed.  
 
These data suggest that inhibiting ACKR4 in cancer may be a promising therapeutic 
target. Given the data presented here is with mice with global ACKR4 knockout, which 
display normal growth, normal rates of reproduction and appear otherwise healthy, it is 
likely that systemic administration of neutralising antibodies or other antagonists would 
be possible without severe clinical consequences. However, there are a few potential 
major limitations which need to be addressed with future work. One key issue is that 
using ACKR4-deficient mice is akin to a prophylactic treatment regime, with disruption 
of this axis occurring prior to tumour implantation or initiation. Thus, if neutralising 
antibodies to ACKR4 are generated, it will be critical to determine whether inhibition 
after tumour onset will still inhibit tumour growth. Alternatively, if the effect of ACKR4 
is entirely due to its scavenging ability, therapeutic administration of CCL21 or its other 
ligands may also be a useful approach. This is supported by previous studies, which have 
shown that exogenous injection of CCL19 or CCL21 into tumours can induce tumour 
rejection113,114,318,319. Although the mechanism for this was undescribed, one report 
indicated it was CXCL9–, CXCL10– and IFN –dependent318. However, this contrasts 
with the data described here, with exogenous administration of CCL21 into established 
E0771 tumours not affecting tumour growth. Thus, future experiments will need to 
address the timing of administration and tumour types used, to investigate if CCL21 may 
represent a plausible target. Lastly, the translatability to human cancer also remains to be 
seen, with analysis of ACKR4 in tumour exome datasets a priority for the future. 
 
5.2 CCR2 regulates maintenance of CD4+ T cell memory 
In Chapter 4, CCR2 was identified as an important regulator of memory CD4+ T cell 
responses. In response to infection with the extracellular bacteria S. pneumoniae or the 
intracellular influenza virus, CCR2 was upregulated on antigen-specific CD4+ T cells at 




CCR2 on CD4+ T cells had no discernible effect on priming of these cells, nor their ability 
to migrate to the lung during the effector phase of the response. However, during the 
resolution of the immune response, CCR2-deficient cells did not persist to the same 
extent as WT cells and contributed less to the memory compartment. CCR2-deficient 
CD4+ cells in influenza also had reduced production of IFN  compared to WT. Despite 
this, the proliferative response of CCR2-deficient CD4+ T cells upon secondary 
rechallenge was unimpaired. Thus, the role of CCR2 appears to predominantly involve 
control of CD4+ memory T cell proliferation or survival during the contraction phase. 
While a precise understanding of the mechanisms behind this remain unclear, these data 
provide the foundation for future investigation into the molecular control of CD4+ T cell 
memory. 
 
5.2.1 Antigen-specific infection models 
The data described in this study were obtained from two independent infection models. 
In the S. pneumoniae infection model, a novel transgenic bacterial strain was generated 
to study antigen-specific CD4+ T cell responses with the transgenic OT-II system.  
Infection with the OVA323-339-expressing S. pneumoniae was shown to induce both IFN  
and IL-17 production by CD4+ T cells, indicative of TH1 and TH17 responses, which is 
consistent with published reports of human and mouse S. pneumoniae 
infection154,275,320,321. In a second approach, the CD4+ T cell response to influenza A virus 
was utilised.  Similarly to the natural course of infection, OT-II cells predominantly 
formed TH1 cells as evidenced by their expression of IFN .  Furthermore, OT-II cells in 
influenza infection displayed much more robust expansion than in response to S. 
pneumoniae infection.  This was evidenced during the optimisation experiments for OT-
II cell numbers for transfer, as transfer of 105 OT-II cells was required for robust analysis 
in S. pneumoniae infection, while transfer of only 103 OT-II cells was sufficient for 
detection in influenza infection. Even with transfer of 105 OT-II cells in S. pneumoniae 
infection, the frequency of OT-II cells recovered was very low, particularly at later 
timepoints after infection. This made analysis of the properties of these cells difficult, 
and likely contributed to with wide variation in cytokine responses often seen between 
mice. This was less of an issue in the influenza model due to the higher cell recovery as 





The extent of proliferation of CD4+ T cells in S. pneumoniae and influenza infections 
may have been influenced by a number of factors, including antigen quantity, which 
would be dependent on the replication of virus or bacteria during infection, as well as the 
expression of the PspA protein in which the epitope is inserted in the bacteria, and antigen 
accessibility, which may be more or less able to be processed and presented by APCs 
depending on its location within the pathogen structure.  The number of transferred OT-
II cells may also have influenced the outcome of response, with previous studies 
demonstrating that transfer of high precursor frequencies can reduce proliferative 
potential, possibly through increased competition for long-lived DC interactions322,323.  
Frequencies of endogenous CD4+ T cell precursors have been estimated to range from 
100-3000 cells per mouse depending on the TCR specificity324-326, suggesting that the 
enhanced naïve T cell frequency in the S. pneumoniae OT-II model may affect their 
subsequent expansion, and potentially their transition into memory. 
 
5.2.2 CCR2 is expressed by antigen-specific CD4+ T cells after infection 
Expression of CCR2 was absent on naïve CD4+ T cells, but induced in response to 
infection with both S. pneumoniae and influenza.  Upregulation of the receptor on this 
population coincided with the resolution of the response and was significantly enhanced 
on antigen-specific CD4+ T cells in the lung, compared with those in the LN and spleen. 
In S. pneumoniae infection, CCR2 expression was more highly enriched on TEM and TRM-
like cells than on TCM in both spleen and lung. This is consistent with mass cytometry 
analysis of human CD4+ T cell subsets, which found CCR2 was enriched on CD69+ 
populations compared with CD69– populations on CD4+ T cells isolated from the colon, 
skin and liver of human patients with a variety of conditions, although expression of 
CCR2 in the lung was low237. This suggests that CCR2 may be more important for TRM-
like populations, as will be discussed later.  Furthermore, in addition to expression on 
TH1 and TH17 subsets, CCR2 was highly expressed by Treg cells, indicating it potentially 
plays a role in the trafficking of additional CD4+ T cell subsets. This is also consistent 
with published reports showing that CCR2 is required for trafficking of Tregs in tumour 
and allograft models101,235. Intriguingly, comparison of the low frequency of OT-II cells 
that induced Foxp3 after influenza infection with Foxp3– OT-II cells revealed that CCR2 
was significantly upregulated in those that had upregulated Foxp3, suggesting it may be 





Expression of CCR2 on CD4+ T cell subsets increased over time in each of the models 
examined. This suggests that the cytokines and transcription factors driving CCR2 
expression are likely those altered late in the response, and act to influence already 
differentiated cells.  Previous data from our laboratory investigated the transcriptional 
regulation of CCR2 and CCR6 on TH17 cells in EAE, specifically in the formation of 
CCR2+ CCR6+ and CCR2+ CCR6– TH17 cells205.  Despite increasing the frequency of 
CCR2+ CCR6+ cells at the expense of CCR2+ CCR6– cells, cell-intrinsic loss of T-bet did 
not affect overall expression of CCR2 on TH17 cells, whereas loss of Eomesodermin 
promoted a significant but minor reduction in CCR2+ TH17 cells.  Further insights can 
also be gained from transcriptional analysis of influenza-specific CD8+ T cells, which 
also upregulate CCR2 after infection (Kevin Fenix, personal communication).  Loss of 
Blimp1, but not T-bet, has been shown to abrogate expression of CCR2 on CD8+ T cells 
in LCMV infection327.   A candidate cytokine that may induce CCR2 is IL-2, which has 
been reported to induce CCR2 expression on human CD4+ T cells stimulated in vitro328.  
IL-2 expression has been reported to peak on day 10 after influenza infection, whilst still 
remaining elevated during the contraction phase329.  IL-2 also promotes Foxp3 expression 
and is indispensable for Treg function, while also acting to suppress TFH differentiation, 
consistent with the low expression of CCR2 on TFH in LCMV212,330-333.  Experimental 
evidence to support this hypothesis, as well as analyzing other potential candidate signals, 
remain a priority for future work. 
 
5.2.3 CCR2 promotes maintenance of CD4+ T cells during the contraction phase 
Loss of CCR2 on antigen-specific CD4+ T cells in both S. pneumoniae and influenza 
infection did not appear to affect priming or production of effector cytokines during the 
peak of the response.  This is perhaps unsurprising given the low level of expression of 
CCR2 at early time-points.  The most prominent defect in CCR2-deficient OT-II cells 
identified from this study was their enhanced contraction after infection compared to WT. 
This suggests that CCR2 promotes the survival or proliferation of CD4+ T cells during 
the resolution of the immune response and potentially promotes their transition into 
memory, which is evidenced by the increased expression of CCR2 on memory CD4+ T 
cells.  In future experiments, analysis of apoptosis rates and cellular turnover of WT and 
Ccr2–/– OT-II cells should be compared.  If Ccr2–/– OT-II cells have a lower rate of 




APCs, whereas if they undergo a higher rate of cell death, this would suggest lack of 
access to survival signals required for their maintenance.  
 
The signals promoting survival and maintenance of CD4+ T cell memory are not well 
described, although a critical role for IL-7 has been identified.  IL-7 has been shown to 
promote the survival of both TEM and TCM through induction of the anti-apoptotic protein 
Bcl2, although is not required for the generation of effector CD4+ T cells334,335.  IL-7 can 
be produced by fibroblastic reticular cells (FRCs) in LN, as well as stromal cells present 
in peripheral sites336-338.  Furthermore, IL-15 can also contribute to CD4+ T cell survival, 
although this appears to be less critical than IL-7, perhaps owing to their reduced 
expression of CD122 (IL-15R )339-342.  In contrast to the stromal expression of IL-7, IL-
15 is predominantly produced by macrophages and DCs343,344. Thus, it is plausible that 
CCR2 may be required for migration towards cells that produce survival cytokines, in 
order for CD4+ T cells to receive IL-7- or IL-15-mediated signals that promote their 
survival (Figure 5.2). If this is the case, then in the absence of CCR2, CD4+ T cells would 
have a reduced ability to colocalize with IL-7/15-expressing cells, leading to the 
enhanced contraction observed.  This could be tested in future experiments by performing 
immunofluorescence to test if there are any apparent differences in localization of WT 
and Ccr2–/– OT-II in SLO or lungs.  In SLO, WT OT-II cells would be predicted to 
localize with IL-7+ FRCs.  In the lung, Thy1+ IL-7+ lymphatic endothelial cells generated 
in inducible bronchus-associated lymphoid tissue structures have been shown to maintain 
pathogenic TH2 cells in allergic inflammation, and may also be important for maintenance 
of CD4+ memory T cells more generally338.  Analysis of the expression of CCR2 ligands 
by cells in these tissues may also assist with this understanding. 
 
An alternative possibility to CCR2 being required for direct migration towards cells 
expressing pro-survival cytokines is that it plays more subtle roles in niche positioning 
during the primary response, which affects formation of memory cells through reduced 
exposure to memory-promoting cytokines.  A contrary scenario has been described for 
CXCR3 expression on CD8+ T cells, where loss of CXCR3 reduces CD8+ T cell 
migration to the marginal zone of the spleen early after infection, thus reducing exposure 
of these cells to the inflammatory milieu required for full effector differentiation and 




conceivable that in the absence of CCR2, CD4+ T cells localize to different niches during 
the effector phase of the response and consequently receive reduced access to cytokines 
promoting development into memory cells. One possible candidate that influences 
formation of CD4+ T cell memory is IL-2, which is required for efficient upregulation of 
IL-7R , necessary for responsiveness to IL-7 which maintains their survival347,348.  
Differential exposure to IL-2 between WT and Ccr2–/– OT-II cells during the effector 
phase of the response may lead to differential upregulation of IL-7R , thus affecting their 
ability to survive during the contraction phase.  IL-2 is also an interesting candidate given 
its potential ability to upregulate CCR2, as discussed above. This creates an interesting 
scenario where if CCR2 enhances migration towards IL-2-expressing cells, and IL-2 then 
further induces CCR2 expression, it creates a feed-forward loop to promote survival.  
Alternatively, if CCR2 is found to be required for migration toward IL-7-expressing cells, 
IL-2 may be the initiating signal to promote both upregulation of CCR2 and IL-7R , thus 
allowing CD4+ T cells to become responsive to memory signals as well as promoting 
their migration towards these signals. However, this currently remains hypothetical and 
future experiments will need to determine empirically whether this holds true. 
 
Analysis of the subsets of WT and Ccr2–/– memory CD4+ T cells formed after S. 
pneumoniae infection revealed no difference in the frequency of TCM or TEM produced, 
although both subsets displayed contraction.  This suggests that CCR2 does not influence 
the formation of different memory subsets and acts more globally to promote their 
maintenance.   However, in the lung, the TCM population appear to undergo more severe 
contraction than the TEM or TRM-like populations, as reflected by the increase in 
frequency of TEM and TRM in Ccr2–/– OT-II cells, compared with WT OT-II cells.  Despite 
this change in frequency, the number of Ccr2–/– TEM still significantly contracted, 
although the number of TRM-like cells remained relatively unchanged. These results are 
perhaps surprising given the increased expression of CCR2 on TEM and TRM-like cells 
relative to TCM in S. pneumoniae infection.  However, these data do suggest that TRM-like 
cells may rely on different signals for their maintenance than TEM and TCM cells, with 
CCR2 not required for their survival.  This is also reflected in the ratio of Ccr2–/– OT-II 
to WT OT-II cells increasing from the peripheral blood to the lung, indicating circulating 
cells are more dependent on CCR2-mediated signals for their survival. Alternatively, this 




although given their contraction in the spleen and LN, the lymphoid organs are not likely 
to be a possible destination.  
 
The above discussion raises the question of why CCR2 is so highly expressed on TRM-
like cells if it is not required for their maintenance.  CCR2 does not appear to be required 
for migration of effector CD4+ T cells into their effector site of the lung, which differs 
from the reported requirement for CCR2 in entry of encephalitogenic TH17 cells into the 
CNS205.  However, CCR2 may still be required for more subtle migration of TRM cells 
within resident tissues.  TRM cells are motile within tissues, which has been proposed to 
facilitate rapid detection of nearby pathogenic insults349,350.  The molecular cues dictating 
this local migration are not well understood, but at least for skin CD8+ TRM have been 
reported to be pertussis toxin-sensitive, but independent of the highly-expressed 
chemokine receptors CXCR3, CXCR6, CCR8 and CCR10351.  Furthermore, the ligands 
for CCR2 are induced in the lung and mucosa in the first 2 to 3 days after infection with 
influenza170 or S. pneumoniae (Duncan McKenzie, PhD thesis) as well as upon other 
inflammatory stimuli226, and thus CCR2 may play a role in TRM migration within tissues 
to scan for nearby pathogenic insults.  
 
The relatively reduced contraction of Ccr2–/– TRM-like cells also suggests that these cells 
are seeded early in the response.  If they were derived from TEM or T effector cells from 
the periphery after antigen had been cleared, then the enhanced contraction of Ccr2–/– 
OT-II cells at these time-points should be mirrored in the TRM-like compartment.  Thus, 
it is likely that these cells seed the lung prior to the contraction phase, and are maintained 
independently of CCR2-mediated signals. This early seeding of TRM cells from the 
effector T cell pool is consistent with previous reports on CD8+ TRM demonstrating that 
only transfer of early effector cells can traffic to the gut epithelium to give rise to TRM 
precursors, whilst effector cells taken from day 7 onwards of LCMV infection cannot352. 
 
Although loss of CCR2 significantly affected the ability of influenza-specific CD4+ T 
cells to persist into the memory phase, the remaining Ccr2–/– OT-II cells had no apparent 
defect in their expansion upon antigenic rechallenge.  This suggests that CCR2 is not 
required for migration to, or engagement with, APCs that drive memory CD4+ T cell 
proliferation, but is still consistent with the possibility that CCR2 is primarily required 




enhanced contraction seen for Ccr2–/– CD4+ T cells would affect their ability to protect 
against rechallenge, given they show unimpaired secondary expansion. This could be 
assessed in S. pneumoniae infection by transfer of WT and Ccr2–/– OT-II cells into 
separate hosts with bacterial burden measured after secondary challenge with S. 
pneumoniae, since the protection seen in secondary challenges is known to be CD4+ T 
cell-dependent243,353. Interestingly, although cytokine production by S. pneumoniae-
specific memory CD4+ T cells was unimpaired by CCR2 deficiency, influenza-specific 
TH1 cells had reduced IFN  production both upon restimulation at memory time-points, 
and after secondary challenge.  IFN  production by memory CD4+ T cells is regulated 
through expression of T-bet and NF B, suggesting these pathways may be impaired at 
later time-points, although this remains to be determined354,355.  
 
Another scenario to be explored in future experiments is whether there is a role for CCR2 
in CD4+ T cell trafficking from the bone marrow.  As well as its role in haematopoiesis, 
the bone marrow is an important site of maintenance of CD4+ T cell memory cells, with 
some studies reporting it as the predominant site for resting CD4+ memory T cells, 
although this is controversial337,356,357.  Entry of CD4+ T cells into the bone marrow has 
been shown to be regulated through expression of CD49b and CD69, although the 
requirements for egress of these cells are as yet unknown337,358,359.  Monocytes can also 
express high levels of CCR2, and this receptor is critical for their egress from bone 
marrow. As a result, CCR2-deficient monocytes pool in the bone marrow and are almost 
absent from the circulation228.  Activation of CCR2 on monocytes has been shown to 
desensitise these cells to CXCR4-mediated signals that normally promote their retention 
in the bone marrow, providing a possible mechanism for CCR2-mediated emigration360.  
Thus, future experiments should assess WT and Ccr2–/– OT-II cell frequencies in the bone 
marrow, as an increase in Ccr2–/– OT-II cells would be predicted if this receptor is 
required for egress.  Interestingly, this hypothesis is partially supported by a recent 
analysis of antigen-experienced CD4+ T cells after LCMV infection, as CCR2 is 
specifically enriched on CD4+ T cells in the bone marrow, compared with splenic CD4+ 
T cells361.  Similarly, analysis of total T cells in CCR2-RFP reporter mice showed highest 
expression of CCR2 in the bone marrow compared with spleen, LN or peripheral 
blood362. Thus, future experiments should aim to address the possibility that CD4+ T cells 





5.3 Concluding remarks 
In summary, the data described in this thesis have revealed novel roles for chemokine 
receptors in regulating diverse aspects of immune cell function. In tumour settings, 
ACKR4 has been identified as a novel regulator of intratumoural DC trafficking and 
affects the magnitude of the tumour-directed CD8+ T cell response. Preliminary evidence 
indicates that this receptor may potentially be a useful therapeutic target, with ACKR4-
deficient mice showing enhanced responsiveness to immunotherapy treatment. In models 
of infection, a previously unappreciated role for CCR2 on CD4+ T cells was described, 
with this receptor required for the maintenance of antigen-specific CD4+ T cell 
populations. Thus, this study has highlighted the complexity of the chemokine system 
and enhanced our understanding of its modulation of immune function.  However, many 
questions remain and as outlined in this discussion, further studies in each of the two 
main areas of focus will be required, particularly to dissect the molecular mechanisms 














Figure 5.1: Proposed model of ACKR4-mediated control of tumour immunity 
CCL21 is expressed by lymphatic endothelial cells309 and potentially by the tumour itself. 
In wildtype (WT) mice, ACKR4 expressed by the luminal epithelium in the mammary 
gland scavenges CCL21, thus creating a chemotactic gradient towards the lymphatic 
vessels. This allows dendritic cells (DCs) present within E0771 tumours to migrate in a 
CCR7-dependent manner to the lymphatic vessels, promoting their egress from tumours 
and migration to the draining lymph node (LN). In Ackr4–/– mice, the absence of ACKR4 
abrogates the development of a CCL21 gradient, and leads to enhanced levels of CCL21 
within the tumour. Thus, DCs show reduced migration into lymphatic vessels and 
subsequently the LNs and are instead retained at higher frequencies in the tumour itself. 
Intratumoural DC accumulation can then induce a greater CD8+ T cell response, 
potentially through enhancing recruitment of CD8+ T cells or enhancing their 












Figure 5.2: Potential models of CCR2-mediated control of CD4+ T cell contraction 
CCR2 is expressed by a relatively low frequency of CD4+ T cells during the effector 
phase of the response, but is increased at later time-points after infection. Furthermore, 
CCR2 is required for maintenance of CD4+ T cell memory cells. (A) CCR2 may 
potentially regulate access to factors required for survival of CD4+ T cells. CCR2 
expression on CD4+ T cells may promote localisation to cells expressing the CCR2 
ligands CCL2, CCL7 and CCL12, with these cells also potentially producing cytokines 
promoting CD4+ T cell survival, such as IL-7 or IL-15. Thus, Ccr2–/– cells or cells lacking 
CCR2 expression may have reduced access to these factors and undergo enhanced 
contraction. (B) Alternatively, CCR2 may drive differential localisation of CD4+ T cells 
during the effector phase of the response, thus allowing different exposure to cytokines 
promoting formation of memory cells. One candidate is IL-2, which is required for 
upregulation of IL-7R , and thus responsiveness to IL-7 and survival348. Cells lacking 
CCR2 expression through transcriptional regulation or genetic deletion may have reduced 
exposure to IL-2, leading to reduced expression of IL-7R  and hence an inability to 
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Abstract
CD4+ T cells are critical regulators of the adaptive immune system and have diverse
roles in regulating responses to the broad array of microbes encountered. Appropri-
ate execution of their effector function requires precise and coordinated migration of
these cells to specific lymphoid niches and peripheral sites. This migration is largely
controlled by dynamic expression of chemokine receptors and the discrete functions
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of distinct subsets of CD4+ T cells can often be determined from their expression of
specific chemokine receptors. In this chapter, we discuss recent advances in the
subset-specific homing of distinct T helper populations, focusing on new insights
stemming from the increased diversity and plasticity now observed among CD4+
T cells as well as how chemokine receptors can govern T cell-fate decisions. We also
discuss current understanding of CD4+ memory T cells with reference to their diver-
sification based on chemokine receptor expression.
1. INTRODUCTION
CD4+ T cells play a pivotal role in the adaptive immune system by
dictating the quality and magnitude of humoral and cellular immune
responses. Central to this role is the ability of CD4+ T cells to migrate
in a spatiotemporally controlled manner. The rare clonal frequency of
antigen specific CD4+ T cells and the large surface areas of the body
exposed to antigen necessitate this efficiency in migration. Precise control
of cell migration ensures that CD4+ T cells encounter antigen when it is
present, permits appropriate crosstalk with other immune cells, regulates
homing to sites of peripheral inflammation, and is also critical for immune
surveillance and memory maintenance. It is well recognized that the var
ious functional states of CD4+ T cells (e.g., naı̈ve, effector, memory) have
profoundly distinct migratory patterns and that the effector subsets of
CD4+ T cells that shape adaptive immune responses (e.g., TH1, TH2,
TH9, TH17, TH22, Treg) all have distinguishable and in some cases defin
ing homing characteristics. The major molecular determinants that confer
these various cell homing patterns on CD4+ T cells are chemokine recep
tors, a subfamily of G protein coupled receptors (GPCRs) that recognize
secreted chemokine ligands, which are produced in niche specific and
context dependent circumstances to attract appropriate chemokine
receptor bearing cell types. The chemokine system is further regulated
through atypical chemokine receptors, which control the bioavailability
of their corresponding chemokine ligands (Nibbs & Graham, 2013)
(Table 1). In this chapter, we will summarize the migration patterns of
mature CD4+ T cells both during homeostasis and during immune
responses with a particular focus on the role of chemokines and chemokine
receptors and highlight recent findings that advance our understanding of
this intricate and critical process.
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2. NAÏVE CD4+ T CELL TRAFFICKING
Naı̈ve CD4+ T cells constantly recirculate through the lymphoid
organs, scanning for cognate antigen presented in the context of MHC II
by antigen presenting cells (APCs). Blood borne naı̈ve CD4+ T cells enter
the T cell areas of secondary lymphoid organs (SLOs), scan APCs for anti
gen, then exit and ultimately reenter the bloodstream where the rec
irculation through SLOs continues. Homeostatic trafficking relies on
shear flow through the blood and lymph, but requires additional cues to ini
tiate rolling, arrest, and extravasation in lymph nodes (LN) and Peyer’s pat
ches (PP). Migration within secondary lymphoid organs is also tightly
regulated to enhance the likelihood of interactions between very rare
antigen reactive and antigen bearing cells. The most important chemokine
receptor for naı̈ve CD4+ T cell trafficking is CCR7, which is highly
expressed by all naı̈ve T cells. Naı̈ve T cells enter LNs and PP through spe
cialized postcapillary vessels known as high endothelial venules (HEVs).
Entry via HEVs is tightly restricted and requires the sequential steps of
rolling, adhesion, and finally extravasation of cells into the LN. Naı̈ve
T cells that enter HEVs express the homing receptor L selectin (CD62L),
which binds to a family of sialomucins collectively known as peripheral node
addressins expressed by the HEV endothelium. This attachment facilitates
rolling of the cell along the luminal surface, followed by firm adhesion of









CXCR5 CXCL13 TFH, TFR,
TH17, TCM
ACKR4a
CXCR6 CXCL16 TH17, TH22 ?
XC Chemokine Receptor
XCR1 XCL1, XCL2a — ?
CX3C Chemokine Receptor
CX3CR1 CX3CL1, CCL26a TH2 ?
aIndicates in humans but not mice.
bCXCL4 binds to the CXCR3-B isoform of CXCR3.
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the cell initiated by CCR7 induced signaling which triggers integrin acti
vation. CCR7 on the naı̈ve T cell is primarily activated via CCL21, a che
mokine highly expressed by the HEV endothelium and presented on the
luminal surface via heparin sulfate (Bao et al., 2010). Additional CCR7 acti
vation can be mediated by CCL19, which has been reported to be trans
cytosed to the HEV luminal surface from the perivascular space
(Baekkevold et al., 2001). However, Ccl19 / mice display similar short
term homing of naı̈ve lymphocytes to SLO, suggesting it is not required
for LN entry but instead mediates survival of naı̈ve T cells within the LN
(Link et al., 2007). Activation of CCR7 on rolling T cells induces activation
of the integrin αLβ2 (LFA 1), allowing firm adhesion to ICAM 1/2
expressed on the luminal endothelium (Gunn et al., 1998; Stein et al.,
2000). In PP and mesenteric LNs, CCL21 triggers high affinity binding
of α4β7 to MAdCAM 1 (Pachynski, Wu, Gunn, & Erle, 1998). In the
absence of functional CCR7 or in plt/plt mice which lack CCL19 and
CCL21ser, T cell arrest and migration into LNs is severely abrogated
(Stein et al., 2000; Warnock et al., 2000). In addition to CCR7, relatively
few other chemokine signals make significant contributions to naı̈ve T cell
trafficking. Indeed, naı̈ve CD4+ T cells do not express high levels of any
other chemokine receptor with the exception of CXCR4. The sole
CXCR4 ligand CXCL12 is also found on the luminal surface of HEVs,
however, this axis seems to play only a minor role in naı̈ve CD4+ T cell
recruitment, with CXCR4 dependent arrest only apparent in mice lacking
CCR7 signals (Okada et al., 2002). Subsequent to integrin mediated arrest
on HEVs, naı̈ve CD4+ T cells crawl on the HEV surface toward preferential
sites of T cell entry where fibroblastic reticular cells (FRCs) in the LN form a
cellular sheath around the HEV and the T cells can there transmigrate across
the endothelium to enter the LN (Bajenoff et al., 2006).
Naı̈ve T cells also enter LNs via the afferent lymphatics once they have
entered the flow of lymph at an upstream LN. Experiments utilizing
intralymphatic injection of naı̈ve T cells demonstrated that these cells enter
the parenchyma of the LN from the subcapsular sinus (SCS) region via
peripheral medullary sinuses independently of CCR7 (Braun et al.,
2011). However, subsequent migration from the medullary sinuses to the
deeper paracortex strictly required expression of CCR7.
Upon reaching the LN paracortex, naı̈ve CD4+ T cells scan for APCs
presenting their cognate antigen in the context of MHC II. To increase
the likelihood of these encounters, naı̈ve T cells appear to migrate through
the LN with a random walk so that each T cell is equally likely to interact
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with a given APC. However, this stochastic migration is guided by FRCs,
which wrap around lymph transporting conduits to form a stromal network
(Roozendaal, Mebius, & Kraal, 2008). Indeed, the exit ramps used by naı̈ve
T cells to leave the HEV and enter the LN are positioned such that they lead
the T cell directly onto the FRC network (Bajenoff et al., 2006). These
FRCs express high levels of adhesion molecules as well as CCL19,
CCL21, and CXCL12 and are essential for dictating the migration of
T cells within the paracortex. Imaging studies have revealed that T cells
in the LN are always in close proximity to FRCs and their migration closely
follows the path of the FRC fibers (Bajenoff et al., 2006). Thus, it appears
that FRC bound chemokines provide a haptotactic signal for intranodal
T cell migration. Indeed, T cells in pltmice orCcr7 / T cells show reduced
velocity and motility in the paracortex, demonstrating that CCR7 signaling
is essential for basal motility of naı̈ve T cells (Worbs, Mempel, Bolter, von
Andrian, & Forster, 2007). Additionally, depletion of FRCs in fibroblast
activation protein α (FAP α) DTR mice resulted in abrogated CCL19
and CCL21 within the T cell zones, as well as disrupted T cell responses
to subsequent influenza infection (Denton, Roberts, Linterman, &
Fearon, 2014).
Egress of naı̈ve T cells from lymph nodes occurs via the cortical sinuses
into the efferent lymphatics (Cyster & Schwab, 2012). Both entry to and
egress from lymph nodes is allowed to occur through reciprocal desensiti
zation of CCR7 and the sphingolipid binding GPCR, sphingosine 1
phosphate receptor 1 (S1PR1) (Pham, Okada, Matloubian, Lo, & Cyster,
2008). In the blood and lymph, S1P is abundantly expressed, leading to
S1PR1 internalization and thus desensitization to the ligand. Therefore,
naı̈ve T cells present in the blood express low levels of S1PR1 and can
respond more effectively to CCR7 signals to promote their entry
into LNs. CCR7 acts as a retention signal for T cells within the LNs,
which regain responsiveness to S1P signals during LN transit. Gradual
desensitization toward CCL21 and CCL19 occurs due to ligand induced
internalization of CCR7, thus shifting the balance toward promoting
S1PR1 mediated LN egress. Once entering the efferent lymph, T cells
can migrate to downstream LNs or return to circulation in the blood.
Naı̈ve T cell trafficking within the spleen has some distinct differences to
that within LNs and PPs, due to the distinct architecture of the spleen. Blood
enters the spleen via terminal arterioles that drain into cords in the red pulp
without an endothelial lining, forming an open vascular system. T cells pre
dominantly localize in the periarteriolar sheath (PALS) in the white pulp
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which surrounds the arterioles. The marginal zone is situated at the interface
between the red pulp and the marginal sinus of the white pulp and acts as a
major transit route for T cells traveling between the blood and the
white pulp.
T cell entry to splenic white pulp cords is dependent onGPCR signaling,
as T cells in mice treated with pertussis toxin (PT) fail to localize to the white
pulp and instead pool in the red pulp (Cyster & Goodnow, 1995). Entry to
the white pulp is also partially facilitated by the integrin LFA 1 and to a lesser
extent, α4β1. However, the precise sequence of events and chemokines
involved in initiating T cell entry into the marginal zone remain unclear.
Trafficking from the marginal zone to the PALS is more well understood,
and similar to LNs, is guided by an FRC network (Bajenoff,
Glaichenhaus, & Germain, 2008; Katakai et al., 2008). Naı̈ve lymphocytes
traffic into the PALS at preferential gaps in the marginal sinus, termed mar
ginal zone bridging channels (MZBCs). FRCs line these channels upon
which naı̈ve T cells migrate, presumably following haptotactic signals to
the T cell zones as seen in LNs. Indeed, CCR7 is essential for effective local
ization to the PALS as displayed by the impaired positioning of T cells in
CCR7 deficient mice or plt/plt mice (Forster et al., 1999; Nakano et al.,
1998). FRCs secrete CCL19 and CCL21 as well as CXCL12, providing fur
ther support for a haptotactic model of chemokine driven cell navigation
through the spleen (Luther, Tang, Hyman, Farr, & Cyster, 2000;
Umemoto et al., 2012). Splenic egress of naı̈ve T cells is not well under
stood, but is believed to rely on similar signals to the lymph node. The
red pulp provides a high concentration of S1P, so it is likely that gradual
CCR7 desensitization in the white pulp promotes S1P mediated migration
through the MZBCs to the marginal zone, and subsequent exit into the cir
culation. In support of this, S1PR1 deficient T cells transferred to congenic
hosts accumulated in the spleen as they were unable to exit (Matloubian
et al., 2004). However, experimental evidence for the role of chemokines
in T cell egress from the spleen is lacking.
Transcriptional control of the naı̈ve T cell homing phenotype is critically
regulated by Foxo1, which promotes expression of CD62L and CCR7, as
well as the transcription factor KLF2, which has previously been reported to
control expression of these surface proteins in addition to S1P1 (Carlson
et al., 2006; Kerdiles et al., 2009; Ouyang, Beckett, Flavell, & Li, 2009). Fur
thermore, Foxo1 is required for Bcl 2 expression and T cells deficient in
Foxo1 show impaired survival. Expression of KLF2 also either directly or
indirectly represses expression of chemokine receptors such as CXCR3,
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CCR3, and CCR5, preventing distraction of naı̈ve T cells toward inflam
matory signals (Sebzda, Zou, Lee, Wang, & Kahn, 2008; Weinreich et al.,
2009). Thus, concerted transcriptional control of migratory receptors is
essential for optimal efficiency of the process of naı̈ve T cell trafficking.
3. CHEMOKINE CONTROL OF CD4+ T CELL PRIMING
Once naı̈ve CD4+ T cells interact with DCs presenting cognate anti
gen, a sequence of events known as T cell priming begins. This leads to a
series of distinct changes in T cell motility that have been well described
(Mempel, Henrickson, & Von Andrian, 2004; Miller, Safrina, Parker, &
Cahalan, 2004;Miller,Wei, Parker, &Cahalan, 2002). Chemokine receptor
expression patterns are also radically altered during T cell priming and this
largely accounts for these changes in T cell motility. Thus, chemokines play
critical roles in governing T cell priming, by altering CD4+ T cell position
ing within the SLOmicroenvironment as well as enhancing interaction time
with APCs.
3.1 Early Stages of CD4+ T Cell Activation
Within the first few hours after initial recognition, CD4+ T cells significantly
decrease their velocity and undergo multiple short interactions with DCs.
This is partly mediated by DC surface bound CCL21, which forms tethers
with CCR7 on naı̈ve CD4+ T cells, potentially enhancing the interaction
time to enable the naı̈ve T cell to scan for the peptide–MHC II complex
(Friedman, Jacobelli, & Krummel, 2006; Molon et al., 2005). Multiple
interactions between naı̈ve T cells with different peptide–MHC II com
plexes on either the same DC or on DCs in trans induces T cell upregulation
of early activation markers such as CD69, which suppresses S1PR1 surface
expression, thus promoting retention in the SLO (Shiow et al., 2006). In the
next stage of activation, CD4+ T cells maintain interactions with DCs for
extended periods of time, (reportedly from 2 to 12 h) (Mempel et al.,
2004), where very close synapse like interactions form. During these
encounters, T cell priming is influenced by TCR signal strength,
costimulatory signals on the APC, and the local cytokine milieu which gov
erns their subsequent differentiation, discussed in further detail below.
Approximately 24–48 h after initial antigen recognition, the CD4+
T cells begin to increase their motility again and proliferate (Hor et al.,
2015; Miller et al., 2004). Constant sporadic engagements of the daughter
cells with DCs seems to be required for full effector differentiation, as
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repeated encounters of CD4+ T cells with Ag bearing DCs is required for
optimal cytokine secretion (Celli, Garcia, & Bousso, 2005).
Chemokine receptors are rapidly upregulated in response to activation,
prior to cell division. Transfer of LPS and poly(I:C) activated DCs pulsed
with OVA induced upregulation of CXCR3 on cognate OT II cells within
24 h of transfer (Groom et al., 2012). In this model, CXCR3 expression was
required for optimal TH1 differentiation, as Cxcr3
/ OT II cells showed
impaired activation and IFNγ production. This was associated with reduced
interactions with CXCL10 producing DCs, suggesting CXCR3–CXCL10
tethering enhances dwell time of the CD4+ T cells on engaged DCs, facil
itating increased TCR engagement and thus increased differentiation. Sim
ilarly, upregulation of CXCR3 within 12 h of influenza vaccination
facilitated clustering of CD4+ T cells with CXCL10+ DCs (Woodruff
et al., 2014). As CXCR3 expression is intrinsically linked with TH1 differ
entiation, it remains to be determined whether early upregulation of char
acteristic lineage specific chemokine receptors is common to all
transcriptional programs, or whether other subset specific chemokine
receptors play similar roles in DC clustering.
As will be discussed inmore detail later, another chemokine receptor that
is upregulated at the early stages of CD4+ T cell activation is CXCR5.
Expression of CXCR5 by both T cells and B cells drives migration to
the follicles, where CXCL13 is expressed by follicular dendritic cells
(FDCs). Coexpression of CXCR5 with PD1 is used to delineate TFH cells,
but there are conflicting reports regarding the timing of when CXCR5 is
first expressed. It was initially reported that OT II cells responding to
OVA/alum immunization did not express CXCR5 until after they had
begun to proliferate, although they expressed Bcl6, the defining transcrip
tional regulator of the TFH program (Baumjohann, Okada, & Ansel,
2011). Subsequent CXCR5 upregulation coincided with increased expres
sion of Bcl6. In contrast, reports have shown that CXCR5 is already
expressed 12 h after activation, preceding upregulation of Bcl6 and cell divi
sion (Chen, Ma, Zhang, Wu, & Qi, 2015; Hardtke, Ohl, & Forster, 2005).
This expression of CXCR5 was dependent on IL 6 production by radio
resistant cells, although the identity of the precise cell type is unknown.
CXCR5 was required for OT II migration to the T B border within the
first 24 h of activation, in accordance with the role of TFH cells in supporting
humoral immune responses. TH2 cells have also been shown to upregulate
CXCR5 and migrate to the perifollicular region of mesenteric lymph nodes
in response to nematode infection (Leon et al., 2012). Expression of
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CXCR5 by both TH2 and TFH in this model of Heligmosomoides polygyrus
was required for optimal differentiation of these subsets, potentially neces
sitated by allowing colocalization with CXCR5+ DCs which are situated
adjacent to the follicles.
3.2 Chemokine Receptor-Directed Control of Early Fate
Decisions
There is accumulating evidence that there is considerable plasticity during
the early phases of CD4+ T cell differentiation toward specific TH lineages.
It is now clear that a single T cell clone has the capability to differentiate into
diverse fates, depending on T cell intrinsic factors such as TCR signal
strength, as well as environmental factors such as antigen abundance and
the local cytokine milieu (Tubo et al., 2013). In the first few days following
T cell activation, cells retain the potential to differentiate into different TH
subsets. This was first supported by the detection of cells with a PD1hi
CXCR5hi TFH like profile at early stages of TH1 differentiation in
in vitro cultures with IL 12 (Nakayamada et al., 2011). By day 3 of culture,
CD4+ T cells display an uncommitted phenotype with coexpression of Bcl6
and the TH1 master regulator T bet, and production of both IL 21 and
IFNγ. However, continued induction of T bet through IL 12 signaling is
ultimately required to polarize the culture to TH1 with no cells expressing
a TFH like phenotype at advanced stages. Similar results were seen in an in
vivo infection model with Toxoplasma gondii, a potent inducer of IL 12,
where in competitive mixed transfer systems Tbx21 / CD4+ cells were
more likely to display a TFH phenotype. This suggests that during the early
path of TH1 differentiation, cells upregulate CXCR5 and have the potential
to divert toward TFH or TH1 development, but signaling which favors
induction of T bet pushes them toward the TH1 pathway.
An intriguing possibility is that migration of nascent TH cells through
CXCR5 determines their fate (Qi, 2016). Cells that are able to exit the
T cell zone and migrate to the follicles escape from the high levels of
IL 2 present in the T cell zone. As IL 2 is a potent suppressor of TFH devel
opment, this follicular localization allows the TFH program to be enforced
(Ballesteros Tato et al., 2012; Oestreich, Mohn, & Weinmann, 2012). In
contrast, TH cells that are unable to reach the follicles and remain in the
T cell zone are exposed to high levels of IL 2, promoting proliferation
and differentiation toward a TH1 or TH2 phenotype. This is partly supported
by recent work from Cyster and colleagues who identified a novel role for
the GPCR EBI2 (GPR183) in promoting TFH development (Li, Lu, Yi, &
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Cyster, 2016). EBI2 was upregulated on T cells within 12 h after protein
immunization and facilitated translocation to the outer T cell zone through
its ligand 7α,25 dihydroxycholesterol, where T cells could interact with
CD4+ DCs. These DCs expressed high levels of CD25 and could quench
IL 2 from the local area, promoting TFH development. Thus, coordinated
migration of recently activated T cells through EBI2 and CXCR5 promotes
TFH development. Given that upregulation of EBI2 and CXCR5 appears to
be fairly uniform among recently activated cells, it remains to be determined if
this GPCR mediated escape from the T cell zone is a stochastic process or if
there are as yet unidentified cues that favor follicular homing.
3.3 Chemokine Receptor-Directed Migration Between DC
Subsets During Priming
CD4+ T cells can interact with multiple DC subsets in SLO and have
recently been reported to track between different DCs at different stages
of the response (Hor et al., 2015). In a model of herpes simplex virus
(HSV) skin infection, antigen specific CD4+ T cells were initially primed
bymigratory DCs in the paracortex, but at later stages were found to interact
with CD8α+XCR1+ crosspresenting DCs, forming the platform for CD8+
T cells to become efficiently crossprimed. This late interaction of CD4+
T cells with CD8α+XCR1+ DCs was also simultaneously reported in
models of vaccinia virus infection (Eickhoff et al., 2015). It is currently
unclear if this interaction with CD8α+XCR1+ DCs is required for optimal
TH differentiation, or if it is simply the execution of a helper function of this
subset. However, given the strict requirement for antigen presence in
maintaining TH cells, it is possible these interactions are required for main
tenance of the TH response (Obst, van Santen, Mathis, & Benoist, 2005).
How and when CD4+ T cells migrate between different DC populations
within the LN is currently unclear, and the migratory cues governing this
require further investigation. One likely candidate is CXCR3, which as
mentioned earlier is upregulated soon after activation in response to protein
immunization. Given that CXCR3 is required for optimal TH1 differenti
ation, and CXCR3 is not expressed on naı̈ve T cells, it is plausible that
upregulation of CXCR3 after initial priming by a migratory DC promotes
attraction toward CXCL10 producing DCs, potentially the XCR1+ DCs,
which is required for full differentiation. Indeed, CXCL10 was reported to
be expressed by CD8α+ DCs in response to influenza vaccination, although
CD11b+ resident DCs had higher production (Woodruff et al., 2014).
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Clearly, further investigation into the precise trafficking events governing
early T cell differentiation needs to be undertaken.
4. CHEMOKINE CONTROL OF CD4+ EFFECTOR FUNCTION
DURING THE ACUTE PHASE
Differentiation into distinct TH lineages allows CD4
+ T cells to
deliver specific help tailored to the type of immune challenge (Kara et al.,
2014). The execution of many TH effector functions primarily involves
egress from SLO and migration to the challenged peripheral tissue, and this
is coordinated through expression of subset specific as well as tissue specific
chemokine receptors. Tissue specific chemokine receptors include CCR9,
which allow trafficking of subsets to the intestinal tract where high levels of
CCL25 are produced, as well as CCR10, which promotes homing to high
levels of CCL27 in the skin. These receptors can be expressed by multiple
TH subsets, as they allow for general trafficking to the desired organ. Subset
specific chemokine receptors are often expressed more strictly and can be
regulated in response to the differentiation cues received during priming
(Fig. 1). These receptors have been useful tools in aiding identification of
TH subsets based on their chemokine receptor profile, but are also critical
for TH cells to execute their effector functions. In this section, wewill discuss
the chemokine receptors that facilitate the function of each described TH
subset.
4.1 TH1
TH1 cells promote cell mediated immunity and are critical for protection
against intracellular pathogens. They are also important for clearance of can
cerous cells, but can contribute to pathology in cases of transplantation or
autoimmunity. These roles are predominantly mediated through TH1 pro
duction of the cytokine IFNγ, as well as TNFα and IL 2. IFNγ is essential
for control against numerous pathogens, through both direct effects on the
pathogen itself as well as more broadly stimulating a concerted immune
response by numerous cell types (Schoenborn & Wilson, 2007). TH1 cell
differentiation is first induced by TCR engagement in the presence of IFNγ
or type I IFNs, which leads to expression of the master transcriptional reg
ulator T bet and consequently the high affinity IL 12Rβ2 chain. IL 12 then
acts via STAT4 to further stimulate expression of T bet, which drives IFNγ
production to create a feedforward loop which stabilizes the TH1 differen
tiation program.
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The canonical chemokine receptor expressed by TH1 cells is CXCR3.
This receptor is directly bound and transactivated by T bet and as such
appears to be highly coupled to the TH1 program. The CXCR3 axis is a
prototypical inflammatory axis, with CXCR3 absent on naı̈ve T cells and
the ligands only induced upon exposure of cells to inflammatory stimuli.
Of the three ligands, CXCL11 is the most potent in humans, followed
by CXCL10 and CXCL9 (Van Raemdonck, Van den Steen, Liekens,
Fig. 1 CD4+ T cell subsets are distinguished by distinct chemokine receptor expression
and differentiation cues. Upon cognate interactions with peptide:MHC II complexes
presented by DCs, priming of naïve CD4+ T cells is influenced by the local cytokine
milieu. This leads to expression of distinct transcription factors that can induce
subset-specific transcriptional profiles, which encompass expression of effector cyto-
kines as well as chemokine receptors that are tailored to enable optimal responses
to the initial antigen. The key subsets of TH cells that have been described are shown
along with the cytokines and transcription factors that drive/maintain their develop-
ment (black text); characteristic cytokines that they produce (blue text); and the chemo-
kine receptors expressed (red text). Arrows indicate differentiation/transdifferentiation
of T cell subsets, ? indicates either uncertain transcriptional regulation or an as yet
unproven transdifferentiation pathway.
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Van Damme, & Struyf, 2015). These ligands can be produced by a broad
range of cell types, with fibroblasts, leukocytes, and keratinocytes all
reported sources of expression. CXCR3 is essential for the peripheral local
ization of TH1 cells in a multitude of diseases, with deletion of CXCR3
broadly inhibiting TH1 migration in infections, autoimmune diseases, and
many cancers (Groom & Luster, 2011). In cases where pathology is driven
by TH1 cells, CXCR3 deletion or ligand neutralization is generally associ
ated with favorable outcomes. In models of rheumatoid arthritis, CXCR3 is
required for T cell recruitment to inflamed joints, and CXCR3 neutraliza
tion delayed and abrogated disease severity (Mohan & Issekutz, 2007;
Tsubaki et al., 2005). In Rag deficient mice, transfer of CXCR3 deficient
CD4+ T cells fails to induce colitis (Kristensen et al., 2006). Recently, it was
shown that IL 10 is protective in colitis models by downregulating CXCR3
expression on TH1 cells, thus reducing their homing to inflammatory sites
(Wadwa et al., 2016). The role of CXCR3 on TH1 cells in experimental
autoimmune encephalomyelitis (EAE) is more controversial, with disparate
reports concerning the importance of this receptor. T cells found in lesions
of multiple sclerosis (MS) patients as well as in mouse EAE CNS infiltrates
show high levels of CXCR3 expression (Balashov, Rottman, Weiner, &
Hancock, 1999; Sorensen et al., 1999; Sporici & Issekutz, 2010). In rats with
EAE, CXCR3 neutralization inhibited migration of blood T cells to the
CNS (Sporici & Issekutz, 2010). Clinical disease induced by passive transfer
of myelin reactive T cells activated in vitro was abrogated with CXCR3
neutralization, and this corresponded to reduced trafficking of CD4+
T cells to the CNS. This was in line with our finding that a peptide antag
onist of CXCR3 inhibited the effector phase of EAE in SJL/J mice (Kohler
et al., 2008). However, clinical disease in a model of active EAE immuni
zation was unaffected by CXCR3 blockade and neutralization of CXCL10
or CXCR3 deletion has been reported to either exacerbate or have no effect
on EAE severity (Byrne et al., 2009; Chung & Liao, 2016; Liu et al., 2006;
Muller et al., 2007; Narumi et al., 2002; Sporici & Issekutz, 2010). These
apparently conflicting findings may potentially be explained in part by the
differential bias toward encephalitogenic TH1 or TH17 cells induced by dif
ferent immunization routes, although even in EAE induced by transfer of
encephalitogenic TH1 cells, CXCR3 deletion did not affect prevent initia
tion of disease (Lalor & Segal, 2013). Furthermore, CXCR3 expression by
glial cells in EAE further confounds interpretation of broadCxcr3 / studies
and highlights the importance of utilization of systems that allow assessment
of the impact of CD4+ T cell subset specific deletion of chemokine
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receptors when studying trafficking. To the best of our knowledge, these
studies have yet to be performed with regard to CXCR3 in EAE.
The precise contributions of the different ligands to TH1 homing is still
unclear, although CXCL10 is more strongly induced by type I IFN, as
opposed to CXCL9 which is more dependent on IFNγ (Groom &
Luster, 2011). This dependence on inflammatory stimuli for CXCR3
ligand expression alludes to another key role of the CXCR3 axis, which
is to amplify the effector response. Expression of IFNγ by TH1 at periph
eral sites stimulates upregulation of CXCR3 ligands, which in turn pro
mote recruitment of more CXCR3 expressing TH1 cells, leading to
augmentation of the initial response. This is also essential for the ability
of TH1 cells to assist development of an effective CTL response, one of
the major roles of TH1 cells in viral and bacterial infections. In HSV infec
tion, CD4+ T cells are essential for CD8+ migration to the vaginal mucosa
and TH1 derived IFNγ is critically required for this (Nakanishi, Lu,
Gerard, & Iwasaki, 2009). TH1 cells at the infection site produce IFNγ
which upregulates expression of CXCL9 and CXCL10 by local epithelial
cells, thereby allowing recruitment of CTLs via CXCR3 where they can
clear infected cells. Given that the TH1 cells required responsiveness to
type I IFN, it is likely that TLR engagement stimulates innate cells to pro
vide an initial source of type I IFNwhich initiates low levels of TH1 migra
tion into the tissue, presumably through CXCR3, which then through
IFNγ production, promotes amplification of CXCL9 and CXCL10 pro
duction and subsequent CTL entry.
Another chemokine receptor classically associated with TH1 cells is
CCR5, which binds to CCL3, CCL4, and CCL5. These chemokines are
induced upon inflammation, with reported stimuli including IL 1β and
TNFα (Kawka et al., 2014). CCR5 is also used by TH1 cells to migrate
to peripheral sites to exert their function. In patients with rheumatoid arthri
tis, CCR5 expression is increased on CD4+ T cells isolated from synovial
fluid, and can be further upregulated upon culture with IL 15 (Wang &
Liu, 2003). In tumor settings, CCR5 is critical for effective antitumor
immunity, with CCR5 expression required on both OT I and OT II cells
for efficient rejection of EG7 tumors (Gonzalez Martin, Gomez, Lustgarten,
Mira, & Manes, 2011). This is at least partly mediated through intratumoral
CCL5, as increased levels of CCL5 in the tumor lead to increased recruit
ment of CD4+ T cells and reduced tumor growth (Lavergne et al., 2004).
CCR5 expression on OT II cells was also required for optimal upregulation
of CD40L on DCs and hence development of IFNγ+ OT I cells, thus
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pointing to a role for CCR5 in promoting crosspresentation by DCs to
induce CTL responses (Gonzalez Martin et al., 2011).
Although CXCR3 and CCR5 are often coexpressed by TH1 cells, they
do not appear to have redundant functions. In chronic hepatitis C infection,
CCR5 ligands are expressed in vessels within the portal triad, whereas
CXCR3 ligands are expressed on the sinusoidal epithelium, suggesting these
receptors may instead control different aspects of TH1 trafficking (Shields
et al., 1999). Furthermore, during malarial infection with blood stage Plas-
modium yoelii, CXCR3 was equivalently expressed in TH1 cells that were
IL 10+ or IL 10 , however CCR5 was preferentially expressed on
IL 10+ TH1 cells (Villegas Mendez et al., 2015). Given that IL 10 in malar
ial infections is critical for regulating inflammatory tissue damage and TH1
cells are the dominant source of this cytokine, it suggests that the CCR5
ligands promote recruitment of TH1 with a regulatory phenotype. This
remains to be formally addressed using cells deficient in these receptors.
4.2 TH2
TH2 cells are induced in response to infection with extracellular parasites, such
as helminths, where they promote expulsion or destruction of the parasite. TH2
cells are also thought to be involved in protection from environmental toxins
and irritants (Palm,Rosenstein, &Medzhitov, 2012). However, excessive acti
vation of TH2 cells can also mediate allergic pathologies such as asthma and
atopic dermatitis. These roles of TH2 cells are predominantly facilitated through
production of IL 4, IL 5, and IL 13 (Islam & Luster, 2012; Licona Limon,
Kim, Palm, & Flavell, 2013). IL 4 acts through STAT6 signaling to drive
IgE driven allergic inflammation, in which IgE binds to the Fcε receptor on
granulocytes to stimulate production of potent inflammatory molecules, such
as cytokines and histamine. IL 5 production is more associated with eosino
philic inflammation, while IL 13 promotes airway hyperresponsiveness and
mucus production. In addition to expression of these cytokines, TH2 cells
are characterized by expression of the lineage defining transcription factor
GATA3. They are generally induced by pathogen or allergen exposure at epi
thelial barriers, where release of cytokines such as TSLP, IL 33, and IL 25 pro
mote the maturation of DCs in a manner to prime TH2 cells (Saenz, Taylor, &
Artis, 2008). TH2 cells can also be primed by basophils independently of DCs in
response to haptens or peptide antigens, although this role has been controver
sial (Kara, McColl, & Comerford, 2013; Otsuka et al., 2013).
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One of the major chemokine receptors expressed by TH2 cells is CCR4,
which binds to the ligands CCL17 and CCL22. CCR4 expression is
enriched on IL 4 producing TH2 cells from both mouse and human
(D’Ambrosio et al., 1998; Sallusto, 2016). IL 4 also appears to drive a pos
itive feedback loop by promoting differentiation of TH2 cells and enhancing
CCR4 expression on TH2 cells (Kim, Nagata, & Butcher, 2003). CCL17
can be produced by endothelial cells, keratinocytes, and DCs in response
to allergic or pathogen challenge (Lonsdorf, Hwang, & Enk, 2009). Conse
quently, CCR4 drives the initial recruitment of TH2 cells to the challenge
site in a variety of models. In an atopic dermatitis model, epicutaneous chal
lenge with OVA induced CCR4 expression on antigen specific OT II cells
(Oyoshi et al., 2011). This was essential for their ability to initiate skin
inflammation, as CCR4 deficient OT II T cells were unable to transfer
allergic inflammation. CCR4 is also important for TH2 trafficking in allergic
asthma, and it is highly expressed on CD4+ T cells recruited to asthmatic
airways (Vijayanand et al., 2010). In an aerosolized OVA challenge, com
petitive transfer of CCR4 / OT II with CCR4+/+ OT II showed that
CCR4 is required for TH2 migration to the lung and BAL (Mikhak
et al., 2009). These sites can produce increased levels of both CCL17 and
CCL22 in response to allergen challenge in atopic asthmatic patients
(Pilette, Francis, Till, & Durham, 2004). These chemokines are produced
by pulmonary dendritic cells in response to aerosolized OVA challenge in
a STAT6 dependent manner, with either CD11b depletion or STAT6 dele
tion leading to reduced TH2 trafficking to the lung and reduced eosinophilic
inflammation (Mathew et al., 2001; Medoff et al., 2009). Similarly, in a
model of lung inflammation induced byNippostrongylus brasiliensis infection,
expression of STAT6 in a bone marrow derived myeloid population was
required for TH2 lung homing (Voehringer, Shinkai, & Locksley, 2004).
However, in some cases of chronic allergic inflammation, TH2 trafficking
has been shown to be independent of CCR4. In a 7 week model of cuta
neous OVA induced inflammation, CCR4 deletion failed to impair the
development of atopic dermatitis, suggesting other chemotactic signals
can drive TH2 migration (Islam et al., 2011).
TH2 cells in cases of chronic antigen are more highly differentiated and
produce increased amounts of IL 5. Indeed, human TH2 cells which were
initially IL 5 ve required multiple rounds of in vitro stimulation to induce
IL 5 production (Upadhyaya, Yin, Hill, Douek, & Prussin, 2011). In accor
dance with this, CCR4 expressing cells isolated from the peripheral blood
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of healthy donors were enriched for IL 4 expression, but produced little
IL 5 (Islam et al., 2011).
Unlike CCR4, CCR8 expression is enriched on IL 5 producing
TH2 cells in mouse and human, suggesting that there is a hierarchical
chemokine receptor expression profile for TH2 cells, with CCR4 expres
sion predominating in the recruitment of TH2 cells to barrier sites upon
initial antigen exposure, but being downregulated upon subsequent
encounters with antigen, in which trafficking occurs predominately
through CCR8.
CCR8 binds to CCL1 and CCL8 in mouse, and CCL1 and CCL18 in
humans (D’Ambrosio et al., 1998; Islam et al., 2011; Islam, Ling, Leung,
Shreffler, & Luster, 2013; Zingoni et al., 1998). As well as being a key pro
moter of eosinophilic responses, the CCR8 axis seems to be crucial for
responses to recurring antigen (Islam et al., 2011). Indeed, CCR8 was only
induced upon in vitro generated TH2 cells after repeated rounds of polari
zation. This fits with previous data showing that theCcr8 gene has both acti
vation sites for the TH2 associated transcription factor STAT6 as well as
repressive sites for the TH1 associated transcription factor STAT4 (Wei
et al., 2010). Thus, it is possible that strong induction of TH2 polarization
made feasible through multiple rounds of antigen recognition is required
for removal of STAT4 and binding of STAT6, to allow CCR8 expression.
This CCR8 expression profile may help to explain conflicting results regard
ing the importance of CCR8 in models of allergic asthma. CCR8 is highly
expressed on CD4+ T cells recruited to asthmatic airways, where increased
levels of CCL1 are found (Gonzalo et al., 2007). In a model of OVA chal
lenge beginning at day 40 after sensitization, CCL1 neutralization or dele
tion of CCR8 reduced airway inflammation and hyperresponsiveness, and
CCR8 deficient mice showed almost complete ablation of expression of
IL 4, IL 5, and IL 13 expression in the lung, supporting the importance
of CCR8 in this pathology (Gonzalo et al., 2007). Similarly, deletion of
CCR8 in an asthmatic model induced by cockroach antigen showed
impaired inflammation, associated with reduced TH2 cytokine expression,
and reduced accumulation of eosinophils (Chensue et al., 2001). However,
other studies using CCR8 deficient mice with shorter sensitization and
challenge periods report no differences in allergic asthmatic models,
although CCR8 expression was induced upon aerosol challenge (Chung
et al., 2003; Goya et al., 2003). Furthermore, competitive cotransfer of
Ccr8 / OT II cells with Ccr8+/+ OT II cells in a 3 day aerosolized
OVA challenge showed increased homing of Ccr8 / OT II cells to the
136 Carly E. Gregor et al.
lung and BAL (Mikhak et al., 2009). It is not clear whether CCR8 is
expressed by OT II cells in this model, and further experiments to elucidate
the mechanism for this enhanced homing are required.
CCR8 is also required for development of chronic allergic skin inflam
mation, with increased numbers of CCR8 expressing cells in skin from
individuals with atopic dermatitis compared with healthy skin (Gombert
et al., 2005; Islam et al., 2011). CCR8 deficient mice were protected from
developing atopic dermatitis in a 7 week OVA sensitization model, but
neutralization of CCL1 during the last 7 days of sensitization did not impair
this inflammation, suggesting this response is instead dependent on CCL8
which, unlike CCL1, was induced in atopic skin. Cotransfer of WT and
CCR8 / TH2 cells showed an intrinsic defect in CCR8 deficient
CD4+ trafficking to the atopic skin and draining lymph node. This
CCR8 mediated recruitment of IL 5 producing TH2 cells is also required
for production of IL 25, the eosinophil attracting chemokines CCL11 and
CCL24, as well as IL 5 mediated class switching to IgG1. However, CCL1
can also mediate TH2 trafficking via CCR8, with the chemokine being
upregulated in response to atopic skin inflammation, allergen challenge,
and microbial products, although not to as great an extent as mouse
CCL8 or human CCL18 (Gombert et al., 2005). Intriguingly, CCL1 has
been reported to have antiapoptotic activity and can promote survival of
thymocytes (Ruckes, Saul, Van Snick, Hermine, & Grassmann, 2001).
More research is required to determine the different contributions the
CCR8 ligands play in TH2 migration, which given the intraspecies differ
ences in ligands between mouse and human, may pose some difficulties.
Another chemokine receptor that was one of the first reported to be
expressed on TH2 cells is CCR3 (Sallusto, Lenig, Mackay, &
Lanzavecchia, 1998; Sallusto, Mackay, & Lanzavecchia, 1997). In cultures
of CD4+ T cells taken from human peripheral blood, CCR3+ cells were
enriched for expression of IL 4 and IL 5. Furthermore, CCR3+ T cells
were enriched in inflamed skin taken from patients with contact dermatitis
as well as on CD4+ T cells in cutaneous T cell lymphoma (Gerber et al.,
1997; Miyagaki et al., 2010). CCR3+ CD4+ T cells were also increased
in peripheral blood from allergic rhinitis patients, with less IL 5 production
observed in cultures where CCR3+ cells had been depleted (Francis, Lloyd,
Sabroe, Durham, & Till, 2007). More recently, CCR3 was found to be
expressed on approximately 50% of CD4+ T cells from normal nasal mucosa
suggesting a potential role for trafficking to mucosal sites, however func
tional evidence for this is still lacking (Danilova et al., 2015).
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Recent evidence has implicated CX3CR1 as another chemokine receptor
critical for TH2 trafficking in allergic inflammation. CX3CR1 binds to
CX3CL1 in mice, as well as CCL26 in humans, with CX3CL1 expression
in the skin of atopic dermatitis patients positively correlating with disease
severity (Echigo, Hasegawa, Shimada, Takehara, & Sato, 2004; Nakayama
et al., 2010). Interestingly, CX3CR1 expression is not required for migration
into inflamed skin, but rather for retention at this site. Topical administration
of a CX3CR1 antagonist specifically promoted egress of TH2 cells and con
sequently reduced skin inflammation. This receptor is also important in
asthma models, with CX3CL1 expression increased in lung and BAL in
response to allergen challenge. CX3CR1 expression on CD4
+ T cells is
required for a robust asthmatic response, as CX3CR1 deficient mice show
impaired responses which can be restored by transfer of WT CD4+ T cells.
Again, CX3CR1 does not appear to have a role in migration of TH2 to
the lung, but rather in promoting survival of these cells. CX3CR1 deficient
TH2 cells showed increased apoptosis in vivo, which could be rescued by
transduction with the antiapoptotic protein BCL 2 (Mionnet et al., 2010).
However, CX3CR1 is expressed at similar levels by TH1 and TH2 cells in
humans and in mouse models of atopic dermatitis, thus not appearing to be
restricted to theTH2 lineage. Similarly, CCR10 is expressed at increased levels
on CD4+ T cells in a variety of skin pathologies, with its ligand CCL27
expressed by keratinocytes in response to the inflammatory cytokines TNFα
and IL 1β (Hijnen et al., 2005; Homey et al., 2002). CCR10 is classified as a
skin homing receptor rather than being specific to a TH subset, although it
also is important for TH2 trafficking under allergic conditions.
Another GPCR recently implicated in human TH2 cells is the orphan
receptor, GPR15 (Nguyen et al., 2015). GPR15 is enriched on colonic
TH2 cells from patients with ulcerative colitis, but is not expressed by
TH2 cells from mouse. Accordingly, GATA3 was found by CHIP Seq to
bind to enhancer regions in GPR15 in humans but not mice. Given these
species differences, it may be difficult to ascertain the functional role of this
receptor in TH2 trafficking in intestinal diseases.
In allergic inflammation, TH2 recruitment is also mediated by GPCRs
that do not bind to chemokines. CRTH2 is a characteristic GPCR
expressed by TH2 in humans but not mice, and binds to prostaglandin
D2 (PGD2), an acidic lipid. CRTH2 is expressed at increased levels on puri
fied CD4+ T cells isolated from patients with atopic dermatitis compared
with those from healthy controls, and is likely to play a role in attracting
TH2 cells to sites of cutaneous inflammation (Hijnen et al., 2005). PGD2
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is also released by mast cells in cases of allergic asthma and polymorphisms in
this gene are associated with altered susceptibilities to asthma in a range of
studies (Islam & Luster, 2012). Similarly, leukotriene B4 (LTB4) is also pro
duced by mast cells and binds to leukotriene B4 receptor 1 (BLT1) which is
expressed by T cells, suggesting these lipid chemoattractants are critical for
the initial wave of TH2 migration to the airways in allergic responses.
4.3 TH17
TH17 cells were first described in 2005 as a lineage independent to TH1 and
TH2, that were capable of producing the proinflammatory cytokines,
IL 17A and IL 17F (Harrington et al., 2005; Park et al., 2005). These cells
are characterized by their expression of the master transcription factor, ret
inoic acid receptor related orphan receptor γt (RORγt), and have since
been described to secrete a diverse repertoire of cytokines, including IFNγ,
GM CSF, IL 10, and IL 22 (Kara et al., 2014). TH17 cells are critical for
host defense against extracellular microorganisms and this protective role
against both bacterial and fungal pathogens is primarily mediated through
IL 17A and IL 17F, which bind to the heterodimeric IL 17 receptor, com
posed of IL 17RA in complex with IL 17RC (Gaffen, 2016). This receptor
is widely expressed on nonhematopoietic cells, and signaling promotes the
induction of neutrophilic chemotactic factors, such as CXCL1, CXCL2,
and CXCL8 resulting in recruitment of neutrophils to the site of pathogenic
insult. In addition, TH17 cells can induce stromal secretion of other inflam
matory proteins such as matrix metalloproteases and the antimicrobial beta
defensins and S100 peptides as well as promoting myelopoiesis through pro
duction of G CSF and GM CSF (Liang et al., 2006; McGeachy, 2011).
However, TH17 cells are also implicated as key drivers of many autoimmune
pathologies, as shown in mouse models of rheumatoid arthritis and MS
where production of proinflammatory cytokines drives pathological
destruction of host tissues (Hirota et al., 2007; Langrish et al., 2005).
TH17 cell differentiation in vitro is triggered by IL 6 and TGF β1, with
IL 21 and IL 23 reinforcing this program (Bettelli et al., 2006; Langrish
et al., 2005; Mangan et al., 2006; Veldhoen, Hocking, Atkins,
Locksley, & Stockinger, 2006). However, in vivo differentiation of
TH17 cells is more complex and it is now clear that a spectrum of
TH17 cellular phenotypes exist with differing capacities to promote inflam
mation. TH17 cells differentiated in the presence of TGF β1 and IL 6 alone
express the antiinflammatory cytokine IL 10 in addition to IL 17, and these
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cells have limited capacity to promote EAE following passive transfer
(McGeachy et al., 2007). In contrast, when differentiated in the presence
of IL 23 or TGFβ3, TH17 cells did not express IL 10 and instead
upregulated proinflammatory cytokines, specifically IFNγ and GM CSF
(Lee et al., 2012). These IFNγ and GM CSF producing TH17 cells have
been described to have higher pathogenic potential than other TH17 cells
due to their production of these inflammatory cytokines. Indeed, studies
using cytokine deficient transgenic CD4+ T cells indicate that it is
GM CSF and not IL 17A or IFNγ that is the key pathological cytokine pro
duced by TH17 cells in EAE (Ponomarev et al., 2007). Furthermore, in con
ditions of persistent antigen and exposure to IL 23, such as in EAE,
TH17 cells can lose IL 17 expression while maintaining IFNγ and
GM CSF production, giving rise to what have been termed
ex TH17 cells (Hirota et al., 2011). The relative contributions to disease
of these differentiation states remain to be elucidated. Conversely, when
antigen is transient, such as following resolution of bacterial infection, path
ogenic TH17 cells can convert to a more regulatory phenotype. Using a
model in which an IL 17A fate mapping mouse was crossed to an
IL 17AKatushkaIL 10eGFPFoxp3RFP triple reporter mice, TH17 cells were
shown to convert to IL 17 veFoxp3 veIL 10+ cells in model of self limiting
inflammation or transient bacterial infection (Gagliani et al., 2015). Given
the similarities of the transcriptional profile of these cells to TR1 cells, these
cells were termed TR1
exTh17 cells. Furthermore, there are reports of
TH17 cells transdifferentiating into cells with a TFH like phenotype in PP
(Hirota et al., 2013). Thus, differentiation of CD4+ T cells to a
TH17 phenotype does not appear to be an endpoint state, with substantial
plasticity being governed by antigenic load.
The characteristic chemokine receptor expressed by TH17 cells is
CCR6, which binds to the sole known chemokine ligand, CCL20.
CCL20 can be upregulated in response to various inflammatory signals,
but is also expressed under resting conditions in a diverse range of tissues,
including the skin, gut, and airways, attracting TH17 cells to these sites
through CCR6 (Comerford et al., 2010; Lee, Eri, Lyons, Grimm, &
Korner, 2013). Expression of CCR6 appears to be tightly coupled to the
initial TH17 differentiation program, as in in vitro generated TH17 cells,
TGF β1 but not IL 6 was sufficient to induce CCR6 expression. IL 2,
which suppresses TH17 differentiation in vitro, also reduces CCR6 expres
sion on the IL 17+ CD4+ cells that are generated (Wang, Kang, Lee, Sun, &
Kim, 2009). However, these cytokines may be influencing CCR6
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expression indirectly through modulation of RORγt expression. Indeed,
forced expression of RORγt in naı̈ve T cells is sufficient to upregulate
CCR6 and in mice with transgenic expression of RORγt and GFP under
the CD4 promoter, the vast majority of GFP+ IL 17+ cells were also
CCR6+ (Hirota et al., 2007; Wang et al., 2009). CCR6 expression can
occur in the absence of RORγt expression but only in RORα sufficient
cells, indicating redundancy in RORγt/RORα function in this regard
(Yamazaki et al., 2008). RORγt also promotes CCR6 expression in human
TH17 cells, as retroviral transduction of cord blood CD4
+ T cells with
RORγt induced CCR6 (Manel, Unutmaz, & Littman, 2008). Ablation
of RORγt activity using the inverse agonist TMP778 also reduced
CCR6 expression in human TH17 cells from both healthy and psoriatic
donors (Skepner et al., 2014). CCR6 is also directly regulated in human
but not mouse TH17 cells by the transcription factor PLZF, which works
synergistically with RORγt and binds to the CCR6 promoter (Singh
et al., 2015). Taken together, these data have led to the widespread notion
that CCR6 is the defining chemokine receptor of TH17 cells and
highlighted the CCR6/CCL20 axis as a potential target for pharmacological
blockade of inflammatory T cell trafficking in human pathologies. However,
there are some important caveats to this that should be considered. These
include the expression of CCR6 on regulatory T cells (Yamazaki et al.,
2008) and our recent discovery that pathogenic GM CSF producing
TH17 cells lose expression of CCR6 and instead migrate through CCR2
(Kara et al., 2015).
TH17 cells are highly enriched in the intestinal tract, which given the
abundance of microbes at this site, is in accordance with the demonstrated
role of TH17 cells in protection against extracellular bacterial infection.
CCR6 has been strongly implicated in TH17 cell recruitment to the intes
tine and as a consequence is suggested to be a driver of intestinal inflamma
tion. However, while a plethora of studies have demonstrated the
importance of CCR6 in intestinal pathology, Tregs, and other cells also
use CCR6 for their migration. Thus, many of these studies do not directly
assess the role of CCR6 on TH17 cells specifically, and disease outcomes in
CCR6 deficient settings depend on the differing contributions of TH17 and
Tregs, or other CCR6 expressing cells, in those models. However, it is clear
that CCR6 is required for efficient homing of TH17 cells to the intestine.
CCL20 is abundantly expressed in the subepithelial dome of PP, as well
as in isolated lymphoid follicles. Accordingly, transferred Ccr6 /
TH17 cells displayed impaired migration to PP, the small intestinal lamina
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propria and the peritoneal cavity (Wang et al., 2009). Similarly, retroviral
transduction of CCR6 in T cells enhancedmigration to PP. The importance
of CCR6 in intestinal TH17 trafficking has also been demonstrated to have a
major role in immune regulation following peripheral inflammation. In
response to anti CD3 antibody injection, which transiently leads to strong
TCR activation and systemic hyperabundance of IL 6 and TGF β1, there is
massive recruitment of TH17 cells to the small intestine, where they are
expelled into the lumen or reprogrammed for immune regulation
(Esplugues et al., 2011). In this model, frequencies of Ccr6 / TH17 cells
were strongly reduced in the intestine but instead pooled in spleen and
LN demonstrating that CCR6 was essential for this process. IL 17 secretion
by intestinal TH17 cells also upregulated CCL20 expression by epithelial
cells in the duodenum, suggesting TH17 cells promote a positive feedback
loop to enhance recruitment of other TH17 cells. Interestingly, CCL20 is
also abundantly produced by TH17 cells, suggesting autocrine amplification
of CCR6 driven inflammation, although experimental data testing this pos
sibility is lacking.
Aside from CCR6, other chemokine receptors may contribute to intes
tinal homing of TH17 cells. TH17 cells from the large intestine have been
shown to express CCR4 and CXCR5 and, although it is not clear if these
are functional in mouse TH17 cells, CCR4 is also expressed on human
memory TH17 cells (Ramesh et al., 2014; Wang et al., 2009). CCR9 is also
enriched in TH17 cells in the small intestine, and along with α4β7 can be
induced on in vitro generated TH17 cells by addition of retinoic acid
(RA) (Wang, Kang, HogenEsch, Love, & Kim, 2010). RA induced
TH17 cells use these receptors to migrate to the small intestinal lamina
propria, where epithelial cells produce the CCR9 ligand, CCL25. CCR9
induction on T cells is dependent on BATF, as Batf / T cells fail to
upregulate this receptor in response to RA and display impaired homing to
the intestine (Wang et al., 2013). BATF binds with RARα in multiple sites
upstream of the CCR9 gene, possibly regulating expression through histone
acetylation. Given that BATF is also required for TH17 differentiation, the
coupling of BATF and CCR9 expression underlines the importance of
homeostatic TH17 trafficking to the gut.
TH17 cells are also critical for controlling bacterial infection at other
peripheral sites, particularly at other mucosal barrier sites such as the lung.
Challenge with an array of extracellular bacteria including Klebsiella
pneumoniae and Streptococcus pneumoniae induces TH17 cells, with IL 17 being
a key mediator of bacterial clearance through induction of a neutrophilic
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response (Happel et al., 2003; Ye et al., 2001; Zhang, Clarke, & Weiser,
2009). Similarly, fungal pulmonary infections such as with Aspergillus
fumigatus or Pneumocystis carinii also induce potent TH17 responses. The traf
ficking receptors used by TH17 cells for migration to the lung are not well
understood, although given that CCL20 is upregulated in response to pul
monary infection, it is likely that CCR6 plays a role here as well (Khader,
Gaffen, & Kolls, 2009). This is supported by studies of human TH17 cells, in
which TH17 memory subsets with a CCR6
+CCR4+ profile responded vig
orously upon incubation with Candida albicans and Staphylococcus aureus.
However, functional evidence identifying chemokine receptors involved
in TH17 homing to the lung is currently lacking.
In addition to control of extracellular microbes, TH17 cells are also
known to be drivers of many autoimmune diseases. Again, CCR6 has been
demonstrated to play a critical role in the onset of these pathologies. CCR6
is required for trafficking of TH17 to arthritic joints in SKG mice, and
CCL20 is abundant in synovial fluid from patients with rheumatoid arthritis
(Hirota et al., 2007; Matsui et al., 2001). CCR6+ TH17 cells are also
enriched in human inflammatory bowel disease lesions (Kleinschek et al.,
2009). In 2,4,6 trinitrobenzene sulfonic acid (TNBS) induced colitis,
CCR6+ TH17 cells are increased in frequency in the gut, and neutralization
of CCL20 blocks their recruitment (Katchar, Kelly, Keates, O’Brien, &
Keates, 2007). Similarly, CCR6 is required for migration to the autoim
mune kidney in the TH17 driven pathology of crescentic glomerulonephri
tis (cGN). Intriguingly, a recent study in Kaede mice using photoconversion
of intestinal TH17 cells showed that TH17 cells migrate from the small intes
tine to the kidney in response to cGN induction (Krebs et al., 2016). Egress
from the small intestine lamina propria was dependent on S1PR1, while
migration into the kidney was dependent on CCR6 expression. Further
more, reducing intestinal TH17 numbers through antibiotic treatment or
germ free mice also reduced cGN pathology, while expanding intestinal
TH17 cells through infection withCitrobacter rodentium enhanced pathology.
This suggests that the small intestine acts as a functional pool for TH17 cells,
that can then be recruited to sites of inflammation and/or autoimmunity
using CCR6 and S1PR1. It is not clear if the TH17 cells that enter the kid
ney from the intestinal pool are specific for kidney autoantigens, or whether
they are simply recruited to the kidney through CCR6 and cause inflamma
tion in a nonantigen specific manner. If the latter is true, this suggests
TH17 cells may constitutively traffic from the intestinal tract to other periph
eral sites. Alternatively, it is possible that the autoimmune kidney produces
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additional, as yet unidentified signal(s), to induce TH17 egress from the gut.
It will be of great interest to answer these questions, as well as determining if
the intestine also harbors differentiated TH17 cells that contribute to auto
immunity in other tissues.
The contribution of CCR6 to TH17 cell migration to the CNS in the
mouse model of MS, EAE, has been tested by a number of investigators over
the past decade. Transfer of MOG reactive CD4+ T cells differentiated in
the presence of IL 23 is sufficient to initiate disease; however, transfer of
these cells from a CCR6 deficient donor did not induce clinical signs of
EAE (Yamazaki et al., 2008). Initial studies indicated that CCR6 deficient
mice were somewhat resistant to development of EAE (Liston et al., 2009;
Reboldi et al., 2009; Yamazaki et al., 2008), but transfer of small numbers of
CCR6 sufficient T cells made Ccr6 / mice susceptible (Reboldi et al.,
2009). Entry to the CNS of CCR6 expressing TH17 cells was shown to
be via the choroid plexus, where epithelial cells produce CCL20 prior to
the onset of neuroinflammation. However, other investigators have
questioned the importance of the choroid plexus as the entry point for
TH17 cells into the CNS in EAE and have identified an IL 6 driven induc
tion of CCL20 by blood endothelial cells that vascularize the fifth lumbar
spinal cord and show this to be the main entry point for TH17 cells into
the CNS (Arima et al., 2012). Regardless of the site of initial entry, once
TH17 cells enter the CNS a cascade of other inflammatory signals follow
which results in further cell recruitment independently of CCR6. Interest
ingly, the initial recruitment of TH17 cells to the CNS that is driven by
CCR6 is not an essential component of disease pathogenesis. This has been
demonstrated by more recent reports that show that CCR6 deficient mice
have only a delay in the onset of EAE, but ultimately develop exacerbated
disease, likely due to a role for CCR6 in Treg recruitment (Elhofy, Depaolo,
Lira, Lukacs, & Karpus, 2009; Villares et al., 2009). The signals that drive
ongoing recruitment of TH17 cells to the inflamed CNS remain to be fully
revealed, however we recently demonstrated an essential role for CCR2 in
this process (Kara et al., 2015), which is discussed below.
Conversion of TH17 to pathogenic TH17 and exTH17 subsets has been
reported in a number of models including EAE. Pioneering work by the
Stockinger laboratory used an IL 17 fate mapper mouse that permanently
marks cells and their progeny with eYFP if IL 17A is expressed. This
showed a sequential change in cytokine production by differentiated
TH17 cells in EAE that transitions from IL 17
+ IFNγ ve to IL 17+ IFNγ+
and then to a IL 17 ve IFNγ+ profile (Hirota et al., 2011). Loss of IL 17
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expression by TH17 cells in EAE was concomitant with downregulation of
CCR6 and CCR6 ve eYFP+ cells had substantially higher levels of Ifnγ
mRNA than CCR6+ eYFP+ cells, suggesting pathogenic TH17 cells may
not use CCR6 for their trafficking. Indeed, we have recently demonstrated
that there is a temporal switch in TH17 trafficking programs during EAE,
with CCR6 only required for migration of TH17 cells during the initial
stages of pathogenesis (Kara et al., 2015). As disease progresses, CCR2
expressing TH17 cells emerge from the SLO, with this being the critical
migratory receptor for homing of encephalitogenic TH17 to the CNS. In
accordance with this, antagonism of CCR6 was only effective at reducing
TH17 migration during the preclinical phase of disease, but had no effect
when administered during peak disease. Conversely, CCR2 antagonism
did not reduce TH17 recruitment during the preclinical phase but signifi
cantly abrogated TH17 accumulation in the CNS during peak disease,
and was effective in inhibiting EAE relapse and blocking TH17 entry to
the CNS when administered during disease remission. Furthermore,
GM CSF and IFNγ production by TH17 cells primarily emanated from cells
with a CCR6 veCCR2+ phenotype. Given that GM CSF production by
TH17 cells is a critical requirement for neuroinflammation in EAE, this indi
cates that CCR2 and its ligands may be tractable therapeutic targets to block
recruitment of pathogenic GM CSF producing T cells. In support of this,
GM CSF and IFNγ production in human TH17 cells taken from healthy
and MS patients was also confined to the CCR6 veCCR2+ population.
In the disease, targeting CCR2 has the added advantages of inhibiting mye
loid cell recruitment, a major contributor to pathology in EAE, while not
affecting Treg homing, unlike therapies directed at CCR6. Expression of
CCR2 by TH17 cells does not appear to be limited to autoimmune disease,
as TH17 cells generated in response to chronic S. pneumoniae nasopharyngeal
infection displayed similar temporal upregulation of CCR2, with CCR6 ve
CCR2+ cells again being the predominant source of GM CSF and IFNγ.
Whether CCR2 is important for TH17 trafficking in situations of transient
infection remains to be determined.
Altogether, it is clear that the canonical TH17 chemokine receptor
CCR6 is critical for a number of TH17 migration events, particularly in
homeostatic trafficking to the gut as well as in some autoimmune patholo
gies. However, as we learn more about the complexities of the TH17 subset,
it is evident that plasticity of these cells is essential to regulate responses and
either amplify or turn off inflammation. In situations of mild insult, such as
for many transient bacterial infections, TH17 cells can express a moderately
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inflammatory cytokine profile (including IL 10), and do not promote
chronic inflammation, whereas in cases of more persistent antigen and
inflammation, IFNγ+ GM CSF+ TH17 cells are generated, and these cells
often contribute to pathological tissue damage. The progression of these cells
to a more highly pathogenic state appears is accompanied by downregulation
of the canonical TH17 program, along with CCR6 expression, while con
comitantly upregulating CCR2. Given that exTH17 cells share many aspects
of a TH1 transcriptional profile, it is likely that these cells may also utilize
canonical TH1 chemokine receptors such as CXCR3, although this remains
to be tested. Thus, it will be crucial to further identify how chemokine recep
tor usage changes with differing TH17 states, in order to more accurately
understand the homing of these cells and develop more targeted therapeutic
approaches to diseases in which TH17 cells play an important role.
4.4 TH22
TH22 cells were first identified in humans as IL 22
+CD4+T cells present in the
skin (Duhen, Geiger, Jarrossay, Lanzavecchia, & Sallusto, 2009; Eyerich et al.,
2009; Nograles et al., 2009; Trifari, Kaplan, Tran, Crellin, & Spits, 2009).
However, there has been some controversy overwhether TH22 cells genuinely
represent a distinct T cell subset, in part because IL 22 production is also a fea
ture of TH17 cells in many scenarios (Ahlfors et al., 2014). Furthermore, the
major transcriptional regulators of TH22 cells reported so far are T bet and
the aryl hydrocarbon receptor (AhR), which are not confined to the
TH22 lineage (Basu et al., 2012; Ramirez et al., 2010). However, at least in
humans, CD4+ T cells that express IL 22 without IL 17 or IFNγ production
have been described, that also have minimal or absent expression of RORγt.
This phenotype is also stable in prolonged culture, lending support to the idea
these cells are an independent subset in humans.
Through their production of IL 22, TH22 cells are believed to have
important roles both in promoting repair of damaged epithelial barriers as
well as in enhancing immune responses against some pathogens. IL 22 acts
on nonhematopoetic cells including keratinocytes and epithelial cells to
stimulate proliferation and differentiation, thus promoting wound healing
and maintaining barrier integrity. Furthermore, IL 22 enhances stromal
secretion of antimicrobial peptides like beta defensins and S100 peptides,
as well as production of the chemokines CXCL9, CXCL10, CXCL11,
CCL2, and CCL20, which promote recruitment of other immune cell types
through CXCR3, CCR2, and CCR6, respectively (Aujla et al., 2008;
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Eyerich et al., 2009; Jia & Wu, 2014; Zheng et al., 2008). Via these mech
anisms, IL 22 has been shown to be protective against a number of bacterial
and fungal pathogens (Aujla et al., 2008; De Luca et al., 2010; Gessner et al.,
2012; Zheng et al., 2008). However, a direct contribution of TH22 cells
was only recently demonstrated for protection against infection, with
IL 22+ IL 17 ve CD4+ cells critical for protection in the late phase of
C. rodentium infection (Basu et al., 2012). TH22 cells have also been pur
ported to play a role in pathological conditions in both mice and humans,
with IL 22 and TH22 cells linked to inflammatory diseases such as psoriasis
and rheumatoid arthritis (Eyerich et al., 2009; Jia & Wu, 2014; Nograles
et al., 2009). However, definitive evidence of a causative pathological role
of IL 22 production by TH22 cells in these diseases is not yet available.
TH22 generation from naı̈ve human CD4
+ T cells in vitro is induced by
IL 6 and TNFα, and enhanced further by IL 1β (Duhen et al., 2009). Sim
ilarly in mice, IL 6 in the absence of TGFβ promotes the development of
IL 22+ IL 17 ve CD4+ cells, with IL 23 also promoting IL 22 but dispens
able for TH22 development (Basu et al., 2012; Rutz et al., 2011). More
recently, IL 21 was also shown to promote IL 22 production without
inducing IL 17, with AhR and STAT3 cooperatively binding the IL 22
promoter in CD4+ cells (Yeste et al., 2014). Furthermore, AhR agonists
such as β napthoflavone and FICZ can further stimulate IL 22 production
(Trifari et al., 2009).
Initial reports of human TH22 cells identified these cells as expressing the
chemokine receptors CCR10, CCR4, and CCR6 (Duhen et al., 2009;
Trifari et al., 2009). Given that the CCR4 and CCR10 ligands are abun
dantly expressed in the skin, and TH22 cells are enriched at this location, this
implicates these two receptors as the homing receptors used by TH22 cells to
enter the skin. TH22 cells are enriched in inflamed skin and blood from
patients with psoriasis or atopic dermatitis and plasma levels of IL 22 are
associated with increased disease severity, indicating that these cells may
contribute to skin inflammation (Eyerich et al., 2009; Nograles et al.,
2009). Although little work has been done to clarify how TH22 cells traffic
in these inflammatory skin conditions, we speculate that it is likely to involve
CCR4 and CCR10, both well known skin homing chemokine receptors.
TH22 trafficking into other organs, such as the intestine, is likely to be
mediated through alternate receptors such as CCR6. In human colon can
cer, IL 22 expression in CD4+ T cells in the absence of IL 17 expression was
restricted to CCR6+ cells (Kryczek et al., 2014). These cells were the pre
dominant source of IL 22 and acted to promote tumor growth, with CCR6
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required for trafficking of IL 22+ CD4+ cells to human colon cancer tumors
in NSG mice. However, although these cells lacked IL 17 expression they
expressed RORγt, making it difficult to determine if these are bona fide
TH22 cells, which further clouds the distinction between TH17 and
TH22 subsets. Recently, CyTOF analysis of human TH cells also identified
expression of CXCR6, CCR2, and CCR5 in the IL 22+ subset, although
whether receptors are functional in TH22 cells awaits further investigation
(Wong et al., 2016). Taken together, there is much still to learn about
the mechanisms used for homing of TH22 cells and the significance of this
subset of cells in human disease.
4.5 TH9
TH9 cells were first reported in 2008 as CD4
+ T cells that produce IL 9 and
that developed independently of other TH lineage specific transcription fac
tors (Dardalhon et al., 2008; Veldhoen et al., 2008). Although initially
thought to be a TH2 cytokine, IL 9 production in the absence of IL 4 pro
duction is the characteristic feature of the TH9 profile. IL 9 has been
described to have a multitude of functions, but is most often associated with
type 2 responses like allergic inflammation and protective immunity against
helminths (Faulkner, Renauld, Van Snick, & Grencis, 1998; McMillan,
Bishop, Townsend,McKenzie, & Lloyd, 2002). IL 9 acts to promote survival
and growth of mast cells, T cells, and ILCs, enhances airway mucus produc
tion, promotes IgE class switching, and generally modulates the activity and
cytokine secretion of a variety of cell types (Kaplan, Hufford, &Olson, 2015).
Unlike the other described TH subsets, no master transcription factor has yet
been shown to define TH9 lineage specification, although PU.1, IRF4, and
BATF promote their development (Chang et al., 2010; Jabeen et al., 2013;
Staudt et al., 2010). Differentiation of TH9 cells in vitro is dependent onTGFβ
and IL 4 (Chang et al., 2010; Veldhoen et al., 2008). Alternatively, under the
iTreg polarizing conditions of TGFβ and IL 2, GITR ligation diverts naı̈ve
T cells from Treg differentiation and instead induces the TH9 program (Xiao
et al., 2015). There has been controversy over whether the TH9 subset rep
resents a distinct lineage due to the difficulty in identifying often transient IL 9
production and the fact that IL 9 is produced by other lineages (Tan et al.,
2010). However, increasing evidence supports their discrete identity, partic
ularly in humans where multiple reports of IL 9+ IL 13 ve IL 4 ve IFNγ ve
CD4+ T cells have been described (Cortelazzi, Campanini, Ricci, & De
Panfilis, 2013; Jones, Gregory, Causton, Campbell, & Lloyd, 2012; Purwar
et al., 2012).
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The contribution that TH9 cells make to the adaptive immune response
is not completely clear and experiments to fully address the dependence of
IL 9 mediated effects on TH9 cells are still required. Recent work using an
IL 9 fate mapper mouse showed that in a model of papain induced
asthma, the majority of IL 9 expression is not by CD4+ T cells, but rather
from ILC2s (Wilhelm et al., 2011). However, IL 9 expression was pre
dominantly restricted to CD4+ T cells in an OVA sensitization and chal
lenge model. Upon infection with N. brasiliensis, transfer of TH9 cells but
not TH2 cells induced worm expulsion in Rag2
/ hosts (Licona Limon
et al., 2013). There is also increasing evidence for an antitumor role of TH9
cells. Transfer of in vitro generated TH9 cells inhibits melanoma growth
and TH9 cells are found in metastases from melanoma patients (Purwar
et al., 2012). Similarly, in vitro generated OT II cells protected mice in
hematogenous metastasis experiments with B16 OVA cells, and transfer
of TH9 cells drastically abrograted subcutaneous tumor growth
(Lu et al., 2012). In these experiments, the antitumor effects of TH9 cells
were IL 9 dependent, and resulted from TH9 induction of CCL20 in
the tumor site, along with a strong CTL response which was CCR6
dependent.
Reports into chemokine receptor expression and trafficking of TH9 cells
are limited. We have shown that TH9 cells express a broad chemokine
receptor profile that includes receptors commonly associated with TH1,
TH2, TH17/Treg cells. Specifically, TH9 cells displayed CCR3, CXCR3,
and CCR6 both in vitro and in models of allergic inflammation and auto
immunity in vivo (Kara et al., 2013). In a type 2 OVA challenge, antagonism
of CCR3 or CCR6, but not CXCR3 inhibited TH9 migration into the
peritoneal cavity. However, in EAE, antagonism of CXCR3 and CCR6
but not CCR3 prevented egress from draining LNs and migration into the
CNS. This shows that different chemokine receptors are utilized by TH9 cells
under different circumstances, likely due to differences in chemokine expres
sion in these scenarios, and suggests that TH9 cells have versatile functions that
contribute to distinct inflammatory environments. This broad chemokine
receptor profile was also apparent in B16–F10 bearing mice, where TH9 cells
were shown to be enriched among CCR3+CXCR3+CCR6+CCR4 ve
CD4+ T cells (Vegran et al., 2014). Questions remain as to which receptors
are used in different aspects of TH9 homing, and if they may use other recep
tors in vivo. In addition, how expression of these receptors is transcriptionally
controlled is also unknown, as T bet and RORγt, known transcriptional
regulators of CXCR3 and CCR6, respectively, are apparently not expressed
in TH9 cells (Veldhoen et al., 2008).
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4.6 TFH
TFH cells specialize in providing help to B cells and are required for devel
opment of high affinity antibodies in the germinal center (GC) as well as for
long lived memory responses. The importance of these cells is clear, as their
help is the limiting factor for affinity maturation of GC B cells and in the
absence of TFH cells, GCs fail to develop (Johnston et al., 2009; Nurieva
et al., 2009; Victora et al., 2010; Yu et al., 2009). TFH cells provide help
through provision of CD40L, ICOS, and SAP signals to B cells as well as
through production of cytokines such as IL 21 and IL 4 (Vinuesa,
Linterman, Yu, & MacLennan, 2016). The lineage defining transcription
factor for TFH cells is Bcl6, although other important regulators of TFH fate
include Ascl2, c Maf, and Batf. TFH generation is promoted by IL 6 and
IL 21 during priming in mice, with TGFβ, IL 12, and IL 23 important
for TFH development in humans (Eto et al., 2011; Karnowski et al.,
2012; Schmitt et al., 2014).
Initial reports of TFH cells described them as CXCR5
+ CD4+ cells
although now GC TFH cells are most commonly and accurately demarcated
as PD 1hi CXCR5hi CD4+ T cells (Breitfeld et al., 2000; Haynes et al.,
2007; Kim et al., 2001; Schaerli et al., 2000). CXCR5 is critical to their
function as it allows T cells to migrate to the follicles, where CXCL13 is
abundantly expressed by FDCs (Ansel, McHeyzer Williams, Ngo,
McHeyzer Williams, & Cyster, 1999). CXCR5 is first upregulated on
pre TFH cells that are generated upon priming by DCs in SLOs and enables
migration to the T:B border, where TFH lineage commitment is conferred
by interactions with Ag expressing B cells (Barnett et al., 2014). CXCR5 is
further upregulated upon entry to the GC and is critical for optimal GC
function, with CXCR5 deficient T cells failing to induce efficient forma
tion of GCs (Arnold, Campbell, Lipp, & Butcher, 2007; Hardtke et al.,
2005; Haynes et al., 2007; Junt et al., 2005). However, residual TFH cells
can still reach the GC in the absence of CXCR5, suggesting alternate migra
tory signals make a minor contribution to TFH homing toward the GC.
CXCR5 is also critical for microanatomical localization within the GC,
as CXCR5 deficient TFH cells able to access the follicle are unable to
migrate to the light zone of the GC, the site of selection of high affinity
B cell clones (Haynes et al., 2007). CXCR5 is also abundantly expressed
on circulating CD4+ T cells from human peripheral blood and these cells
are capable of assisting B cell responses in vitro. However, the precise rela
tionship of these cells to TFH cells requires further investigation (He et al.,
2013; Locci et al., 2013; Morita et al., 2011).
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As Bcl6 is a transcriptional repressor, it is unlikely to directly promote
CXCR5 expression. However, one of the major targets of Bcl6 is the mutu
ally antagonistic transcription factor Blimp1 (encoded by Prdm1), which is
capable of repressing CXCR5 and other TFH like genes through direct
binding to the promoter region (Oestreich et al., 2012). CXCR5 is also
repressed by the Bcl 6 regulating miRNA miR 17–92 (Yu et al., 2009).
However, monitoring induction of Bcl6 using Bcl6–IRES–GFP reporter
mice concurrently with CXCR5 expression showed different kinetics, with
CXCR5 rapidly increased at day 2 postimmunization and maintained at
high levels, whereas Bcl6 was gradually upregulated beginning from days
2 to 7 (Liu et al., 2012). Indeed, it was recently reported that Ascl2 is the
critical factor promoting CXCR5 expression prior to Bcl6 induction, with
retroviral transduction of Ascl2, but not Bcl6, sufficient for CXCR5 induc
tion and migration to the follicles (Liu et al., 2014). Ascl2 directly regulates
CXCR5 expression and binds to multiple regions of the CXCR5 gene. The
E proteins E2A and HEB also promote CXCR5 upregulation, and as they
are expressed at earlier time points than Ascl2, have been hypothesized to be
the preceding signal promoting TFH differentiation, although this remains to
be determined (Shaw et al., 2016).
Although CXCR5 is required for migration to the follicle, over
expression of CXCR5 alone does not permit entry (Haynes et al., 2007).
Pre TFH cells must also downregulate CCR7, in order to escape the
CCL19 and CCL21 signals abundant in the T cell zones. Both Ascl2 and
Bcl6 act to reduce CCR7 expression (Hatzi et al., 2015; Liu et al., 2014).
Ascl2 also upregulates CXCR4, which may play roles in localization to
the dark zone, as well as in extrafollicular responses, although this remains
to be formally addressed (Elsner, Ernst, & Baumgarth, 2012). Non
chemokine signaling cues are also important for TFHmigration, with expres
sion of S1PR2 required for retention of TFH cells in the GC (Moriyama
et al., 2014). Interestingly, recruitment of activated T cells to the follicles
requires ICOSL expression by bystander B cells, which promotes pseudo
pod formation and enhances motility of ICOS expressing TFH cells
(Xu et al., 2013). These signals are essential for TFH migration from the
T B border to the follicle, with the ICOS driven increase in motility all
owing these cells to be influenced by other chemotactic signals including
those through CXCR5 for optimal homing.
Recent analysis of TFH cells using two photon photoconversion with
intravital microscopy has elucidated the differential kinetics of migration
during primary and secondary responses (Suan et al., 2015). During the
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primary response, TFH cells are generally confined to one GC, with limited
trafficking between GCs. Although most TFH are confined to the center of
the GC, there is a subpopulation of TFH that cross into the follicular mantle
(FM) region, although the functional significance of these cells requires fur
ther investigation. FM TFH cells have a distinct profile from GC TFH cells,
with FM TFH cells expressing less CXCR5 and more CCR7 and the non
chemokine GPCR, EBI2. EBI2 expression is repressed by Bcl6, with the
receptor promoting localization to the subcapsular and interfollicular regions
(Hatzi et al., 2015; Suan et al., 2015). EBI2 deficient CD4+ T cells display
increased GC localization during the primary response, but upon
rechallenge are equally as able as WTTFH cells to localize to the GC, despite
their high expression of this receptor. Also in contrast to the primary
response, TFH cells in secondary responses readily migrate from the GC
to the FM, as well as between neighboring GCs, with almost all TFH cells
having done so 24 h after GC photoconversion (Shulman et al., 2013;
Suan et al., 2015). This is believed to enhance the efficiency of T cell help,
however the distinct migratory cues for this differential movement remain to
be determined.
4.7 Treg
Treg cells play a critical role in negative regulation of immune responses and
are essential both to maintain tolerance against self antigens and to limit
pathogen induced inflammation to prevent excessive damage to host tissues.
The two major subsets of Treg are thymic Treg (tTreg), which develop in
the thymus, and induced Treg (iTreg) which are derived from naı̈ve CD4+
T cells following suboptimal antigenic stimulation, encompassing lack of
inflammatory signals during priming as well as reduced TCR signal strength
(Josefowicz, Lu, & Rudensky, 2012). Both of these cell types are defined by
the expression of the transcription factor Foxp3 and the importance of these
cells is clear from studies of Foxp3 deficient mice, which succumb to an
early onset systemic inflammatory disorder (Brunkow et al., 2001). Treg
can suppress immune responses through a variety of mechanisms, including
through production of cytokines such as TGFβ and IL 10, through direct
cell–cell contacts or through metabolic disruption of inflammatory T cells
(Schmitt &Williams, 2013). The tTreg and iTreg populations share a similar
surface profile which has made it difficult to study differences in their func
tion and migration, although in some scenarios tTreg can now be distin
guished from iTreg based on their higher expression of neuropilin 1
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(Weiss et al., 2012; Yadav et al., 2012). This will facilitatemore detailed anal
ysis of the contribution of these subsets in the future. Other Foxp3 ve reg
ulatory T cells exist, including TR1 and TH3 cells, but are not discussed here.
Given that Treg are responsible for suppressing T cell mediated inflam
mation in a diverse range of scenarios, it is perhaps not surprising that they
appear to differentiate in a manner parallel to Foxp3 ve CD4+ T subsets.
Treg that develop in response to a particular challenge often express the same
transcription factors and chemokine receptors as the inflammatory TH cells
generated alongside them, which allows for similar trafficking to peripheral
tissues and hence suppression. For instance, in TH17 mediated colitis, Treg
require expression of the TH17 generating transcription factor STAT3 for
optimal activity, as STAT3 deficient Treg fail to suppress colitis in vivo,
although show similar suppressive capacity in vitro (Chaudhry et al.,
2009). This was associated with reduced expression of CCR6 by
Treg, which is required for TH17 migration to the gut. Treg also use
CCR6 to migrate to the CNS and kidney in EAE and glomerulonephritis
models (Turner et al., 2010; Yamazaki et al., 2008). Similarly to TFH cells,
there also exists a CXCR5+ Bcl6+ population of Foxp3+ CD4+ cells termed
T follicular regulatory (TFR) cells. These cells use CXCR5 to localize to the
follicles where they can suppress GC responses (Chung et al., 2011;
Linterman et al., 2011).
The TH2 associated transcription factor IRF4 is also required for optimal
Treg development, as IRF4 deficient Treg show impaired suppression of
TH2 responses (Zheng et al., 2009). IRF4 ablation also reduces expression
of CCR8, which in models of graft vs host disease (GVHD) has been shown
to be important for Treg maintenance (Coghill et al., 2013). CCR8 expres
sion on transferred Tregs in this model allows colocalization with donor
APCs to receive signals promoting survival, with CCR8 deficient Treg
showing increased death. Treg also express the TH2 receptor CCR4 in asth
matic cases of both mice and humans (Afshar et al., 2013). CCR4 expression
on Treg is required for Treg suppression during the challenge phase of aller
gic asthmatic models but not during the sensitization phase. CCR4 is also
more generally required for Treg recruitment to the skin and lung, as mice
with a Treg specific deletion of CCR4 show impaired Treg homing to
these sites and develop severe inflammatory pathology (Sather et al.,
2007). This axis may be a useful therapeutic target in skin pathologies such
as vitiligo, where overexpression of CCL22 in depigmented skin of vitiligo
prone mice enhanced Treg migration to the site and reduced depigmenta
tion (Eby et al., 2015).
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Treg can also express CXCR3 in models of TH1 mediated inflamma
tion, such as T. gondii infection, autoimmune diabetes, and following
anti CD40 treatment (Hall et al., 2012; Koch et al., 2009; Kornete et al.,
2015). Akin to TH1 cells, CXCR3 expression on Treg is dependent on
T bet, STAT1, IL 27, and IFNγR signaling (Hall et al., 2012; Koch
et al., 2009). T bet regulation of trafficking receptors is critical for optimal
function of tTreg, as in an islet allograft model, T bet deficient Treg dis
played impaired migration to dLN and accumulated in the graft (Xiong,
Ahmad, Iwami, Brinkman, & Bromberg, 2016). This was associated with
reduced expression of CXCR3 and increased expression of CCR4,
inhibiting recruitment into lymphatic vessels and ultimately preventing graft
survival.
In addition to exerting their suppressive effects in peripheral tissues, it is
clear that localization of Treg to SLO is essential for multiple aspects of their
function, including their activation and control of inflammatory T cell prim
ing (Rudensky & Campbell, 2006). CCR7 is critical for Treg recirculation
through LN as well as for exit from peripheral tissues, although some
CCR7 independent trafficking into the medulla has been reported
(Menning et al., 2007; Schneider, Meingassner, Lipp, Moore, & Rot,
2007; Ueha et al., 2007). In the LN, CCR7 allows localization of tTreg to
the paracortex, where they can access the high levels of IL 2 required for their
maintenance (Smigiel et al., 2014; Ueha et al., 2007). Alternatively, CCR7lo
Treg can bemaintained through continuous signaling through ICOS (Smigiel
et al., 2014). LNs are not only important sites for generation of Treg, as
sequential trafficking of Treg from peripheral sites to LN during an ongoing
immune response is required for optimal immune suppression. In an islet
allograft model, Treg first migrate from the blood to the graft using a variety
of inflammatory receptors including CCR2, CCR4, and CCR5, as well as
P and E selectin ligands (Zhang, Schroppel, et al., 2009). Treg then migrate
from the graft to the dLNusing a combination of CCR2,CCR5, andCCR7.
The importance of this sequential migration is demonstrated by transfer of
CCR7 deficient Treg, which migrate normally to inflamed grafts but show
inhibitedmigration todLNs, and consequently cannot suppress graft rejection.
The inflammatory chemokine receptors CCR2 and CCR5 are impor
tant for Treg trafficking to a broad range of responses. CCR2 is used for
Treg trafficking to antigen in a model of delayed type hypersensitivity,
as well as for entry into tumors in a range of experimental models
(Hamano et al., 2014; Loyher et al., 2016). CCR5 is required for Treg
recruitment to the site of Leishmania major infection, with CCR5 deficient
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Treg unable to inhibit the antiparasitic response leading to protection
(Yurchenko et al., 2006). CCR5 is also required for Treg trafficking in
models of intestinal inflammation and P. brasiliensis infection (Kang et al.,
2007; Moreira et al., 2008). In contrast to these broadly inflammatory che
mokine receptors, Treg can also express more tissue specific receptors such
as CCR9 which allows homing of Treg cells to the gut (Guo et al., 2008).
Expression of CCR9 in Treg is regulated by BATF and RA (Benson, Pino
Lagos, Rosemblatt, & Noelle, 2007; Wang et al., 2013).
One factor recently shown to critically regulate Treg migration to
peripheral tissues is KLF2 (Pabbisetty et al., 2016). KLF2 deficient Treg
express increased levels of CCR4, CCR6, CCR8, and CCR9, and reduced
levels of CCR7. Mice with Treg specific KLF2 ablation displayed impaired
LNmigration of Treg and ultimately developed autoimmunity, highlighting
the critical role of Treg LN trafficking for maintenance of peripheral toler
ance. Transduction of CCR7 into KLF2 deficient Treg restored their ability
to migrate to LN and prevented pathology in colitis models. Furthermore,
therapeutic intervention to increase KLF2 activity in Treg using simvastatin
or retroviral transduction promoted LNmigration and reduced pathology in a
GVHD model. This suggests that therapeutic targeting of Treg may be
achieved through manipulation of their trafficking receptors. However, given
that Treg and TH cells often use the same chemokine receptors for migration,
selectively targeting Treg cells may present some difficulties, and identifying
receptors that are differentially expressed will be useful. As mentioned earlier,
we have recently shown in EAE that although TH17 and Treg both express
CCR6, during peak disease TH17 trafficking is instead mediated predomi
nantly through CCR2 (Kara et al., 2015). Thus, targeting of the CCR2 axis
may be a more effective strategy to prevent recruitment of pathogenic
TH17 cells while allowing CCR6 dependent trafficking of Treg into the
CNS to dampen existing inflammation. More detailed analysis of trafficking
receptors used concomitantly by inflammatory and regulatory T cells in alter
nate models may assist in the development of other therapeutic strategies.
5. CHEMOKINE CONTROL OF CD4+ MEMORY FUNCTION
Upon antigen clearance, CD4+ effector T cells rapidly contract, with
approximately 90% of cells dying within 1–2 weeks. However, memory
CD4+ T cells persist long term and are critical for the rapid response to sub
sequent antigen encounter. The precise mechanisms by which CD4+
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memory T cells develop and function is still not well described, particularly
compared to CD8+ T memory, however significant advances to improve
our understanding have been made in recent years. CD4+ memory
T cells are a heterogenous population and have been divided into at least
three categories based on their migratory patterns (Fig. 2). The first division
of function of memory T cells was first described by Sallusto and colleagues
in 1999 on the basis of CCR7 expression (Sallusto, Lenig, Forster, Lipp, &
Lanzavecchia, 1999). Central memory (TCM) cells are defined as CCR7
+
Fig. 2 Formation and trafficking of CD4+ T cell memory. Long-lived CD4+ memory cells
are classified into three subsets based on their patterns of recirculation. TCM cells are
mainly found in the blood and SLO, with expression of CCR7 and CD62L enabling their
migration into SLO through HEVs. TEM recirculate through peripheral tissues and can
reenter LNs through the afferent lymph. TRM permanently reside in peripheral tissues
after infection and are restricted from reentering the circulation. The ontogeny of
the different memory subsets is still unclear and markers of memory precursors in
the effector phase of the response has not yet been reported, unlike that of CD8+
T cells. There is evidence that CXCR5+ TCM cells derive from TFH cells, although CXCR5
!ve
TCM also exist. At which stage memory fate is conferred remains to be determined. Che-
mokine receptor alterations between these memory subsets are depicted. Arrows indi-
cate differentiation/transdifferentiation of T cell subsets, ? indicates an as yet unproven
transdifferentiation pathway.
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CD62Lhi CD4+ T cells that preferentially produce IL 2 upon restimulation
and cross HEVs to recirculate from blood through SLOs (Reinhardt,
Khoruts, Merica, Zell, & Jenkins, 2001). Conversely, effector memory
(TEM) cells were described as CCR7
veCD62Llo and migrate to inflamed
peripheral tissues for immunosurveillance and enter LNs via afferent lymph.
Upon antigen engagement, these cells preferentially produce effector cyto
kines such as IFNγ and IL 4. More recently, resident memory (TRM) that
permanently reside in previously infected peripheral tissues and are restricted
from accessing the circulation were described, with these cells being critical
for protective immunity upon rechallenge at the site of the primary infection
(Gebhardt & Carbone, 2009; Teijaro et al., 2011). These subsets of CD4+
T cells, and the chemokine receptors that control their functions, will be
described here.
5.1 TCM
TCM cells are mainly restricted to recirculating through the blood and lym
phoid organs, where they rely on APCs in SLOs for their reactivation.
Because of this, TCM cells are the slowest of the memory cell subsets to
respond to antigen and take days to expand. However, TCM cells have an
unique role in that they produce high levels of IL 2 and display enhanced
proliferative capacity, giving rise to multiple effector subsets that can then
emigrate from SLO to traffic to peripheral sites. The expression of CCR7
by TCM is critical for this recirculation, and along with CD62L expression
allows trafficking patterns akin to naı̈ve T cells.
TCM can also express CXCR5, which has raised interesting questions
regarding the relationship of these cells to TFH cells both in regard to their
ontogeny and functional capabilities. For example, Ag specific CD4+ TCM
cells (CCR7+CD62Lhi) at 60 days postinfection with Listeria monocytogenes
displayed a characteristic CXCR5+ T betlo phenotype, while TEM were
CXCR5 veCCR7 ve T bethi (Pepper, Pagan, Igyarto, Taylor, & Jenkins,
2011). These CXCR5+ memory cells efficiently produced IL 2 but secreted
less IFNγ than TEM, supporting their status as TCM cells. Perhaps surprisingly
given their expression of CXCR5, these cells were excluded from follicles and
localized to the paracortex upon adoptive transfer, which suggests that other
migratory cues, possibly including CCR7, confine them to T cell areas.
However, CXCR5+ TFH cells can also persist into memory in the absence
of continued antigen, where they drive enhanced secondary responses and
can provide more efficient B cell help than TFH cells in the primary response
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(Hale et al., 2013; Luthje et al., 2012). This potential relationship between
TFH cells and TCM cells is currently controversial and the interdependence
of these cells in memory formation remains to be established. Like TFH cells,
TCM cells that develop in response to L. monocytogenes infection are also
dependent on Bcl6 and ICOS signaling by B cells, suggesting TCM cells
may actually arise exclusively from TFH cells in some scenarios (Pepper
et al., 2011). However, during the acute phase of infection, two populations
of CXCR5+ CD4+ T cells have been described: PD 1hi CXCR5+ TFH cells
and PD 1 ve CXCR5+ CCR7+ T betlo cells, which were termed TCM pre
cursor cells given their similarity to the TCM cell phenotype described earlier.
This posits a model by which during the effector phase of a response, a pool of
CXCR5+ CD4+ cells exists in SLOs, some of which increase expression of
CXCR5 and PD 1, and enter the follicle to become TFH cells. Upon cessa
tion of the GC, some TFH cells then downregulate PD 1 expression and form
CXCR5+ memory cells, although entry into the GC has been shown to not
be essential for memory formation (He et al., 2013; Tubo et al., 2016). In the
memory phase, the CXCR5+ CD4+ population can be divided into
CCR7loPD 1hi TFH precursors, as well as a CCR7
hiPD 1lo subset character
istic of restingmemory cells (He et al., 2013). In response to LCMV infection,
a bifurcation of these CXCR5+ CD4+ populations into Ly6Clo and Ly6Cint
subsets was reported, with the Ly6Clo cells displaying a transcriptional profile
similar to that of TFH cells (Hale et al., 2013). The Ly6C
int population has
a less polarized gene signature with features of both TFH cells and TH1 cells,
and also has significantly higher proliferative potential than either the
CXCR5+Ly6Clo or CXCR5 ve memory populations and thus is more sim
ilar to the classical TCM phenotype. However, a CD62L
hi CXCR5 ve pop
ulationwas also described in LCMV infection, suggesting someTCM cells may
also arise from the CXCR5 ve population. Thus, further evidence is required
to determine the precise ontogeny of TCM cells, whether they derive exclu
sively from TFH cells or from a common precursor to TFH cells, and whether
they can derive from CXCR5 ve populations in other scenarios.
Further evidence for this complex interplay between TCM and TFH cells
is found in human peripheral blood, where 20% of memory CD45RA ve
CD4+ T cells are CXCR5+ (Morita et al., 2011). The majority of these cells
coexpress CCR7, indicative of circulating memory cells. Circulating
CXCR5+ CD4+ memory T cells retained the ability to differentiate into
TH1 or TH2 subsets, as expected for TCM cells (Messi et al., 2003). However,
CXCR5+ memory cells were also capable of helping B cells in ex vivo
culture, with CXCR3 veCCR6+ and CXCR3 veCCR6 ve but not
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CXCR3+CCR6 ve cells able to promote class switching, suggesting the
ability to differentiate into TFH cells was restricted to only a proportion of
these CXCR5+ memory cells (Morita et al., 2011). In other studies, TFH cells
were preferentially confined to CCR7lo CXCR5+ circulating memory cells
(He et al., 2013). Clearly, many questions regarding the ontogeny of TCM cells
as well as their differentiation potential remain unanswered.
Other chemokine receptors have also been reported to be expressed by
human CD4+ TCM cells and correlate to the differentiation capability of
those TCM cells, suggesting reduced multipotency and perhaps partial differ
entiation (Rivino et al., 2004). CXCR3+ TCM cells secrete low levels of
IFNγ and are able to generate fully differentiated TH1 cells in vitro, while
CCR4+ TCM cells secreted low levels of IL 4 but not IL 5 and gave rise to
TH2 cells. In contrast, CXCR5
+ TCM that were CXCR3
ve and CCR4 ve
were not polarized and relied on exogenous cytokines to divert them to a
TH1 or TH2 phenotype. Evidently, there is much to learn about the further
classification of diversity within TCM cells based on their chemokine recep
tor expression. Furthermore, the precise role of these chemokine receptors
in guiding TCM cells to specific SLO niches supportive of their function is
also largely unexplored.
5.2 TEM
Under steady state conditions, TEM circulate through the blood and periph
eral tissues. CD4+ TEM are generally thought to be excluded from entering
HEV due to low expression of CCR7 and CD62L, but can migrate into
reactive LN through CD62P where they can promote naı̈ve T cell priming
(Martin Fontecha et al., 2008). Owing to their efficient expression of effec
tor cytokines, TEM provide an earlier response to secondary infections than
TCM and can be recruited to the site of infection to respond within hours to
days. TEM are thought to arise from T effector cells that have survived the
contraction phase, although it is not clear at which point memory fate deter
mination is conferred. Certainly, the markers used to define CD8+ memory
precursors such as CD127 and KLRG1 do not apply to CD4+ memory
(Marshall et al., 2011). It is also not clear if all TH subsets equally form mem
ory, with most reports describing TH1 like memory cells, although TH2 and
TH17 memory cells have been described (Pepper & Jenkins, 2011). Indeed,
recent data from our laboratory indicated that the highly inflammatory sub
set of TH17 cells that coexpress GM CSF and IFNγ also clearly persist into
memory (Kara et al., 2015).
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Very little is known about the migration patterns and cues used by CD4+
TEM to migrate through the periphery. However, it is clear there are sub
stantial differences compared to memory CD8+ T cells. For example, in skin
following cutaneous HSV infection, CD4+ memory T cells are confined to
the dermis, while CD8+ memory T cells populate the epidermis
(Gebhardt & Carbone, 2009). Similarly, intravaginal HSV infection permits
localization of memory CD4+ T cells to the lamina propria and memory
CD8+ T cells to the epithelium of the genital tract. In HSV infection, mem
ory CD4+ T cell trafficking to the skin is transient and these cells exit the
tissue and recirculate. Chemokine receptor expression on TEM has been
reported. In response to EAE immunization, memory CD4+ T cells express
higher levels of CXCR3 and CCR5 than Teff (Elyaman et al., 2008). Trans
fer of these TEM into Tcrαβ / mice given EAE induced greater disease
severity than transfer of effector T cells, which was associated with enhanced
trafficking to the CNS, suggesting TEM migration was mediated through
these axes. We have recently shown that IL 17 producing CD4+ memory
cells are present in the lung after S. pneumoniae infection and these cells
express high levels of both CCR6 and CCR2, with the proportion of
CCR2+ CCR6 ve TH17 cells predominantly increasing upon rechallenge
(Kara et al., 2015). Furthermore, TEM from human PBMCs have also been
reported to express CCR10, CCR5, CXCR3, CCR6, and CCR4,
suggesting diverse trafficking within the TEM population that may follow
similar classification to TH cells (Brodie, Brenna, & Sallusto, 2013). This
was partially supported by analysis of TEM from human cord blood, in which
CXCR3+ TEM cells preferentially produced IFNγ, and CCR6+ TEM cells
displayed a transcriptional profile biased to a TH17 phenotype, although
could not robustly secrete IL 17 (Zhang et al., 2014). In contrast, CCR4
expression was not restricted to TEM with a TH2 signature and IL 4 produc
tion was detected in both CCR4+ and CXCR3+ TEM cells. Taken together,
it is clear that the signals controlling tissue niche occupancy and recirculation
for memory CD4+ T cells is not well understood and there is still much to be
learned in this area.
5.3 TRM
TRM are the most recently discovered subset of memory cells with parabiosis
experiments first definitively revealing CD8+ TRM in 2009 and CD4
+ TRM
in 2011 (Gebhardt & Carbone, 2009; Teijaro et al., 2011). The essential
defining property of these cells is that they are resident in peripheral tissues
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and do not recirculate through the blood or lymph, although the factors pro
moting their residence are still not well understood. TRM cells reported to
date display enhanced protective responses upon reencounter of antigen and
due to their peripheral location can have the shortest response time of all
memory subsets. CD4+ TRM generated in response to L. major infection
in the skin are essential for optimal protection against secondary parasite
challenge as they enhance recruitment of circulating memory cells through
production of CXCL9 and CXCL10 (Glennie et al., 2015). A recent study
also demonstrated that CD4+ TRM resident in the spinal cord and dorsal root
ganglia (DRG) in response to HSV 2 infection facilitate protection through
production of IFNγ which enhances vascular permeability thus allowing
access of antiviral antibodies to the brain (Iijima & Iwasaki, 2016). Again,
CD4+ TRM are much less well described than their CD8
+counterparts,
although they generally express a CD44hi CD62Llo CD11ahi CD69+ phe
notype (Iijima & Iwasaki, 2014; Teijaro et al., 2011).
CD4+ TRM generated in the genital tract in response to intravaginal
HSV 2 immunization do not express CCR7, in support of their restriction
from entering lymphatic circulation (Iijima & Iwasaki, 2014). However,
chemokine signaling is required to maintain their residency in the vaginal
parenchyma, as treatment with PT results in expulsion into the lumen. Fur
thermore, neutralization of CCL5 reduces the numbers of TRM in the
vagina and accordingly reduces the protection observed in the presence
of these cells. TRM in this model express the CCL5 receptors CCR1 and
CCR5 as well as CXCR3, although neutralization of the CXCR3 ligand
CXCL9 does not affect CD4+ TRM residency. CD4
+ TRM are also gener
ated in the spinal cord and DRG in response to HSV 1 infection, with the
ligands for CXCR3, CCR5, and CCR2 expressed in DRG (Iijima &
Iwasaki, 2016). However, the migratory cues required for entry into these
regions remain to be determined.
Another potential subset of memory cells, referred to as recirculating
memory (TRCM) cells, has also been reported (Bromley, Yan, Tomura,
Kanagawa, & Luster, 2013). Photoconversion of the skin of Kaede mice
delineated two populations within homeostatic skin: CCR7 ve CD69+
TRM cells and CCR7
int/+ CD62Lint CD69 ve TRCM cells. Owing to their
expression of CCR7 and lack of CD69, these TRCM were able to leave the
skin and could also enter nondraining lymph nodes. The function of these
cells is also intriguing, as they produce IL 2 but negligible IFNγ or IL 10
following restimulation. The relationship of these cells to TEM, as well as
their presence in other settings, remains to be investigated.
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6. CONCLUDING REMARKS
More than 20 years of intensive research have shed much light on the
significance and molecular mechanisms of CD4+ T cell migration. As dis
cussed above and summarized in Fig. 1 and Table 1, this is tightly controlled
through regulation of chemokine receptor expression, which contribute
importantly to almost all aspects of CD4+ T cell function. Coordinated
migration of the CD4+ T cell is required for the optimal efficiency evident
in priming, influences early fate decisions, and dictates the trafficking and
effector functions of differentiated TH cells. Furthermore, differential migra
tion mediated through specific chemokine axes is essential for the diversity
seen in memory CD4+ responses, enabling broad protection from the
diverse range of pathogenic insults encountered during life (Fig. 2).
Although our knowledge of CD4+ T cell function and migration is steadily
increasing, many unanswered questions remain. The timing and determi
nants involved in deciding lineage and memory formation are still not well
understood, and continuing research is needed into whether expression of
distinct chemokine receptors facilitates these decisions. Furthermore, it is
increasingly apparent that vast diversity and plasticity exists within TH sub
sets, and more detailed analysis of how homing receptors change with trans
differentiation will enable more appropriate targeting of the specific T cells
involved in disease. Lastly, the area of CD4+ memory is still largely not well
explored and understanding the migratory requirements for these cells may
facilitate manipulation of their function, potentially enhancing vaccination
strategies. Altogether, it is hoped that this more detailed understanding of
molecular control of CD4+ T cell migration will bring about the means
for more effective therapeutic intervention in a wide range of human
pathologies.
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